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1. INTRODUCTION 
1.1. CYTOKININS: BIOLOGICAL ROLE AND FUNCTION IN PLANTS 
Cytokinins (CKs) were discovered during the 1950s as substances able to induce the 
division of plant cells. They are a class of plant hormones that play various roles in many aspects of 
plant development, including apical dominance, the formation and activity of shoot stems, leaf 
senescence, nutrient mobilization, seed germination, root growth, and stress responses. Generally 
natural CKs are N6-substituted adenine derivatives and generally the substitution at position N6 
consists of an isoprenoid or an aromatic group [1] (Figure 1).  
N
NN
N
HN
O
OHOH
HH
HH
HO
N
NNH
N
HN
R R
general structure of 
a cytokinine CK
general structure of 
a cytokinine riboside CKR
R = N6-isopentenyl Adenine (iPAde)
Isoprenoid CKs
R = trans-Zeatin (tZ)OH
Aromatic CKs
R = R =
OH
N6-benzyl adenosine (BA) N6-hydroxybenzyl adenosine(HBA, topolin)
OR =
kinetin (K)
3
9 2
1
4
5
67
8
 
Figure 1. Structure of naturally occurring cytokinins (CKs) and their β- ribosides (CKRs) 
N6-furfuryladenine (kinetin, K) was the first cytokinin discovered as a degradation product 
of DNA and was shown to be able to promote cell division in plants [2]. Since then, a large number 
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of biochemical, physiological and genetic studies have focused on elucidating the diverse roles of 
CKs in plant growth  and development [3].  Both isoprenoid and aromatic CKs are naturally 
occurring, with the former more frequently found in plants and in greater abundance than the latter. 
Common natural isoprenoid CKs are N6-(Δ2-isopentenyl) adenine (iPAde), trans-zeatin (tZ) and the 
related stereoisomer cis-zeatin (cZ) (Figure 1). Among them, the major derivatives generally are tZ 
and iPAde, as well as their sugar conjugates, but there is a great variation depending on plant 
species, tissue, and developmental stage [4]. Aromatic CKs, N6-benzyladenine (BA) and the three 
isomeric HydroxyBenzylAdenine (HBA, topolins) (Figure 1) were identified in several plant 
species including poplar and Arabidopsis [5-7], but it is not yet clear whether they are ubiquitous in 
plants. Usually, for all natural CK nucleobases the corresponding nucleosides, nucleotides, and 
glycosides have been isolated (Figure 2).  
 
Figure 2. CK conjugates with sugars, sugar phosphates and others. O-Glycosylation of side chain 
(colored in blue) is catalyzed by zeatin O-glucosyltransferase or O-xylosyltransferase. N-
glucosylation of adenine moiety (colored in red) is catalyzed by cytokinin N-
glucosyltransferase (reported from ref. [4]). 
 
Glycosylation of CK has been observed at the N3, N7 and N9 position of the purine moiety 
as N-glycosides, and at the hydroxyl group of the side chains of tZ, cZ, and dihydrozeatin (DZ, 
saturated analog of tZ) as O-glucosides or O-xylosides (Figure 2). O-glycosylation is reversible and 
deglycosylation is catalyzed by a β-glucosidase. On the contrary, N-glycoconjugates are not 
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efficiently cleaved by β-glucosidase [8] and N-glycosylation results in a practically irreversible 
process. The physiological consequences of the differences in stability of N-glycosides and O-
glycosides are not fully understood to date. However, it has been suggested that the readily cleaved 
O-glycosides represent inactive, stable storage forms of CKs [4].  
 
1.2 BIOSYNTHESIS OF CYTOKININS and CYTOKININ RIBOSIDES 
1.2.1. Isoprenoid cytokinins 
CK ribosides and their phosphates predominantly represent the primary products of CK 
biosynthesis and the concomitant occurrence of CK and the corresponding nucleosides and 
nucleotides in plant tissues suggests that important metabolic steps are shared with the purine 
metabolic pathway, i.e., salvage pathway [3]. Thus, the metabolic flow from CK nucleotides to the 
active nucleobases is probably not unidirectional but circular (Figure 3).  
 
Figure 3. Current model of isoprenoid CK biosynthesis pathways in Arabidopsis. Methylerythritol 
phosphate (MEP) and mevalonate (MVA) pathways as isoprenoid side chain sources of 
cytokinins (reported from ref. [4]). 
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The first step in the isoprenoid CK biosynthesis [4]  is N-prenylation of adenosine 5'-
phosphates (AMP, ADP, or ATP) at the N6-terminus with dimethylallyl diphosphate (DMAPP) or 
hydroxymethylbutenyl diphosphate (HMBDP); this reaction is catalyzed by adenosine phosphate-
isopentenyltransferase (IPTl; EC 2.5.1.27) (Figure 3).  
CKs may derive from tRNA degradation as well and shortly after the discovery of CKs, it was 
assumed that tRNA is a major source of CKs because isoprenoid CKs were identified in the 
hydrolysates of tRNAs [9-11]. Thus, tRNA prenylation could contribute, at least to some extent, to 
CK production. Early calculations of turnover rates of tRNA led to the conclusion that tRNA 
degradation was not a major pathway of CKs synthesis [12].   
1.2.2 Aromatic cytokinins 
N6-benzyladenosine has been long considered an artificial cytokinin until this compound 
was isolated from a cytokinin-autotrophic cell culture of anise, Pimpinella anisum L. Additional 
compounds structurally related to BA and BAR,  are the three isomeric N6- hydroxybenzyl adenine 
and adenosine isolated from leaves of Populus robusta and N6-(O-hydroxybenzyl)-2-methylthio-9-
β-D-glucofuranosyladenine isolated from fruits of Zantedeschia aethiopica robusta [5]. Despite the 
fact that BA is one of the most effective and affordable cytokinins and has been widely used in 
plant biotechnology for several decades, cytokinin research has typically been focused on the 
isoprenoid class of cytokinins, typified by zeatin, dihydrozeatin and isopentenyladenine.  
The biosynthesis and degradation pathways of aromatic CKs remain to be elucidated, 
although the mechanisms of glycosylation and of their interaction with the cellular signaling system 
appear to be shared with isoprenoid CKs. Apparently, the enzymes and receptors involved 
recognize members of both groups [13, 14]. Indirect evidences on the metabolism of BA [and 
possibly BAR] seems to indicate that the HBA (topolins) could be the result of the action of 
CYP735A or some other P450s on BAR or BA [15]. 
1.2.3. Kinetin and Kinetin  Riboside 
A recent review describes in details the multiple biological activities of K [16]. K has been 
the first and the best-known cytokinin, isolated for the first time in 1950 [1] from autoclaved 
herring sperm DNA [2]. For a long time, N6-furfuryladenine was recognized as an unnatural 
synthetic product and was found in commercially available DNA, in freshly extracted cellular DNA 
from human cells, in plant cell extracts and human urine [17, 18]. The native K was identified in 
plant root nodules of Casuarina equisetifolia [19]. Recently K free base and its riboside- KR have 
been detected in the endosperm liquid of fresh young coconut fruits [20], at concentrations of 0.31 
and 0.33 nM, respectively [21]. These findings contribute strongly to answer the question 
concerning the origin of K and other cytokinins (Scheme 1). It has been shown that the cells of 
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legume nodules contain catalytic amounts of iron, which is required for Fenton reaction and 
formation of hydroxyl radical.  
 
Scheme 1. Biosynthesis of kinetin and its riboside. Furfural as a product of DNA oxidation 
product reacts with ribo- or deoxyadenosine (reported from ref. [24]).    
 10
The highly reactive oxygen species (ROS) cause degradation of cellular component in 
nodule extracts. The high yield of Fe-catalyzed Harber-Weiss reaction of deoxyribose damage 
sustained in vitro by the cytosol of bean and cowpea nodules during senescence suggests their 
potential to generate •OH. These data strongly support the hypothesis that cytokinins can be 
recognized as the products of the oxidative metabolism of the cell [22, 23]. The proposed 
mechanism of kinetin formation in DNA in vivo starts with the hydroxyl radical oxidation of the 
deoxyribose residue at the carbon 5' to yield furfural. This newly formed aldehyde subsequently 
reacts with the amino group of adenine to form the Schiff base followed by intramolecular 
rearrangement, which can yield K formation in vivo (Scheme 1). 
 
1.3. OCCURRENCE OF ISOPENTENYL ADENOSINE AND KINETIN RIBOSIDE IN 
MAMMALIANS 
As stated in Section 1.2.3, there are good evidences that K and KR are formed in vivo in 
mammalians as an important component of a new salvage pathway of hydroxyl radical constituting 
a ‘free radical sink’. By this mechanism, the cell can find a way for response to oxidative stress, 
inducing defence mechanisms of maintenance and repair [24]. According to this hypothesis, KR is 
formed from adenosine to neutralize the harmful properties of hydroxyl radical reaction products, 
such as, e.g. furfural, which is formed by degradation of sugar residues in DNA and is one of the 
major routes of cellular damage in addition to the other modifications of nucleic acid bases [25]. In 
conclusion, although KR is found in mammalians, the product represents an artefact of DNA 
oxidative stress. 
iPAdo has been found in tRNA from a wide variety of eukaryotic and prokaryotic cells [26]. 
The modified base is derived from 3-methyl-2-buten-1-yl pyrophosphate, an intermediate in cellular 
isoprenoid biosynthesis. The enzyme that catalyzes the first reaction is Δ2-isopentenyl 
pyrophosphate: 5'-AMP Δ2-isopentenyltransferase (EC 2.5.1.) commonly referred to as isopentenyl 
transferase (IPT) and is the enzyme central to all isoprenoid CKs biosynthesis [27]. Isopentenyl 
transferase (IPTs) constitute a family of enzymes that are conserved from micro organisms to 
mammals and are involved in post transcriptional modification of tRNA, that, in the case of iPAdo, 
consists in the addition of  the isopentenyl chain to adenosine of the residue 37 of tRNA (Scheme 2) 
[28]. iPAdo is found adjacent to the 3' end of the anticodon of tRNAs. This modified nucleoside 
appears only in tRNAs that bind to codons containing uridine as the first base [29]. 
In bacteria, isopentenylated tRNAs have been implicated in the regulation of aromatic acid 
uptake [30] and aerobiosis [31], whereas the precise role of the modified nucleotide in tRNA 
metabolism of eukaryotes is unknown. In general, all of RNA modifications are essential in 
maintaining the correct reading frame of the translational machinery, thus improving fidelity and 
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efficiency of protein synthesis and avoiding errors that could be detrimental for cells [32]. In this 
respect, it has also been demonstrated that tRNA containing iPAdo binds more efficiently the 
ribosome than the unmodified analogues. Therefore the loss of modified nucleotide from the tRNA 
can produce pleiotropic effects on accuracy of protein synthesis leading to altered cell proliferation 
and differentiation [33].  
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Scheme 2. Isopentenyl transferase (IPT)-catalized transfer of isopentenyl chain to adenosine-5'-
phosphate-tRNA 
 
Starting from the consideration that isoprenylated proteins may regulate DNA synthesis and 
the level of the isoprenylated protein would be low in cells expressing reduced rates of DNA 
replication it was demonstrated that a 26-kDa protein (termed iA26) was present in growing 
Chinese hamster ovary cells [29]. Regenerating liver tissue also exhibited elevated levels of iA26. 
Thus, the expression of iA26 correlates with cellular proliferation and growth. It was proposed that 
iA26 contains iPAde moieties and mediates isoprenoid regulation of DNA synthesis, thus affecting 
cell proliferation and differentiation in plants and animals.    
Free, non-tRNA-associated iPAdo has been observed in yeasts [34] and the cellular level of 
free iPAdo was not decreased in defective yeast strains possessing mutations that result in severely 
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reduced amounts of isopentenylated tRNAs. This latter result indicates that free iPAdo may be 
derived via a 
synthetic pathway independent of isopentenylated tRNA degradation. iPAdo is formed from 
adenosine monophosphate (AMP) into isopentenyladenosine-5'-monophosphate (iPAMP) and 
following phosphate hydrolysis (Scheme 3). This reaction is catalyzed by Δ2-isopentenyl 
pyrophosphate: 5'-AMP Δ2-isopentenyltransferase (EC 2.5.1.) commonly referred to as isopentenyl 
transferase (IPT) that is the main enzyme to all isoprenoid CKs biosynthesis [35].  
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Scheme 3.  Biosynthesis of N6-isoPentenyl Adenosine in plants. AMP and DMAPP (dimethylallyl 
pyrophosphate) are converted in (iPAMP) isoPentenyl Adenosine-5'-monophosphate and 
iPAdo. IPT (isopentenyl transferase) is the key regulatory enzyme of the biosynthesis 
(reported from ref. [35]). 
 
1.4. ANTIPROLIFERATIVE ACTIVITY OF CYTOKININ RIBOSIDES 
Crown gall disease that is characterized by the development of neoplastic growth on the 
infected plant affects many dicotyledonous plants and is caused by the soil bacterium 
Agrobacterium tumefaciens [36].  A small region of the Ti plasmid (the tmr locus), thought to be 
involved in phytohormone metabolism in Agrobacterium tumefaciens-transformed plant tissue, was 
cloned and expressed in Escherichia coli [37].  By enzyme assay, the tmr locus was shown to 
encode IPT, the enzyme that catalyzes the first step in cytokinin biosynthesis. This established a 
connection between CKs and induction of callus, a cluster of differentiated plant cells that are 
immortal and proliferate indefinitely, to re-differentiate into adventitious buds. In this respect, plant 
 13
callus cells are similar to human cancer cells and cytokinins were expected to be able to affect the 
differentiation in some human cancer cells, probably, through a common signal transduction system 
[38].   
This connection between CKs/CKRs cytokinin and antiproliferative activity has been 
confirmed by a recent report that examined the control of differentiation and apoptosis of human 
myeloid leukemia HL-60 cells by CKs and their CKRs [39]. The HL-60 (Human promyelocytic 
leukemia cells) cell line is a leukemic cell line that has been used for laboratory research on how 
certain kinds of blood cells are formed. The cell line was derived from a 36-year-old woman with 
acute promyelocytic leukemia at the National Cancer Institute [40]. With this line, spontaneous 
differentiation to mature granulocytes can be induced by compounds such as dimethyl sulfoxide 
(DMSO), or retinoic acid. Other compounds like 1,25-dihydroxyvitamin D3, 12-O-
tetradecanoylphorbol-13-acetate (TPA) and GM-CSF can induce HL-60 to differentiate to 
monocytic, macrophage-like and eosinophil phenotypes, respectively. The HL-60 cultured cell line 
provides a continuous source of human cells for studying the molecular events of myeloid 
differentiation and the effects of physiologic, pharmacologic, and virologic elements on this 
process. HL-60 cell model was used to study the effect of DNA topoisomerase (topo) IIα and IIβ on 
differentiation and apoptosis of cells [41].  Using HL-60 cell lines, it has been shown that CKs such 
as K, BA and iPAde were very effective in inducing nitroblue tetrazolium reduction and 
morphological changes of the cells into mature granulocytes (Table 1).  
 
 
Table 1. Effects of adenine analogues on growth of HL-60 cells. Cells were cultured with 
various concentrations of the analogues for 5 days. Means of three separate 
experiments are shown. The IC50 is the concentration of compound required for 
50% inhibition of cell growth (reported from ref. [39]). 
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On the other hand, examining the corresponding ribosides- CKRs, these compounds were 
more potent than the corresponding CKs for growth inhibition and apoptosis. CKRs greatly reduced 
the intracellular ATP content and disturbed the mitochondrial membrane potential, consequentially 
impairing the accumulation of reactive oxygen species. The same effect was not observed for CKs. 
When the cells were incubated with CKRs in the presence of O2.- scavenger, antioxidant or caspase 
inhibitor, apoptosis was significantly reduced and differentiation was greatly enhanced (Table 1).  
Above results suggest that both CKs and CKRs can induce granulocytic differentiation of 
HL-60 cells, but CKRs also induce apoptosis prior to the differentiation process.  
In another study [42], the in vitro induction of apoptosis by N6-substituted derivatives of 
adenine (CKs and analogues) or adenosine (CKRs and analogues) in HL-60 cells has been 
investigated. Using reversed phase HPLC/MS analysis they demonstrated that both N6-substituted 
derivatives of adenosine and adenine are phosphorylated within cells to the monophosphate level. 
While N6-substituted derivatives of  adenosine were phosphorylated by adenosine kinase and 
corresponding mononucleotides were produced in large quantities, N6-substituted derivatives of 
adenine were converted into the corresponding mononucleotides via the phosphoribosyl transferase 
pathway, which yielded 50–100 times lower amounts of the mononucleotides than the adenosine 
kinase pathway. Accordingly, N6-substituted derivatives of adenine were relatively inefficient 
inductors of apoptosis (Figure 4).  
 
Figure 4. Efects of N6-substituted derivatives of adenosine or adenine on apoptosis induction in 
HL-60 cells. Cells were treated with N6-substituted derivatives of adenosine or adenine. 
Cells were incubated for 12 h (black columns) or 24 h (white columns) and the number of 
apoptotic nuclei was evaluated using fuorescence microscopy. 1-Control (untreated cells), 2-
10 µM N6-benzyladenosine, 3-100 µM N6-cyclopentyladenosine, 4-10 µM N6-
dimethyladenosine, 5-10 µM N6-furfuryladenosine, 6-100 µM N6-(4-hydroxy-3-methyl-2-
buten-1-yl)adenosine, 7-10 µM N6-isopentenyladenosine, 8-100 µM N6-benzyladenine, 9-
100 µM N6-dimethyladenine, 10–100 µM N6-furfuryladenine, 11-100 µM N6-(4-hydroxy-3-
methyl-2-buten-1-yl)adenine, and 12-100 µM N6-isopentenyladenine. The experimental 
points represent mean values from three replicate experiments with standard deviations 
(reported from ref. [42]). 
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Inhibitors of adenosine kinase, that abrogated the formation of the monophosphates from 
N6-substituted derivatives of adenosine, completely prevented cells from going into apoptosis. 
These results consistently support the idea that pro-apoptotic effects of N6-substituted derivatives of 
adenosine are related to their intracellular conversion into corresponding mononucleotides which 
activate apoptosis when accumulated. This accumulation leads to a rapid decrease in ATP 
production and consequently to apoptosis induction. Nevertheless, the detailed mechanism is 
unknown. 
These results proposed an interesting working hypothesis related to a different activity of 
CKs and their CKRs, although this difference was limited only to human myeloid leukemia HL-60 
cells. Among examined CKs and related CKRs, it has been shown that BAR, KR and iPAdo are 
more effective than related adenine derivatives BA, K or iPAde (Table 1).   
 
1.4.1. isoPentenyl Adenosine antitumor activity in vitro 
Nearly forty years ago, Gallo and co-workers [43] observed that iPAdo can exert a 
promoting or inhibitory effect on human cell growth, on the bases of used concentration and the cell 
cycle phase. They reported that iPAdo is a potent inhibitor or a stimulator of the DNA synthesis, 
since addition of iPAdo at μM concentration produced inhibition. Lower concentrations (0.1-1.0 
μM ) had a stimulatory effect. Moreover they demonstrated that the addition of iPA at increasing 
times, after cells seeding and proliferation stimulation, determined a decrease of mitotic figures, 
suggesting that iPAdo effects depend on the phase of cell cycle. It was also demonstrated that the 
effects on DNA synthesis are preceded by the inhibition of RNA and protein synthesis In 1973, 
Divekar et al. demonstrated that iPAdo is cytotoxic for Sarcoma 180 cells as for the majority of the 
mammalian cells [44]. It was observed that iPAdo at the concentration of 22 and 100 μM inhibited 
the growth of Sarcoma 180 cells (50% and 100% respectively) acting as a potent inhibitor of the 
uptake of purine and pirimidine nucleosides. Studies performed on the extracts of these cells 
demonstrated that iPAdo is a substrate for adenosine kinase and it is also a weak inhibitor of 
adenosine deaminase, glucose-6-phosphate-dehydrogenase and methylase of mammalian tRNAs. 
The authors suggested that iPAdo cytotoxicity for these cells might be due to its conversion into 5'-
monophosphate that is cytotoxic at high intracellular levels affecting the enzymes involved in 
purine metabolism (Scheme 4). 
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Scheme 4. The modified nucleotide iPAdo-5´-phosphate as iPAdo derivative, responsible for its 
cytotoxicity 
 
The ability of cytokinins to induce apoptosis was studied by Meisel et al. [45] in several 
human cell lines and it was observed that iPAdo was the most active cytokinin, especially with 
respect to Caco-2 and HL-60 cancer lines. As previously reported, cytokinin ribosides such as KR 
and iPAdo inhibited growth and differentiation of human myeloid leukaemia HL-60 cells, inducing 
their apoptosis [39, 42]. Laezza and co-workers [46] demonstrated that iPAdo in thyroid cell FRTL-
5 influences the cAMP dependent organization of the microfilaments. The same authors have later 
demonstrated that iPAdo caused a dose-dependent arrest of G0-G1 cell phase transition associated 
with a reduction of cells in S phase [47]. In this paper, it was shown that iPAdo is able to inhibit 
farnesyl diphosphate synthase (FPPS) and to affect protein prenylation. This can explain the arrest 
of tumour cells proliferation in a reversible mode, since the addition of farnesol could reverse the 
process. This effect was not mediated by the adenosine receptors but was due to a direct modulation 
of FPPS enzyme activity as a result of its uptake inside the cells.   
In 2005 Dragani and coworkers showed by a pharmacogenomic approach that the human 
tRNA-isopentenyltransferase (TRIT1) gene could be a candidate lung tumor suppressor [48]. 
tRNA-isopentenyltransferase (tRNA-IPT) catalyses the addition of iPAdo on residue 37 of tRNA 
molecules that bind codons starting with uridine [28]. In the cited study [48], TRIT1 expression in 
normal lung parenchyma was compared with that in A549 lung cancer cells. Cancer cell lines 
overexpressing the biochemically functional TRIT1 variant were analyzed and, as a result, the 
TRIT1 gene was identified as a potential negative regulator of lung carcinogenesis. The results 
obtained by Laezza et al. [47] suggesting that the capability of iPAdo of  inhibiting farnesyl 
diphosphate synthase (FPPS) could concur to arrest tumour cells proliferations was not confirmed 
by Dragani and co-workers  in another study. The antiproliferative activity of iPAdo in 9 human 
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epithelial cancer cell line derived from different types of malignant tissue was examined [49] and 
FPPS downregulation in A549 cells was not involved in the antiproliferative activity of iPAdo. 
Dragani et al. observed complete suppression of clonogenic activity in 8 of the cell lines after 
exposure to iPAdo at a concentration of 10 μM. A clonogenic assay is a microbiology technique for 
studying the effectiveness of specific agents on the survival and proliferation of cells. It is 
frequently used in cancer research laboratories to determine the effect of drugs or radiation on 
proliferating tumor cells [50].  Although this technique can provide accurate results, the assay is 
time-consuming to set up and can only provide data on tumor cells that can grow in culture. The 
word "clonogenic" refers to the fact that these cells are clones of one another. The experiment 
involves as major steps plating the cells are in a tissue culture vessel and allowed to grow, 
production of colonies, and tratment of the formed colonies (the colonies produced are fixed, 
stained, and counted). Any type of cell could be used in an experiment, but since the goal of these 
experiments in oncological research is the discovery of more effective cancer treatments, human 
tumor cells are a typical choice. The cells either come from prepared cell lines, which have been 
well-studied and whose general characteristics are known, or from a biopsy of a tumor in a patient 
[51]. The cells are put in petri dishes or in plates which contain several circular «wells» and 
counting the cell colonies is usually done under a microscope. Figure 5 shows A549 colonies in 
untreated and 10 μM iPAdo-treated cells for 24, 48 or 72 h and maintained thereafter in culture 
medium alone until the end of the experiment. 
 
 
Figure  5. Representative plates showing A549 colonies in untreated and 10 μM iPAdo-treated cells 
for 24, 48 or 72 h. and maintained thereafter in culture medium alone until the end of the 
experiment (reported from ref. [49]).  
 
In the cited work [49], a complete suppression of clonogenic activity in 8 of the lines after 
exposure to iPAdo was observed at a concentration of 10 μM.  Specifically, iPAdo was effective 
with human lung cancer cell lines NCI-H520 and  NCI-H596, with breast cancer cell lines 
MDAMB-361 and MCF7, and  nasal septum squamous cell carcinoma cell line RPMI 2650 (Figure 
6).  
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Figure 6. Representative plates showing colony formation in untreated (top) or 10 μM iPAdo-
treated (bottom) cancer cell lines of different tissue origins (reported from ref. [49]). 
 
Human lung cancer cell lines A549 and Calu-3, hepatocellular carcinoma cell line HepG2, 
and colorectal adenocarcinoma cell line HT-29 were also examined (Figure 7). Only the cell line 
HT-29 derived from a colorectal cancer showed a significant but incomplete inhibition upon iPAdo 
treatment, with about 70% colony inhibition as compared to untreated control cells. The incomplete 
inhibition of HT-29 cell clonogenic activity might rest in reduced intracellular adenosine kinase 
activity, with a consequent slower or decreased formation of intracellular iPAdo-5'-monophosphate 
which appears to be the ultimate cytotoxic agent. [44]. Alternatively, a lower permeability of these 
cells to iPAdo, as compared to the other cell lines, cannot be excluded. 
 
 
Figure 7. Representative plates showing colony formation in untreated (top) or 10 μM iPAdo-
treated (bottom) cancer cell lines of different tissue origins. Only colorectal 
adenocarcinoma cell line HT-29 growth was not completely inhibited (reported from 
ref. [49]).  
 
Differently from the results obtained with the human myeloid leukemia cell line HL-60 [39], 
only a modest increase in apoptosis after iPAdo treatment was revealed in epithelial cancer lines 
[49]. Indeed, in lung cancer cells tumor growth suppression appears to be mediated by inhibition of 
cell proliferation due to a block of DNA synthesis rather than apoptosis. These findings are 
consistent with the reported iPAdo-induced inhibition of proliferation of rat thyroid tumour cells 
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[47]. Moreover, iPAdo is able to cause a pronounced change in the morphology of A549 cells [49]. 
This is associated to disorganization of actin fibers in the cytoplasm (Figure 8) and overall results 
suggest a stress situation for that cell line under iPAdo exposure.  
 
 
 
Figure 8. Changes in cell morphology and in distribution of actin fibers by iPAdo treatment of 
A549 cells. (a) Representative microscopic fields of A549 cells stained with 10% 
Giemsa 18 h after treatment with 0.10 or 100 µM iPAdo. (b) Untreated (left) and 100 
µM iPAdo-treated (right) cells showing fluorescence-labeled actin fibers (green) and 
DAPI nuclear staining (cyan) (reported from ref. [49]). 
 
In 2009, Laezza et al. studied iPAdo effects on DLD1 human colon cancer cells [52]. iPAdo 
suppressed the proliferation of cells through inhibition of DNA synthesis, causing a cell cycle arrest 
that correlated with a decrease in the levels of cyclins A, D1 and E with a concomitant increase in 
the levels of cyclin-dependent kinase inhibitor p21waf and p27kip1.  iPAdo induced apoptosis 
through an increase in the number of annexin V-positive cells, a downregulation of antiapoptotic 
products and caspase-3 activation. The apoptotic effects of iPAdo were accompanied by sustained 
phosphorylation and activation of c-jun N-terminal kinase (JNK) that induced phosphorylation of c-
jun. The authors concuded, that JNK could play an important role in iPAdo-mediated apoptosis in 
DLD1 human colon cancer cells.  
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1.4.2. Kinetin Riboside: in vitro antitumor activity 
Only a few, recent reports are available in literature about in vitro antitumor activity of KR. 
In the seminal work by Ishii and coll., it has been reported that KR along with iPAdo and BA were 
more potent than the corresponding N6-substituted purines for growth inhibition and apoptosis of 
human myeloid leukemia HL-60 cells [39]. It has also been reported that, at 1.5 and 0.2 μM 
concentration, KR shows cytotoxic effects on M4 Beu human and B16 murine melanoma cells. At 
these concentrations, cell growth is reduced by 50%, respectively, but there was no effect on the 
growth of mice leukaemia P388. KR is toxic at the dose of 25 mg/kg [53]. More recent results have 
shown that KR induces apoptosis in HeLa and mouse melanoma B16F-10 cells [54]. B16F10 
mouse melanoma cell line is an established model for metastasis [55, 56].  HeLa cell is a cell type in 
an immortal cell line used in scientific research. It is one of the oldest and most commonly used 
human cell lines [57]. The line was derived from cervical cancer cells taken from a patient named 
Henrietta Lacks, who eventually died of her cancer on October 4, 1951. The cell line was found to 
be remarkably durable and prolific as illustrated by its contamination of many other cell lines used 
in research [58]. It has been estimated that the total number of HeLa cells that have been propagated 
in cell culture far exceeds the total number of cells that were in Henrietta Lacks' body [59]. HeLa 
cells were used by Jonas Salk to test the first polio vaccine in the 1950's. Since that time HeLa cells 
have been used for "research into cancer, AIDS, the effects of radiation and toxic substances, gene 
mapping, and countless other scientific pursuits" [60]. According to author Rebecca Skloot, by 
2009, "more than 60,000 scientific articles had been published about research done on HeLa, and 
that number references was increasing steadily at a rate of more than 300 papers each month [61].  
The apoptotic effect of KR in HeLa and mouse melanoma B16F-10 cells was explained 
through disruption of the mitochondrial membrane potential, induction of the release of cytochrome 
c, and activation of caspase-3. Tumor growth in mice was dramatically suppressed by KR. In 
contrast, human skin fibroblast CCL-116 and bovine primary fibroblast cells show resistances to 
KR and no significant changes in Bad, Bcl-XL, and cleaved PARP were observed. Reported data 
suggest that KR selectively induces apoptosis in cancer cells through the classical mitochondria 
dependent apoptosis pathway [54]. More recent results have added information on the mechanism 
of KR-induced antiproliferation and apoptosis of cancer cell lines. It has very recently demonstrated 
that KR induced marked suppression of CCND2 transcription and rapidly suppressed cyclin D1 and 
D2 protein expression in primary myeloma cells and tumor lines, causing cell-cycle arrest, tumor 
cell–selective apoptosis, and inhibition of myeloma growth in xenografted mice [62].  
 21
In another very recent study, a hypothesis about the cytotoxic effects of KR (N6-
furfuryladenosine, FAdo) was tested [63]. KR effects may involve interference with DNA integrity 
and cellular energy status leading to stress response gene expression and cell cycle arrest. Results 
obtained from MiaPaCa-2 pancreas carcinoma, A375 melanoma, and various other human cancer 
cell lines indicate that massive ATP depletion and induction of genotoxic stress occurs rapidly in 
response to KR exposure (Table 2). This is followed by early upregulation of HMOX1, CDKN1A, 
and other DNA damage/stress response genes. These data suggest that early induction of 
genotoxicity and energy crisis are causative factors involved in KR cytotoxicity and anticancer 
activity [63]. 
 
Table 2. FAdo anti-proliferative activity against primary human skin cells and human melanoma, 
colon, and pancreas cancer cell lines. IC50 values of FAdo-induced inhibition of 
proliferation of human skin cells [primary keratinocytes (HEK) and dermal fibroblasts 
(Hs27)] and melanoma (A375, G361, and LOX), colon (HT29 and HCT116), and 
pancreas (MiaPaCa-2) cancer cell lines (mean ± S.D., n = 3) were determined in 
proliferation assays (reported from ref. [63]).  
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2. THE PhD PROJECT: BACKGROUND 
The present thesis describes the results of a research project designed in view of exploring a 
few aspects of the wide spectrum of biological activities potentially related to cytokinin ribosides. 
We have selected iPAdo and KR as the most interesting compounds, in order to study their most 
promising biological activities (Figure 1). 
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Figure 1. Structures of N6-isoPentenyl Adenosine and Kinetin Riboside 
 
A former PhD thesis within the Doctorate in Biochemistry has reported in 2009 the 
synthesis of new iPAdo analogues and the results of the evaluation of their antiproliferative activity 
in vitro [1]. Relying on these results, we intended to investigate the synthesis of other analogues of 
iPAdo with the aim of finding compounds with improved IC50 value with respect to iPAdo (in 
collaboration with Dr. T. Dragani, Istituto Tumori, Milano, Italy). Another aspect of iPAdo activity 
is related to the lack of iPAdo antitumour activity in vivo [2]. In this respect, we have evaluated the 
possibility of preparing derivatives of iPAdo that could be effectively delivered into the tumour cell. 
Additionally, we have investigated the synthesis of a few analogues of iPAdo endowed with a 
higher in vivo half-life (in collaboration with Dr. T. Dragani, Istituto Tumouri, Milano). In the 
research related to iPAdo delivery, we have used as a model for the chemical investigation KR, 
more easily available in commerce than iPAdo.  
In the following Sections, the background of the lines of the project and an outline of 
selected strategies will be reported and discussed, in order to evidence the rationale of the project of 
this PhD thesis.  
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2.1. iPAdo STRUCTURAL ANALOGUES:  ANTIPROLIFERATIVE ACTIVITY in vitro. 
In the afore-mentioned PhD thesis [1], several iPAdo have been prepared implying ribose 
modification, introduction of substituents at position 2 or substitution of N6 with oxygen (O-
isopentenyl analogues) (Figure 2). However none of these compounds presented cytotoxic activity. 
Similar negative results have been obtained preparing acyclo- analogues of iPAdo [2, 3].   
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Figure 2. iPAdo structural modifications: sugar moiety, purine base and isopentenyl chain as the 
constitutive elements for performing the feasibility studies.  
 
Sixteen analogues of iPAdo bearing different substitution at N6 have been prepared and 
iPAdo resulted the most active N6-substituted adenosine [1].  
 
2.2. isoPENTENYL ADENOSINE ANTITUMOUR ACTIVITY in vivo. 
After an early report on iPAdo inhibition of the proliferation of cells derived from human 
myelogeous leukaemia and S-180 cells [4], iPAdo was studied in vivo in order to evaluate its 
antitumour activity in animals (rodents and dogs) prior to a clinical trials [5]. Different tumours 
were implanted subcutaneously in animals at various doses depending on species (transplantable 
tumours in solid form were implanted subcutaneously following standard trocar procedures. Ascites 
tumours were inoculated i.p. (1x106 cells/mouse). iPAdo LD50 was different depending on the way 
of administration  and species (from ca. 200 to 800 mg/Kg). iPAdo inhibited in vivo the growth of 
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Erlich carcinoma ascites and leukaemia L1210, but not that of Sarcoma 180, adenocarcinoma 755,  
and Walker 256 carcinosarcoma. Various toxicological effects were observed and antiproliferative 
effects were observed in the lymphoid tissue, the gastrointestinal mucosa, and the regeneration of 
liver. iPAdo cause granulocytosis in both rats and dogs and hypotension in dogs was observed as 
well. 
In a preliminary clinical study, i.v. (30-50 mg/Kg/day) administration of iPAdo to 30 
patients with leukaemia and other forms of cancer has been followed for 1-9 weeks [6]. Among 
various clinical notes, a limited toxicity was observed and this was due to hepatic injury which was 
readily reversible. iPAdo caused haematological and clinical remission in a child with acute 
promyelocyitic leukaemia [6].  
In 1975 Mittelman et al. described a clinical study on the therapeutic use of iPAdo on 
twenty leukaemia patients who were treated daily with intravenous infusion of iPAdo [7]. Three 
unequivocal remissions were observed in this initial study. The first case was a 12 years old girl 
with a promyelocytic leukaemia. After 2 weeks of treatment with iPAdo (30mg/Kg) the result was a 
complete clinical remission consistent with a return of the appetite, weight gain and a sense of well 
being. There was a significant change even in the histological character of her bone marrow. 
Therapy was interrupted for four days with a prompt bone marrow relapse. Therapy was resumed 
and a progressive fall in the percentage of bone marrow promyelocytes and a concomitant increase 
in red cell precursors were seen. This demonstrated that chronic therapy is required for the clinical 
use of iPAdo. In the second case, a patient in the blastic phase of chronic myelogenous leukaemia 
iPAdo treatment caused the decrease of white blood cells from 20000 to 6000 and the reduction of 
blasts and promyelocytes from 25% to 1% in peripheral blood, with an improvement in a bone 
marrow. Remission was sustained for one month but prompt relapsed was seen within one week 
after the end of intra venous therapy. In a third patient with lymphatic chronic leukaemia there was 
a reduction in circulating lymphocytes only four days after the initiation of intra venous therapy 
(30-40mg/Kg daily). The reduction in total circulating lymphocytes and the percentage of 
granulocytes was maintained during the therapy. The authors described that the primary toxicity of 
iPAdo was hepatic and that all abnormalities in hepatic function regressed 48 hours after cessation 
of therapy. At the end it has been described that modified purines and pyrimidines, deriving from 
RNA turnover, were quantitatively excreted in human urine. In conclusion, although above results 
were limited in number and related to different forms of leukaemia, these findings suggested that 
iPAdo could represent a potential new anticancer drug [7].  
No additional example of in vivo anticancer activity has been reported for humans or, in 
general, mammalians up to the present. Only in 2006, the successful inhibition of a rat tumour by 
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iPAdo injected in a nude mouse directly at the tumour site has been reported [8].  Here, the effects 
on the growth of xenograft tumours induced by KiMol cells were studied.  This cell line 
corresponds to transformed FRTL-5 thyroid cells obtained by infecting the FRTL-5 cells with the 
Kirsten-Murine sarcoma virus [9]. The KiMol cells express high levels of v-K-ras protein and no 
longer require TSH for growth. Moreover, KiMol cells have lost the thyroid differentiation markers 
and have acquired the capability to grow in semisolid medium and to induce the growth of tumours 
when injected in athymic mice [10]. KiMol cells were injected s.c. into the flank of 30 athymic 
mice and after 15 days when tumours were clearly detectable, iPAdo was injected (0.5 mg/kg/dose) 
in the peri-tumoural area on days 2 and 5 of a 7-day cycle for three cycles and this treatment 
induced a significant reduction in tumour weight (80%) with respect to the control mice. No 
detectable toxic or hypolocomotor effects on the treated animals were observed.  
However, it has been later pointed out  [11] that this successful inhibition of a rat tumour 
injected s.c. in nude mice by injection of iPAdo directly at the tumour site likely reflects the more 
persistent and higher levels of the compound surrounding the tumour cells than a systemic 
administration (i.p. or i.v.) would provide. In fact, Colombo et al. have shown no in vivo activity of 
iPAdo injected intraperitoneally into female athymic Swiss nude mice inoculated with IGROV1 
cells (2.5x106 cells/mouse) [2].  IGROV1 are ovarian-carcinoma cells originating from an ovarian 
carcinoma of a 47-year-old woman and has been established in tissue culture and in nude mice [12].  
Maintained in monolayer cultures, IGROV1 cells exhibit a 20-h doubling time and highly 
tumourigenic properties. The s.c. injection of 2x106 cultured cells into nude mice gave rise to fast 
growing tumours, while the i.p. route induced a peritoneal carcinomatosis with ascites which killed 
the animals in 2 months. The epithelial morphology of IGROV1 cells was retained during in vitro 
and in vivo passages, as judged by both the light and the electron microscopes. These characteristics 
have made the IGROV1 cell line a suitable experimental model for the treatment of human ovarian 
carcinomas and for biological studies of human solid tumours (tumour xenograft assay, i.e. an in 
vivo methods of screening investigative anticancer drugs or biologic response modifiers or 
radiotherapies: human tumour tissue or cells are transplanted into mice or rats followed by tumour 
treatment regimens).  
Among many applications of IGROV1 cells, we mention a paper where a folate-based 
radiopharmaceutical has been used as imaging agent and for potential radiotherapy of folate 
receptor (FR)–positive malignant tissue (e.g., ovarian carcinomas). The γ-emitting 111In-DTPA-
folate (DTPA - diethylenetriaminepentaacetic acid) is injected in a human ovarian cancer 
xenografted mouse model, i.e. female athymic nude mice bearing subcutaneous FR-positive ovarian 
tumours as IGROV-1 [13]. SPECT/CT images are shown in Figure 3.  
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Figure 3.  SPECT/CT images of female mice bearing subcutaneous IGROV-1 tumour xenografts, 4 
h after injection of 111In-DTPA-folate in a 3-dimensional view (A–C), as coronal (D–
F) and transaxial sections (G–I). Control scan (A, D, and G), scan of a mouse co-
injected with folic acid (B, E, and H), and scan of a mouse injected with PMX 1 h 
before injection of radiofolate (C, F, and I) (reported from [13]). 
 
 
In the previously cited work [2], Colombo et al. studied also the in vitro survival of 10 
cancer cell lines, nine of which already reported [11] with the addition of the  ovarian-carcinoma 
cell lines IGROV1, that has been used for the tumour xenograft assay in vivo [2].  Figure 4 shows 
that, at concentration 10 μM, iPAdo completely inhibited the growth of IGROV1 cells as for other 
eight cell lines, being relatively not effective on HT-29 cells. 
 
 
 
 
Figure 4. Inhibition of clonogenicity after in vitro treatment of 10 human cancer cell lines of 
epithelial origin with iPAdo (compound 1) 10 μM (reported from [2]). 
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In the in vivo tumour growth assay, the potential in vivo antitumour activity of iPAdo was 
tested in nude mice inoculated i.p. with IGROV1 cells, an in vivo model that can be considered the 
most similar to an in vitro assay because i.p.-injected IGROV1 cells grow in the peritoneal cavity as 
ascites and the i.p.-injected drug quickly comes in contact with tumour cells. Female athymic Swiss 
nude mice were inoculated i.p. with IGROV1 cells (2.5x106 cells/mouse) and, starting on the same 
day, injected i.p. with  a solution of iPAdo in 0.9% NaCl solution and 5% ethanol (10 mg/kg body 
weight) for 5 days/week for 2 weeks. However, iPAdo was unable to affect mouse survival as 
compared to untreated mice, suggesting that the pharmacokinetics of the compound do not allow 
them to reach time-average concentrations comparable to those in vitro. The lack of activity might 
rest in the rapid clearance and short half-life in vivo of circulating nucleosides and, most likely, of 
circulating iPAdo.  
 
2.3. in vivo TRANSPORT OF SYNTHETIC NUCLEOSIDES 
2.3.1 Nucleoside transporter proteins 
A complex sequence of events influence the pharmacokinetic and pharmacodynamic fate of 
a nucleoside drug administered externally to a living organism. Pharmacokinetics is often studied in 
conjunction with pharmacodynamics, since pharmacodynamics explores what a drug does to the 
body, whereas pharmacokinetics explores what the body does to the drug. Pharmacokinetics 
includes the study of the mechanisms of absorption and distribution of an administered drug, the 
rate at which a drug action begins and the duration of the effect, the chemical changes of the 
substance in the body (e.g. by enzymes) and the effects and routes of excretion of the metabolites of 
the drug [14].   
In the case of a synthetic nucleoside (SN) used as an anticancer compound, the transport into 
cells is of fundamental importance for the active targeting of SN to tumour-specific cell receptors or 
antigens, that proceed at the cellular level. Most of SN are relatively hydrophilic molecules and 
their passive diffusion across biological membranes is limited. Therefore, passage of nucleosides 
across plasma membranes or between intracellular compartments occurs primarily via specialized 
nucleoside transporter proteins (NTs) [15, 16].  Once inside, they are activated by intracellular 
metabolic steps to triphosphate derivatives. In general, active derivatives of nucleoside analogues 
can then exert cytotoxic activity by being incorporated into and altering the DNA and RNA 
macromolecules or by interfering with various enzymes involved in synthesis of nucleic acids, such 
as DNA polymerases and ribonucleotide reductase (Figure 5). These actions result in inhibition of 
DNA synthesis and apoptotic cell death [17, 18].    
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Figure 5. Common characteristics in metabolism and drug–target interactions of nucleoside 
analogues (reported from [18]).  
 
 
NTs recognize most nucleoside-derived drugs used in anticancer and antiviral treatments 
and thus are pharmacological determinants that likely influence drug bioavailability and the 
consequent response to therapy [19, 20]. There is emerging evidence that the abundance and tissue 
distribution of nucleoside transport proteins contributes to cellular specificity and sensitivity to 
nucleoside analogues (NA). The consideration that each NA transport requires specific NT 
interactions helps to explain their differences in activity in various diseases [21]. 
 
Two major families, the equilibrative NTs (ENTs) and concentrative NTs (CNTs), have 
been identified by molecular cloning and functional expression of cDNAs encoding NT proteins 
from a variety of species, including mammals, protozoan parasites and bacteria [22,23]. 
In the exhaustive review dedicated to NTs [16], the functions and characteristics of the 
human NTs have been herein summarized.  Four human ENT and three hCNT subtypes have been 
identified by molecular cloning and functional expression [24-30]. hENT1 and hENT2  are found 
primarily in plasma membranes, accept both purine and pyrimidine nucleosides as permeants 
although hENT2 also transports some nucleobases (e.g., hypoxanthine) [31]. hENT3, which is also 
broadly selective, is believed to be a transporter of intracellular membranes [26, 32, 33] whereas 
hENT4 transports adenosine and monoamine neurotransmitters across plasma membranes in brain 
and cardiac tissue.  hENTs mediate facilitated diffusion of nucleosides across membranes 
bidirectionally in accordance with permeant concentration gradients, although both hENT3 and 
hENT4 exhibit enhanced activity at acidic pH, suggesting a proton-coupled transport mechanism 
[26, 34].  hCNTs transport nucleosides against their concentration gradients by coupling the inward 
transport of nucleosides to inwardly-directed electrochemical Na+ gradients. hCNT3 was shown to 
be capable of also coupling transport to protons [35]. hCNT1, 2 and 3 all accept uridine as a 
permeant but differ functionally with respect to their selectivities for other permeants. hCNT1 
prefers pyrimidine nucleosides but also transports adenosine, whereas hCNT2 prefers purine 
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nucleosides but also transports uridine [28, 29, 36, 37]. hCNT3 transport both pyrimidine and 
purine nucleosides [30].  
Due to the important role of NTs, research on structure-activity relationships of nucleosides 
and NT proteins should improve understanding of the structural determinants for nucleoside-
transporter interactions and of nucleoside translocation mechanisms. Studies of NT-mediated 
nucleoside drug uptake processes have greatly aided the understanding of drug sensitivity and 
resistance in nucleoside chemotherapy. Evidence from both in vitro and in vivo studies suggests that 
transport deficiencies contribute to clinical resistance to nucleoside drugs in some cancer cases. The 
ultimate goal is to use all the above-outlined knowledge to guide nucleoside-based chemotherapy 
[15].  
 
2.4 DRUG DELIVERY INTO CANCER CELLS 
As previously discussed, the transport of a synthetic anticancer nucleoside into cells is 
fundamental for the active targeting of SN to tumour-specific cell receptors or antigens and, due to 
the chemical structure of these compounds, their passive diffusion across biological membranes is 
limited. Therefore,  passage of nucleosides across plasma membranes or between intracellular 
compartments occurs primarily via specialized nucleoside transporter proteins (NTs), that, as 
previously observed, often require special structural reciprocal features protein/drug to be 
transported [15,16]. In alternative to natural protein transporters, the approach relying on chemical 
drug delivery plays an important role in oncology. Drug delivery methodology pain aim is to 
enhance half life of drugs and numerous research efforts have concentrated on conjugating 
anticancer drugs with a wide spectrum of low- and high-molecular-weight carriers including sugars, 
growth factors, vitamins, peptides, antibodies, polysaccharides, lectins, serum proteins, and 
synthetic polymers. In most prodrug systems the drug is bound to the carrier through a spacer that 
incorporates a pre-determined breaking point that allows the bound drug to be released at the 
cellular target site. Designing truly tumour-specific carriers remains a challenge in modern drug 
development. The molecular weight, three-dimensional structure, and immunogenic potential, as 
well as the heterogeneity of the tumour with respect to tumour marker expression, vascularization, 
and interstitial pressure influence the biodistribution of the drug carrier and dictate the amount of 
drug that reaches the target site.  
Optimizing the physicochemical properties of a given carrier is the first critical aspect of 
carrier-linked prodrug design. The second aspect relevant for the design of carrier-linked prodrugs 
is that the modification of the carrier with the drug should preserve the targeting properties of the 
carrier and ensure a controlled release of the drug inside or outside the tumour cells. The 
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predetermined breaking point introduced in the prodrugs should have sufficient stability in the 
bloodstream, yet allow the drug to be released effectively at the tumour site by enzymatic cleavage, 
reduction, or in a pH-dependent manner [38].  
Another more universal strategy exploits anomalies of malignant tissue on a 
vasculolymphatic level that directly result from the tumour’s pathophysiology. Following this 
approach, often classified as passive targeting, an accumulation of drugs in tumour tissue is simply 
achieved by employing large molecules (synthetic or biopolymers) or nanoparticles as inert carriers 
that do not necessarily interact with tumour cells but strongly influence the drug’s biodistribution. 
The underlying concept has been termed enhanced permeability and retention (EPR) and recently 
published reviews deal with mechanisms of drug transport to solid tumours including the EPR 
effect [39-42].   
At a size of 2–3 mm, tumour cell clusters induce angiogenesis to satisfy their increasing 
demands for nutrition and oxygen. The new blood vessels formed during this process often differ 
markedly from those of normal tissue. Neovasculature generated by the tumour is characterized by 
an irregular shape and dilated, leaky or defective vessels. The endothelial cells are poorly aligned or 
disorganized with large fenestrations; whereas the healthy vessel is smooth and has tight endothelial 
junctions, the tumour vessel shows widened intercellular spaces, overlapping endothelial cells, and 
other abnormalities (Figure 6). Other differences affect the perivascular cells, the basement 
membrane, and the smooth-muscle layer which are frequently absent or abnormal. These 
anatomical features make the vasculature of tumour tissue permeable to macromolecules or even 
larger nanometer-scale particles, whereas in the blood vessels of healthy tissue only small 
molecules can pass the endothelial barrier. 
 
Figure 6. Scanning electron micrographs of the luminal surface of healthy (mouse mammary gland, 
left) and tumour (MCa-IV mouse mammary carcinoma, center and right) blood vessels 
(reported from ref. [38]).  
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The pore size of tumour microvessels was reported to vary from 100 to 1200 nm in diameter 
(depending on the anatomic location of the tumour) [43, 44]. In contrast, the tight junctions between 
endothelial cells of microvessels in most normal tissues are less than 2 nm in diameter [notable 
exceptions include postcapillary venules (up to 6 nm) and the kidneys, liver, and spleen (up to 150 
nm) [45].  Macromolecules used as carriers for the development of macromolecular prodrugs 
typically have hydrodynamic radii that are >2 nm and <10 nm (e.g. serum albumin (67 kDa) has an 
effective diameter of 7.2 nm), allowing extravasation into tumour tissue but not into normal tissue. 
However, the enhanced uptake of macromolecules in tumour tissue cannot be solely explained by 
an enhanced permeability of the vascular system, as this would affect smaller molecules in a similar 
manner. A more striking difference between small and large molecules is found in the decreased 
clearance from the tumour if the molecular weight exceeds 40 kDa. [46]. When smaller molecules 
were shown to be rapidly cleared from the tumour interstitium, large molecules are retained, thus 
showing high intratumour concentrations even after 100 h post-application [47]. This enhanced 
retention of macromolecules in tumour tissue is primarily caused by a lack of lymphatic drainage 
due to an impaired or absent lymphatic system. Hence, it is the combination of both enhanced 
permeability and retention (EPR) that is responsible for the accumulation of macromolecules in 
solid tumours, as illustrated in Figure 7.  
The extent of accumulating macromolecules depends on the size and type of the tumour. 
Large tumours that usually have extensive vascular regions are less EPR active than smaller 
tumours.  
 
 
Figure 7. Schematic representation of the anatomical and physiological characteristics of normal 
and tumour tissue with respect to vascular permeability and retention of small and large 
molecules (EPR effect) (reported from ref. [47]). 
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However, because neovasculature is a prerequisite for EPR, macromolecular prodrugs are 
not capable of targeting small metastases at a pre-angiogenic stage. Furthermore, it has been found 
that transplanted tumours (e.g. in xenograft models) are often better vascularized than 
spontaneously growing tumours [45]. Other factors reported to have a positive impact on tumour 
vascular permeability are high blood pressure and certain vascular mediators such as bradykinin, 
nitric oxide, prostaglandins, matrix metalloproteinases, and peroxynitrite [47]. Besides the EPR 
effect, macromolecular prodrugs show one further important difference relative to low-molecular-
weight drugs. Macromolecules are not efficiently cleared by the kidneys and, consequently, they 
show an enhanced circulatory retention with prolonged plasma half-lives. Moreover, the appropriate 
carrier molecule has to fulfil further requirements: it should be sufficiently water soluble, nontoxic, 
non-immunogenic and should ideally be biodegradable and have low polydispersity.  As an 
example of delivery of an active chemotherapeutic in a cell-specific fashion, we report here a paper 
dealing with lung cancer-targeting peptides isolated from a peptide library placed on a pegylated 
tetrameric scaffold (Figure 8). 
 
 
 
Figure 8. The tetrameric peptide-doxorubicin conjugates designed for Cell-Specific Delivery of the 
Chemotherapeutic to Lung Cancer Cells (reported from ref. [48]). 
 
2.4.1 Gold nanoparticles for selective delivery in cancer cells 
Among different systems for the delivery of pharmacologically active compounds, gold 
nanoparticles (GNPs) have recently emerged as an attractive candidate for delivery of various 
biomolecules [49], going from polymeric macromolecules such as proteins, DNA and RNA to small 
molecules [50, 51]. This is especially relevant if small molecules are drugs, since the efficient 
release of these therapeutic agents is a prerequisite for effective therapy (Figure 9). GNPs rely upon 
their unique chemical and physical properties for transporting and unloading the pharmaceuticals 
and additional advantage is represented by the fact that the gold core is essentially inert and non-
toxic [52]. 
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Figure 9. Gold nanoparticles as efficient tools for drug delivery 
Apparently, the preparation of golden monolayer protected clusters (MPCs) is relatively 
easy and could be carried out in scalable fashion using the one-pot protocol developed by Schiffrin 
et al. (Figure 10) [53]. In this preparation, AuCl4 - salts are reduced with NaBH4 in the presence of 
the desired thiol capping ligand or ligands. The core size of the particles can be varied from 1.5 nm 
to 5 nm by varying the thiol–gold stoichiometry. The functional diversity of MPCs can be extended 
through the formation of mixed monolayer protected clusters (MMPCs) that can be synthesized 
directly or through post-functionalization of MPCs. A versatile method for the creation of MMPCs 
is the place-exchange reaction developed by Murray (Figure 10). In this protocol, foreign thiols 
displace the native ligands of MPCs in an equilibrium process. Taken together, the control of 
monolayer structure provided by nanoparticle synthesis, place displacement, and other postsynthetic 
modification methods [55] can be used to display a wide range of functionality at the particle 
surface, including biocompatible oligo(ethylene glycol) (OEG) and poly(ethylene glycol) (PEG) 
moieties [56].   
 
Figure 10. Formation of MPCs using the Schiffrin reaction and MMPCs using the Murray's place-
exchange reaction (reported from ref. [54]). 
 
. 
Drug delivery systems using GNPs may provide positive attributes to a ‘free’ drug by 
improving solubility, in vivo stability, and biodistribution. They can also alter unfavorable 
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pharmacokinetics of some ‘free’ drugs. Moreover, huge loading of pharmaceuticals on GNPs can 
become a ‘drug reservoir’ for controlled and sustained release to maintain the drug level within 
therapeutic window. For example, a gold nanoparticle with 2 nm core diameter could be, in 
principle, conjugated with about 100 molecules to available ligands (n ≈ 108) in the monolayer 
[57]. Zubarev et al. have recently succeeded in coupling of ca. 70 molecules of paclitaxel, a 
chemotherapeutic drug, to a GNP with 2 nm core diameters [58].   
For in vivo applications, the goal of nanocarriers is to arrive at the diseased tissues after 
administration into circulatory system and two approaches have been developed for targeting — 
namely ‘passive’ and ‘active’ targeting (Figure 11) [59, 60]. ‘Passive’ targeting depends on homing 
of the vectors in unhealthy tissues due to extravasation through leaky (gaps 6 of 00 nm) blood 
vessel. An important aspect of carrier systems in the 5–10 nm scale is their ability to take advantage 
of the enhanced permeation and retention (EPR) effect (Figure 11) [61]. On the other hand, ‘active’ 
targeting presents ligands on the carrier surface for specific recognition by cell surface receptors. 
The ligands could be small molecules, peptides or proteins. Combination of both types of targeting 
will render an ideal carrier for in vivo delivery. 
 
Figure 11. A schematic illustration of drug delivery via ”active” and ”passive” targeting, solid and 
dotted line respectively (reported from ref. [49]). 
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Among current methodologies of binding drugs to carriers, the disulfide linkage between the 
drug and carrier can be effective and, as an important result, one example of application in the clinic 
has been already reported [62]. One disadvantage can be the thiol–disulfide exchange that can occur 
with surface cysteines of proteins in the bloodstream, potentially creating protein–carrier conjugates 
with altered bioavailability and pharmacokinetic profiles. GNPs are expected to be resistant to 
exchange with proteins due to the steric shielding of the gold–thiol interface. Release of the thiol-
linked drug may rely on GSH-mediate exchange of –SH, due to the dramatic differential in 
intracellular GSH concentration (1–10 mM) [63, 64] versus extracellular thiol levels [65]. The 
predominant thiols in blood plasma are glutathione (2 μM) and cysteine (8 μM) [66] and this should 
favour the required –SH interchange. This GSH-mediated release of a thiolated compound bound to 
a GNP has been demonstrated using a hydrophobic dye (BODIPY) as a model of a hydrophobic 
drug [67]. The particles (core diameter ~ 2 nm) featured a mixed monolayer composed of 
tetra(ethylene glycol)ylated cationic ligands (TTMA) and fluorogenic ligands (HSBDP) (Figure 
12a). The cationic nature facilitates the crossing of cell-membrane barrier, and the fluorophore 
probes possible drug release mechanism. BODIPY-conjugated GNPs are non-fluorescent as the 
gold core quenches fluorescence via energy and/or electron transfer processes [68, 69]. The 
fluorescence signal emanates upon triggering the GNPs with GSH in cuvette, or cellular thiols in 
human liver cells (Hep G2) (Figure 12b). Controlled release of the dye was verified by treating 
mouse embryonic fibroblast cells (MEF, having ~ 50% lower intracellular GSH levels than Hep 
G2) with varying concentration of glutathione monoester (GSH-O-Et: 0,5 and 20 mM) (Figure 
12c). GSH-O-Et is rapidly internalized into cells and hydrolyzed to GSH, and hence transiently 
manipulates cellular GSH levels. 
 
Figure 12.  a) A schematic depiction of the GSH-mediated payload release via place-exchange 
reaction; b) Bright field and fluorescence micrographs of human Hep G2 cells after 
incubation with GNPs for 96 h; c) Fluorescence images showing dose-dependent release 
of the payloads (reported from ref. [49]). 
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2.5. CATABOLIC TRANSFORMATIONS OF MODIFIED NUCLEOSIDES 
A modified nucleoside has to satisfy many requirements for exerting antitumour activity and 
among these it is expected to resist to the effect of degradative enzymes or to act as specific 
inhibitors of catabolic enzymes (Scheme 1). The design of synthetic nucleosides with an augmented 
resistance towards catabolyzing enzymes can nowadays rely upon a greater understanding of the 
metabolism and mechanisms of action of modified nucleosides [18].   
 
Scheme 1. Currently applied strategies to increase the cytotoxicity of nucleoside analogue  
 
Modified nucleosides with anticancer activity like pyrimidine and purine nucleoside drugs 
already used clinically are resistant to degradative enzymes. This is the case of gemcitabine, 
cladribine and fludarabine, cladribine, and troxacitabine that are resistant to degradation by 
adenosine deaminase and cytidine deaminase, respectively (Figure 13). Another drug, eniluracil, 
inhibits fluorouracil degradation by dihydropyrimidine dehydrogenase.  
 
Figure 13. Modified nucleosides resistant to degradative enzymes 
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In the case of a modified nucleoside, specific catabolic enzymes such as purine nucleoside 
phosphorylase (PNP, EC 2.4.2.1) and adenosine deaminase (ADA, EC 3.5.4.4) can be highly 
responsible of the degradation and inactivation of most of pharmacologically active modified 
nucleosides.  ADA and PNP are two important enzymes involved in the so-called purine salvage 
pathway (Scheme 2) and can become extremely important in the complex biochemistry of cancer 
cells and related design of chemotherapeutics [70].  
 
Scheme 2. Purine salvage pathway (reported from ref. [70]). 
 
For instance, the salvage pathway may become important in tumour cells because the 
enzymes that are involved can have higher activities than the rate-limiting enzymes of de novo 
synthesis [70] and may increase in parallel with neoplastic transformation [71]. Scheme 3 contains 
a simplified representation of the inactivation a nucleosidic drug with deaminating ferment and 
purine nucleoside phosphorilase as key-biocatalysts. 
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Scheme 3. Deactivation of nucleosidic drug
a. deaminating enzyme; b. purine nucleoside phosphorylase 
  
2.5.1. Purine nucleoside phosphorylase 
Purine nucleoside phosphorylase (PNP, EC 2.4.2.1)  catalyzes the cleavage of the glycosidic 
bond of ribo- and deoxyribonucleosides, in the presence of inorganic orthophosphate (Pi) as a 
second substrate, to generate the purine base and ribose(deoxyribose)-1-phosphate (Scheme 4).  
HN
N N
N
O
OH
OH
HO
O
NH2
+ H2PO4 
-
HN
N NH
N
O
NH2
+
O
OH
OH
HO
OPO3H
 -
PNP
Keq = 0.02
 
Scheme 4. PNP-catalyzed scission of the glycosidic bond in nucleosides (reported from ref. [73]). 
 
For the natural substrates, the reaction is reversible and the equilibrium of the reaction is 
shifted in favour of nucleoside synthesis, and in the case of the mammalian enzymes, the 
equilibrium constant is ca. 50 [72]. However, in vivo phosphorolysis is highly favoured over 
synthesis, due to coupling with two additional enzymatic reactions, i.e. oxidation and 
phosphoribosylation of the liberated purine bases by xanthine oxidase and hypoxanthine±guanine 
phosphoribosyltransferase, respectively. The catalytic mechanism has been recently explained in 
more details taking advantage of X-ray crystallography, molecular modelling, and site-directed 
mutagenesis studies [73].  
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PNP is a ubiquitous enzyme of purine metabolism that functions in the salvage pathway, 
thus enabling the cells to utilize purine bases recovered from metabolized purine ribo- and 
deoxyribonucleosides to synthesize purine nucleotides (Scheme 5).  
 
 
Scheme 5. Central role of PNP in purine metabolism, salvage of purines from ribo- and 
deoxyribonucleosides. AMP deam., AMP deaminase; Guase, guanase; PRM, 
phosphoribomutase; Xan, xanthine (reported from ref. [74]). 
 
The properties, function and clinical aspects of PNPs have extensively been reviewed [74]. 
PNPs with differing specificities have been identified, and, in a number of instances, purified from a 
broad range of organisms. The majority may be tentatively assigned, on the basis of various criteria 
(Scheme 6), to two main categories. (1) Low-molecular-mass (low-mm) homotrimers, with Mr 80-
100 kDa, specific for catalysis of 6-oxopurines and their nucleosides, and some analogs. Enzymes 
of this type have been isolated from many mammalian tissues [75], and from some microorganisms 
(Scheme 6). (2) High-molecular-mass (high-mm) homohexamers, with Mr 110-160 kDa, with 
broader specificity in that they accept as substrates both 6-oxo- and/or 6-aminopurines and their 
nucleosides, and are found in microorganisms. For some of these, Ado is a much better substrate 
than inosine and guanosine, e.g., Bacillus subtilis so-called ``Ado-PNP'' [76], Klebsiella [77], and 
Sulfolobus solfataricus [78].  
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Scheme 6.  Tentative classification of PNPs from various sources, based on Mr, subunit 
composition, and substrate specificity (reported from ref. [74]).  
 
 
The natural substrates of low-mm PNPs are 6-oxopurines and their ribosides and 2'-
deoxyribosides, whereas the high-mm enzymes additionally accept 6-aminopurine (adenine) and its 
nucleosides. With the low-mm enzymes, rates of phosphorolysis and/or synthesis of Ado, if 
detectable, are well below 1% the rate for inosine [79, 80].  However, some are competitively 
inhibited by, and, hence, bind, Ado or/and Ade, as for example, the PNPs from Proteus vulgaris 
[81], and Cellulomonas [82] (Wielgus-Kutrowska et al., 1998). Several enzymes exhibit stricter 
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specificity, limited largely or exclusively to 6-aminopurines and their nucleosides, and are referred 
to as adenine nucleoside phosphorylases or Ado phosphorylases. 
 
2.5.2. Adenosine deaminase 
Adenosine deaminase (ADA, EC 3.5.4.4) catalyzes a rapid and irreversible transformation 
of adenosine to inosine (Scheme 7) [83]. The enzyme is also able to deaminate a wide range of 
structurally diverse purine nucleosides [84] and plays a key role in purine metabolic pathway as 
well as in mammalian immune system development. 
N
NN
N
N H2
O
HO
O H O H
N H
NN
N
O
O
H O
O H O H
Ad en os in e I no sin e
AD A
 
Scheme 7.  ADA-catalized conversion of adenosine to inosine 
 
Early kinetic determinations of ADA-activity with different substrates have shown that 
ADA is also able to deaminate 6-substituted purine ribosides, such as 6-chloro, 6-methoxy and 6-
hydroxyamino nucleosides, [85-87] (Scheme 8), albeit at a slower rate than adenosine. 6-Hydrazino 
riboside seems to be a substrate as well, although data are controversial due to the instability of the 
compound [88].   
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Scheme 8.  6-Substituted ribosides, substrates for adenosine deaminase 
 
ADA is able to catalyze the deamination of structurally modified purine nucleosides, [89] 
provided that a hydroxyl group is present at the 5-position [90]. In fact, adenosine 5'-deoxy 
analogues (Figure 14a) are not transformed by ADA. 
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Figure 14. Adenosine analogs: (a) 5'-deoxy- analogues of adenosine are not suitable ADA-
substrates; (b) ADA requires 5'-hydroxyl for acting as biocatalyst.  
 
 On the contrary, a steric hindrance at the positions 2 and 3 does not influence dramatically 
ADA activity that smoothly transforms 2, 3-O-isopropylidene adenosine derivatives. A methyl 
group is well tolerated at the position 5  whereas a butyl substituent dramatically slowers the 
reaction (Figure 14b) [91-93]. 
ADA is able to catalyze the deamination of several modified nucleosides presenting 
variously substituted purine ring and/or the ribose (or 2-deoxyribose, or ribose epimers) protected 
or substituted or structural variations in both the purine and furanose moieties. Many of these 
modified nucleosides find practical applications as antiviral and antitumour agents. Many other 
adenosine analogues in which the furanose has been replaced with a cyclopentane system 
(carbocyclic nucleosides) or in which part of the furanose or cyclopentane moiety has been removed 
(acyclic nucleosides) can be substrate for ADA, that represents the more active catabolic enzyme 
for a synthetic nucleoside [94].   
 
2.5.3 Adenosine Deaminase and Purine Nucleoside Phosphorylase in cancer 
 
Due to the metabolic importance of ADA and PNP, the two enzymes have been investigated 
also in pathological states and, specifically, the properties, function and clinical aspects of PNPs 
have extensively been reviewed [74]. PNP activity has been proposed as a specific marker for 
hepatic endothelial cell injury [95-97]. Abnormalities of some enzyme levels, including PNP, in the 
purine pathway have been noted in leukemic cells and malignant lymphoid tissues [98]. In various 
types of leukemia and lymphoma, PNP levels were lower, and ADA/PNP ratios significantly 
higher, relative to normal cells [99, 100].   
No significant differences in kinetic properties were noted between the PNPs isolated from 
lung and kidney tumours and those from the corresponding normal tissues [101]. Nor have any 
differences in various properties been observed between the enzymes from leukemic and normal 
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mononuclear cells, the inference being that the lower levels in the former are the result of a 
decreased rate of PNP synthesis [98]. On the other hand, the significant enhancement of PNP, as 
well as ADA and HGPRT, activities in human colon tumour tissues, appear to be related to the 
degree of tumour invasiveness [102]. The activities of adenosine deaminase (ADA) and purine 
nucleoside phosphorylase (PNP) in the cytoplasmic fraction of various cultured cell lines derived 
from human leukemias and malignant lymphomas were measured and compared in terms of cell 
lineage and differentiation of these cultured cell lines as based on cell surface markers. Generally, 
T-cell lines had higher ADA activity. Above all, two lines (P12/1chikawa and MOLT-3) which had 
the same differentiation markers as common thymocyte showed the highest ADA activity. There 
were no differences in the ADA activity among five non-T non-B cell lines, five B-cell lines and 
five normal B-cell lines. The ADA activity was lower in myeloid cell lines. No significant 
differences in PNP activity among all these cell lines were observed [103].  
2.5.4. Catabolism of isoPentenyl Adenosine  
Important information on the stability of iPAdo can be found in an early paper by Robins 
[104] after the isolation of the modified nucleoside from yeast RNA hydrolysis [105]. 
 
 
Scheme 9. Synthetic manipulations on isoPentenyl Adenosine (reported from ref. [104]). 
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When IPA was hydrolyzed in dilute acid, the free iPAdo was not obtained but rather the hydrated 
product II (Scheme 9) was formed. On continued acid treatment the hydroxyl group was expelled 
forming, presumably, a carbonium ion intermediate that undergoes ring closure forming the 
compound III. This compound was stable to acid but degraded in alkaline solution to form a product 
that appeared to be an imidazole derivative. The ready hydration of the allylic double bond under 
relatively mild chemical conditions indicates that the N6- position of the purine residue actively 
promotes reaction of the side chain. Thus, the spatial arrangement of the allylic double bond in the 
side chain and the N6- position may well play an important role in the biological function of the 
iPAdo molecule. The reactivity of the allylic double bond of iPAdo is also illustrated by the rapid 
oxidation by permanganate under very mild conditions to produce the compound VI.  
 
No clear evidence is present in the literature about the action of single catabolic enzymes on 
iPAdo. The action of ADA on iPAdo has not been reported yet and it would constitute an 
unprecedented hydrolytic process proceeding on a N6-substituted adenosine derivatives. Studying 
the degradation of iPAdo in a crude extract of tobacco tissue, Hall and collaborators observed that 
the enzyme activity that catalyzes the degradation of iPAdo was not limited to plant tissue [106]. In 
another paper, they reported the transformation of iPAdo into inosine by and enzymatic preparation 
partially purified from chicken bone marrow [107] and this enzymatic activity was found in a crude 
extract of human bone marrow [108].  
However, the adenosine aminohydrolase from calf intestinal mucosa (the enzymatic 
preparation at present commercially available from Sigma (Type II, 1–5 units/mg protein and is the 
most frequently biocatalyst used in works dealing with ADA abiotransformations [84]) was almost 
unable to convert iPAdo into inosine. The overall rate of conversion was 1/3300 with respect to 
adenosine. This result is especially important, considering N6-methyl and ethylAdo were 
deaminated by ADA [109] and, on the basis of these considerations, it was concluded that ADA 
from calf intestinal mucosa presented virtually no activity with adenosine N6-alkyl derivatives 
containing more than two carbon atoms.  
Nothing is known about PNP activity on iPAdo, although its β-glycosidic bond has been 
hydrolyzed by a nucleosidase isolated from Lactobacillus acidophilus cells   to its corresponding 
base, N-6(delta-2-isopentenyl) adenine [110]. The activity of this nucleosidase can be distinguished 
from the spleen enzyme (EC. 2.4.2.1), a purine nucleoside transferase, on the basis of its substrate 
specificity, electrophoretic behavior, and nondependence on phosphate.  The bacterial enzyme 
hydrolyzes both inosine and isopentenyl adenosine, giving Km values of 63.3 μM and 177 μM 
respectively.  This enzyme should belong to the class of nucleoside hydrolases (NHs, EC 3.2.2.1) 
that catalyze the irreversible hydrolysis of the N-glycosidic bond of β-ribonucleosides, releasing the 
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corresponding free purine or pyrimidine base and ribose [74]. These enzymes impose a stringent 
specificity for the ribose moiety but exhibit variability in their preferences for the nature of the 
nucleic base. NHs are widely distributed in Protozoa, Bacteria, yeasts, insects, Mesozoa, plants and 
recently they were found also in Archaea.  However, these enzymes are not present in mammalians 
[74]. In plants, a nucleoside hydrolase could be involved in the metabolism of iPAdo, as reported by 
Hall and coll.  [106]. Using radioactive iPAdo as a substrate, the authors detected the presence of 
enzyme activity in a crude extract of tobacco tissue that converts iPAdo into adenosine. This 
degradation (Scheme 10) can be explained through the action of two distinct enzymes present in 
plants. One of these enzymes, cytokinin oxidase/dehydrogenase (CKX), is responsible for most 
cytokinin catabolism and inactivates the hormone in a single enzymatic step; another one exerts 
strong hydrolase activity, which converts adenosine to adenine [111, 112].   
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Scheme 10. Degradation of isoPentenyl Adenosine in tobacco cells (reported from ref. [106]) 
 
 
The first report of CKX activity dates back to 1971 when Pačes et al. reported the 
conversion of labeled isopentenyladenine to adenine in crude tobacco cell culture extracts [106]. It 
is also been established that the breakdown of the active cytokinin N6-(2-isopentenyl)adenine 
(iPAde) yields adenine and an unsaturated aldehyde, 3-methyl-2-butenal (Scheme 11) [113, 114].  
 
Scheme 11. The CKX-catalyzed scission of isoPentenyl Adenine. 
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In the iPAdo degradation in tobacco cell, the N6-alkyl nucleoside is transformed into 
adenosine and a CKX should be present. Then adenosine is hydrolytically converted into adenine 
and this catabolic transformation might be catalyzed by a nucleoside hydrolase activity, as it has 
been shown for a plant enzyme recently purified and characterized [115].  
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Scheme 12. Plausible catabolic transformations of isoPentenyl Adenosine in man 
 
Our present knowledge about iPAdo catabolim in man still relies upon a seminal work that 
has been published in 1972 [116]. In this report, after intravenous administration of N6(Δ2-
isopentenyl)adenosine-8-14C (iPAdo-8-14C) to human subjects, several metabolites were isolated 
along with a small quantity of unchanged iPAdo. A large quantity of the radioactivity (50 per cent) 
was excreted in the form of non-ultraviolet absorbing compounds, suggesting saturation or cleavage 
(or both) of the purine portion of IPAdo. Orally administered iPAdo produced comparable urine 
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levels and gave a very similar metabolic picture. The ultraviolet spectra and paper chromatography 
of purified metabolites led to the identification of 6-N-(3-methyl-3-hydroxybutylamino)purine, and 
some N6-alkylated adenines and xanthines. Therefore, cleavage of the glycosidic bond iPAdo 
takes place and, since the described catabolism is human, PNP should be the phosphorylitic enzyme 
at work. A problem arises from these findings. In the purine salvage pathway PNP cleaves the 
glycosidic bond of inosine, i.e. after ADA-catalyzed deamination of adenosine. Therefore, only a 
non-specific PNP-catalyzed phosphorolys could explain the formation of N6-(Δ2isopentenyl)adenine 
(iPAde) from iPAdo. The formation of N6-(Δ2isopentenyl)xanthine can be related either to xanthine 
oxidase-catalyzed oxidation of iPAdo at the 2-position followed by a phosphorolytic cleavage 
catalyzed by the a specific PNP.  Xanthine catalyzed double oxidation of iPAdo at 2 and 8 positions 
followed by hydrolysis can explain the formation of 2,8-dihydroxy-iPAde, that could alternatively 
be formed by oxidation of N6-(Δ2isopentenyl)xanthine. The overall metabolic pathway is 
summarized in Scheme 12.  An alternative oxidation of iPAde formed by an aspecific PNP-
catalyzed hydrolysis of iPAdo  at positions 2 and/or 8 has been indirectely confirmed by the fact 
that when  iPAde  was incubated with xanthine oxidase,  a rapid oxidation, presumably, to 2,8-
dihydroxy-iPAde  was observed.  As a final observation, chemical hydrolysis of unstable 2 and/or 8 
oxidized iPAdo cannot be excluded.  
N6-(3-methyl-3-hydroxybutylamino)purine that has been found among radioactive 
metabolites could have been catabolically formed in vivo  either from the N6-isopentenyl- adenine 
or -adenosine (Scheme 13).  
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Scheme 13. iPAdo and iPAde as precursors of  N6-(3-methyl-3-hydroxybutylamino)purine 
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In addition to N6-alkyl adenines, N6-dealkylated purines such as hypoxanthine or adenine 
were also found. Radioactive uric acid that is the common ultimate oxidation product of purine 
nucleosides could not be detected and no increment of uric acid level was observed after ingestion 
of iPAdo. It is possible to speculate that degradation of the isopentenyl chain is possible in vivo, but 
only starting from N6-alkyl adenines and not from N6-alkyl adenosines that should produce uric acid 
as the final product of the purine salvage pathway. 
The catabolism of iPAdo in cancer cell cultures has been examined by a few authors.  In one 
report [117] it has been shown that iPAdo, at a concentration of 3 μM inhibits the growth of a line 
of cells derived from the circulating leukocytes of a patient with myelogenous leukemia (Roswell 
Park Memorial Institute line 6410). iPAdo could not be detected as a nucleoside free in the cells or 
culture medium, and an explanation is that 6410 cells contain an enzyme activity that converts 
iPAdo to the corresponding base, which is much less toxic to these cells.  In another report [118], 
twenty-one cell lines (among them, six human lines and nine mouse lines) were compared with 
respect to inhibition of growth by iPAdo. Six of these [mouse Sarcoma 180, Ehrlich ascites 
carcinoma, mammary adeno carcinoma (TA3), leukemia Ll210, mouse kidney, and canine kidney 
cells], differed by up to 16-fold with respect to their sensitivity and were chosen for further study. 
In these resistant cells iPAdo was cleaved further to the free base, iPAde, which accumulated in the 
medium. The rate of formation of iPAde constitutes an indication on irreversible inactivation of 
iPAdo, because iPAde does not present growth inhibitory.  
The importance of the catabolic inactivation of iPAdo through the oxidative pathways 
outlined above cannot exclude the involvement of non-specific biochemical oxidations. In this 
respect it should be reminded that the cytochrome P450 superfamily of hemoproteins (CYP) could 
become relevant, due to CYP involvement in the oxidative metabolism of a wide variety of 
xenobiotics and endogenous compounds [119]. The oxidative metabolism generally transforms 
drugs into more hydrophilic products and this decrease in lipophilicity, ostensibly reduces the 
retention, and enhances the rate of clearance and excretion of a compound, so that the P450s 
contributes to the clearance of over 70% of drugs cleared by metabolism. Of the 57 cytochrome 
P450 proteins encoded by the human genome, nearly 15 are involved in the metabolism of drugs 
and other xenobiotic chemicals. Only five, however, are responsible for the oxidative metabolism of 
95% of all drugs (CYPs 3A4, 2D6, 2C9, 2C19, 1A1/2). CYP3A4 and CYP2C9 account for 46 and 
12% of all drug oxidative metabolism, respectively and CYP2C19 and CYP2D6 each account for 
about 12%.  Although P450s are distributed widely throughout most tissues, the liver contains the 
greatest concentration of those P450s that oxidize drugs efficiently. P450s exhibit broad substrate 
tolerance as versatile catalysts while at the same time demonstrating comparatively high Km for the 
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substrates. Although many enzymes exhibit partially overlapping of substrate specificities, it has 
become apparent that a single P450 may be exclusively or primarily responsible for the detoxication 
or bioactivation of a particular compound [120].  
Among various involvements of metabolic enzymes, in Section 1 the hypothesis has been 
reported that in one cancer cell line the modest antiproliferative effect of iPAdo could be related to 
a slow or low intracellular activity of adenosine kinase. This should lead to slower or decreased 
formation of intracellular iPAdo-5'-monophosphate (iPAMP) which is thought to be the ultimate 
responsible of the cytotoxic activity (Scheme 14) [121]. 
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Scheme 14. iPAdo-5'-monophosphate, a presumable responsible for iPAdo cytotoxic 
activity 
  
Alternatively, a higher activity of the enzyme that degrades iPAMP could lower the 
concentration of the cytotoxic agent and the related antiproliferative effect. The enzyme involved in 
the catabolism of iPAMP could correspond to a 5'-nucleotidase, a hydrolytic enzyme that catalyzes 
the hydrolysis of a nucleotide into a nucleoside and a phosphate. For example, it converts adenosine 
monophosphate to adenosine, and guanosine monophosphate to guanosine. These enzimes can be 
classified into various kinds depending on their substrate preferences and subcellular localization 
[122]. Membrane bound 5'-nucleotidases displays specificity towards adenosine monophosphates 
and are predominantly involved in the salvage of preformed nucleotides and in signal transduction 
cascades involving purinergic receptors. Soluble 5'-nucleotidases are further subclassified in 
mitochondrial (mdN) and cytosolic nucleotidases (cN). cN-I is characterized by its affinity towards 
AMP as its substrate. cN-II is identified by its affinity towards either IMP (inosine monophosphate) 
or GMP (guanosine monophosphate) or both. cN-III is a pyrimidine 5' nucleotidase.  The 5'-
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nucleotidases are also involved in and drug metabolism [122] and serum level of the enzyme is 
reported to be elevated in different cancers [123, 124]. Increased ecto-5'-nucleotidase (ecto-5'NT) 
protein expression in several multidrug-resistant (MDR) cell lines has been also demonstrated 
[125].    
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3. THE PhD PROJECT 
From the background reported in Chapters 1 and 2, it can be concluded that iPAdo is able to 
inhibit in vitro cell proliferation, but lacks in vivo antitumor effect. Further studies are needed to 
identify active analogues with improved in vitro activity and potentially useful in vivo.  For this 
purpose, the PhD project has moved in three main directions. 
3.1. isoPENTENYL ADENOSINE DELIVERY INTO CANCER CELLS 
We intended to explore a delivery system that could preferentially direct iPAdo or its 
analogues to tumour cells. This approach might show therapeutic efficacy as well as reduced 
systemic toxicity.   
Starting from the great potentiality of gold nanoparticles (GNPs) illustrated in the Section 2, 
we have selected them for the delivery of iPAdo in cancer cells. For this purpose, iPAdo should be 
bound to a thiol-containing compound in such a way that the whole nucleoside derivative would 
bind an atom of gold, giving rise to a colloidal nanoparticle (Scheme 1). The choice of this program 
was related to the opportunity offered by a collaboration with Prof. Francesca Porta and Dr. Zelijca 
Krptevic (Department of Inorganic, Metallorganic and Analitical Chemistry -University of Milan) 
that had already reached a good experience in the preparation of gold nanoparticles [1, 2] and were 
interested to develop a program aimed to exploit the potentiality of the selective entrance of GNPs 
into cancer cells [3]. 
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Scheme 1. Our strategy for grafting dihydrolipoate bound to drug (iPAdo) to GNPs  
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Therefore, the first part of the project of the present PhD thesis has been aimed to the 
preparation an ester linkage between the 5'-hydroxyl of iPAdo and lipoic acid (LA) [LA-iPAdo]. 
LA presents the required structural framework for binding to iPAdo, whereas reduction of LA-
iPAdo at the disulfide moiety should furnish a good dithiol linkage to Au atoms, as a prerequisite 
for the formation of GNPs (Scheme 1). 
 
3.2. iPAdo ANALOGUES RESISTANT TO CATABOLIC TRANSFORMATIONS 
 
Previous results have shown that a main requirement for iPAdo in vitro activity is the 
integrity of the ribose moiety and only a limited number of modifications at the N6-substitution 
result in active iPAdo analogues [4]. However, none of the N6-modified nucleosides were as active 
as iPAdo. The number of compounds that could be designed is so wide that we have selected only a 
few structures that could be prepared in a reasonable time within the second-third year of the PhD 
project. Therefore, in this part of the PhD program we had the aim to prepare only a few N6-
isopentenyl adenosine analogues with the aim to find compounds with improved IC50 value with 
respect to iPAdo and endowed with a higher in vitro activity. This part of the project relied on the 
collaboration with Dr. T. Dragani (Istituto Tumori Milano).  
The synthesis of iPAdo analogues designed to prevent metabolic transformation of the 
compound that could deactivate iPAdo was also considered. Catabolic processes could constitute 
one of the more important causes of lack of in vivo activity. However, in vivo activity requires time- 
consuming procedures and expensive experiments with living animals. For this reason, new 
analogues were expected to show an in vitro activity similar or much better than that of iPAdo and 
this has been fixed as a prerequisite for the set-up of demanding in vivo experiments.  From the 
observations on iPAdo metabolism reported in Section 2, the plausible catabolic transformations of 
the compound could involve the isopentenyl chain transformations, the cleavage of the β-glycosidic 
bond and the oxidation of the purine positions 2 and/or 8 (Figure 1).  
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Figure 1. iPAdo: points of catabolic modifications 
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3.3. ASSAYS ON CANCER CELLS 
 3.3.1. Human breast cancer cell lines: MCF-7 and MDA-MB-231 
The mechanism by which a compound that inhibits the proliferation of a cancer cell can be 
better studied in vitro where the other physiological regulatory mechanisms, which are present in 
the in vivo system, are absent. In vitro studies provide the advantages, from an experimental point 
of view, of being able to observe cells and tissues in isolation and away from the controlling and 
modifying influences of other tissues in the body. The human breast cancer cell (BCC) line MCF-7 
provides an unlimited source of homogenous self-replicating material, free of contaminating 
stromal cells, and can be easily cultured in simple standard media. Such a cell line is ideal to study 
the interaction between a chemopreventive drug and a cancer cell.  
For above-mentioned observations, in the present thesis we have limited the assays of the 
antiproliferative activity of compounds prepared by us mainly to breast cancer cells. Only 
occasionally, a colon cancer cell line has been considered, since DLD1 cell line has been used for a 
study on the effect of iPAdo on cell cycle arrest and apoptosis in human adenocarcinoma colon 
cancer [5]. The colon cancer cell line available for our investigations is the HT-15 line that is 
derived from a colorectal carcinoma as DLD1, but is characterized by different chromosome 
changes but the same genetic origin [6].   
We have selected MCF-7 and MDA-MB-231 as the BCC lines, in consideration of the fact 
that MCF-7 and two other lines, namely T-47D and MDA-MB-231, account for more than two-
thirds of all abstracts reporting studies on mentioned BCC lines, as concluded from a Medline-
based survey [7]. The main work in the frame of the current thesis has been done with MCF-7 cell 
line. 
MCF-7 cancer line was isolated in 1970 from a 69-year-old Caucasian woman. MCF-7 is the 
acronym of Michigan Cancer Foundation -7, referring to the institute in Detroit where the cell line 
was established in 1973 by Herbert Soule and co-workers [8]. The patient, whose name is unknown 
to the vast majority of cancer researchers, died in 1970. Her cells were the source of much of 
current knowledge about breast cancer [9]. Her name was Frances Mallon, and she was at the time 
of sampling nun in the convent of the Immaculate Heart of Mary (Monroe, Michigan) under the 
name of Sister Catherine Frances. MCF-7 cells have been isolated from the pleural effusion of a 
primary tumor (invasive breast ductal carcinoma) and give a proliferative response to estrogens. 
They are characterized by the presence of estrogen and progesteron receptors, causing 
tumorigenicity in mice only with estrogen supplementation.  This cell line retained several 
characteristics of differentiated mammary epithelium including the ability to process estradiol via 
cytoplasmic estrogen receptors and the capability of forming domes. Tumor necrosis factor alpha 
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(TNF alpha) inhibits the growth of MCF-7 breast cancer cells. It has been well established that the 
MCF-7 cell line is a tool for the study of breast cancer resistance to chemotherapy, because it 
appears to mirror the heterogeneity of tumor cells in vivo [10]. Numerous similarities have long 
been found between cell lines and tumors. Recent technical advances, including the use of micro-
array and comparative genetic analysis have established the fact that breast cancer cell lines like 
MCF-7 reflect, to a large extent, the features of breast cancer cells in vivo. It has already been 
proved that breast cancer cell lines are considered as representative models of transformed cells in 
vivo [7].  
An additional  reason of the interest in MCF-7 cell line is related to the possibility to use 
technologies that facilitate the study of biological processes in vivo such as in vivo molecular and 
cellular imaging, that combine molecular biology with imaging modalities as a means to real-time 
acquisition of functional information about disease processes in living systems. One of these 
techniques of molecular imaging is in vivo bioluminescence imaging (BLI) that throws a real light 
on the complex molecular and cellular events leading to uncontrolled cellular proliferation and 
eventually tissue destruction and metastases [11]. Differently from the in vitro examination of 
cultured tumour cells that permit the molecular dissection of early pathways in tumorigenesis on 
cellular and subcellular levels, by molecular imaging techniques the interrogation of these processes 
within the complexity of organ systems of the living animal can reveal the full range of 
pathophysiological changes that occur in neoplastic disease [12]. For instance, Human DU-145 
prostate and MCF-7 breast tumor cell lines were stably transfected with plasmid pcDNA3.1-Luc 
expressing firefly luciferase [13]. The transfected cell lines were studied in order to evaluate 
luminescent imaging for measuring the efficacy of anti-cancer agents (Figure 2). In vitro 
experiments demonstrated a dose response of both cell lines to topotecan (Hycamtin®) with an IC50 
of 0.013 μM for MCF-7 Luc cells and 0.002 μM for DU-145 Luc cells. In vivo imaging experiments 
were performed using athymic nude mice inoculated i.p. with 5×106 MCF-7 cells or s.c. with 5x106 
DU-145 cells and then treated with topotecan at 2.5 mg/kg body weight. Tumor progression and 
regression were monitored for 27 days. Animals inoculated s.c. with DU-145 Luc cells and then 
treated with topotecan demonstrated significant tumor growth and regression as measured with 
callipers and luminescent imaging.  
High correlation was observed between calliper and imaging results. The correlation 
coefficient was 0.75 for the control untreated group and 0.93 for the topotecan-treated group. 
Similarly, tumour progression and regression were measurable using luminescent imaging for 
untreated and topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. These data indicate that 
luminescent imaging is a useful tool for evaluating anti-cancer drugs in vivo and may prove to be 
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particularly useful for the development of novel agents. Luminescent imaging could also be used to 
locate and harvest residual tumors in drug-treated animals in order to study mechanisms of drug 
resistance.  
 
 
Figure 2. Representative imaging results on days 6, 12, 16 and 20 for mice treated with topotecan 
(2.5mg/kg) or PBS on days 9, 13, 17 and 21 after i.p. inoculation of 5x106 MCF-7 Luc 
cells. (A–D) Imaging results for a mouse treated with topotecan. (E–H) Imaging results for 
a control PBS-treated mouse (reported from ref. [13]). 
 
MCF-7-luc-F5 is a luciferase expressing cell line that was derived from MCF-7 human 
mammary adenocarcinoma cells by stable transfection of the North American Firefly Luciferase 
gene expressed from the CMV promoter. This cell line is commercially available and, since MCF-7 
cells have been isolated from the pleural effusion of a primary tumor (invasive breast ductal 
carcinoma) and give a proliferative response to estrogens, MCF-7-luc-F5 can be used in vivo to 
establish estrogen dependent tumor growth for mammary fat pad orthotopic model using techniques 
of bioluminescense (Figure 3).  
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Figure 3. Orthotopic Growth of Breast Tumor Cells: studies with MCF-7-luc-F5 cells via the 
techniques of bioluminescense (reported from ref [14]).   
 
Using the same imaging system, in vivo imaging revealed metastases in the thoracic region, 
while end point ex vivo imaging confirmed metastases in the lungs, forelimbs, and brachial lymph 
node (Figure 4).  
 
Figure 4. MCF-7-luc-F5 cells: in vivo metastasis signals are confirmed via imaging in the 
thoracic area, lungs, forelimbs, brachial lymph node (reported from ref. [14]. 
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The MDA-MB-231 breast cancer cell line was obtained from pleural effusions of a Caucasian 
breast cancer patient in 1973 at M. D. Anderson Cancer Center [7]. As above-mentioned, it plays an 
important role in finding new solutions in fighting against breast cancer invasion. It has been 
recently used in a detailed study regarding the involvement of chemokine receptors in breast cancer 
metastasis [15]. As a result of this joint research, it was found, that chemokines and their receptors 
have a critical role in determining the metastatic destination of tumour cells. Induction of apoptosis 
in breast cancer cells MDA-MB-231 by genistein - a prominent isoflavonoid in soy products, has 
been lately reported [16]. These authors investigated the effects of genistein on cell growth and 
apoptosis-related gene expression in breast cancer cells MDA-MB-231. They found up-regulation of 
Bax and p21WAF1 expressions and down-regulation of Bcl-2 and p53 expression in genistein-treated 
cells. Furthermore, DNA ladder formation, CPP32 activation, and PARP cleavage were observed after 
treatment with genistein, indicating apoptotic cell deaths. From the obtained results it was concluded on 
genistein potentiality as effective chemopreventive or therapeutic agent against breast cancer.  
In vivo imaging is successfully applied with MDA-MB-231 cells too, along with MCF-7 cell 
line. MDA-MB-231-luc-D3H2LN is a luciferase expressing cell line that was derived from MDA-
MB-231 human adenocarcinoma cells by stable transfection for the North American Firefly 
Luciferase gene expressed from the SV40 promoter. MDA-MB-231-luc-D3H2LN cells are derived 
from a spontaneous lymph node metastasis from a D3H1 mammary fat pad tumor. This cell line can 
be used in vivo to establish experimental metastasis model (intravenous) and intracardiac (Figure 5) 
and orthotopic mammary fat pad model with metastasis (Figure 6) [14, 17-20].  
 
Figure 5. Intracardiac injection: experimental metastasis (reported from ref. [17]).  
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For the investigation of experimental metastasis via intracardiac injection the following 
protocol was employed: MDA-MB-231-luc-D3H2LN cells (1x105) were injected into the left 
ventricle of female nude mice (n=8). Mice were imaged weekly from dorsal and ventral views for 5 
weeks. Selected tissues were imaged ex vivo to confirm in vivo signals. It was established that 
metastatic signals begin to appear after 2 weeks. By week 3, metastases were detected in vivo in 
100% of mice (8/8) to multiple sites. 
 
Figure 6. Orthotopic Mammary Fat Pad Tumor Growth-Nude beige mice (CR) (reported from 
[17]).  
 
The following experimental procedure was used for the detection of metastatic signals after 
orthotopic injection of luminescent MDA-MB-231 cells: MDA-MB-231-luc-D3H2LN cells 
(2x106) were injected orthotopically into the abdominal mammary fat pad of female nude mice 
(Harlan) (n=8). Mice were imaged weekly for five weeks from the ventral view. Primary tumors 
were shielded in order to detect low signals from secondary metastases. Selected tissues were 
analyzed by ex vivo imaging and processed for subsequent histology. It was concluded, that 
metastatic signals begin to appear after 3-4 weeks. By week 4, lymph node metastases were 
detected in vivo in 100% (8/8) of mice. Subsequent histopathology confirmed metastases in 5/8 
lymph nodes.  
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4. EXPERIMENTAL. Materials and Methods 
 
 
Melting points were determined with a Stuart Scientific SMP3 melting point apparatus and 
left uncorrected. 
NMR spectra were registered on a Bruker AVANCE 500 spectrometer equipped with a 5 
mm broadband reverse probe with field z-gradient operating at 500.13 and 125.76 MHz for 1H and 
13C, respectively. All NMR spectra were recorded at 298 K in CDCl3 (isotopic enrichment 99.95%) 
or CD3OD (isotopic enrichment 99.95%) or DMSO-d6 (isotopic enrichment 99.95%) solution and 
the chemical shifts were reported on a δ (ppm) scale and coupling constants (J) are given in Hertz. 
The central peak of CDCl3 signals (7.26 ppm for 1H and 77.7 ppm for 13C) and of CD3OD signals 
(3.31 ppm for 1H and 49.1 ppm for 13C) and of DMSO-d6 (2.49 ppm for 1H and 39.50 ppm for 13C) 
were used as internal reference standard. The usual NMR descriptions are used, as follows: s, 
singlet; d, doublet; t, triplet; q, quartet; m, multiplet, br. s, broad singlet and br. m, broad multiplet). 
The assignments were confirmed with two-dimensional 1H,1H (COSY) or 1H,13C (HSQC, HMBC) 
experiments using standard Bruker pulse programs. When reported, the 15N chemical shifts were 
measured with respect to external 1M urea in DMSO-d6, and converted to the δ 15N (liq. NH3) = 0 
ppm scale, using the relation: δ 15N (urea) = δ 15N (liq. NH3) + 77.0 ppm. The uncertainties in the 
measurements of 15N chemical shifts are ±0.5 ppm. The assignment of numbers to the N6-
substituent atoms is performed as described in literature [1-3]. The reactions progress was 
monitored by analytical thin-layer chromatography (TLC) on pre-coated glass plates (silica gel 60 
F254, Merck) and the products were visualized by UV light. The elemental analyses of all 
synthesized compounds were determined by standard microanalysis on Vario-EL-III-CHNOS 
Elemental Analyzer and are within ± 0.4% of theoretical values. All the reagents and solvents were 
purchased from Sigma-Aldrich. Chemicals were of commercially available reagent grade, and used 
without further purification.  
Experimental details on chemical synthesis, bioactivity assays on MCF-7, MDA-MB-231 
and HL-60 cell lines, as well as docking experiments on adenosinic receptors: hA3 and hA2b are 
given in subsequent sections. 
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5. RESULTS, DISCUSSION and EXPERIMENTAL PROCEDURES 
5. 1.  GOLD NANOPARTICLES FOR isoPENTENYL ADENOSINE SELECTIVE 
DELIVERY INTO CANCER CELLS 
 
In order to enhance iPAdo in vivo activity, a suitable delivery system should be envisaged 
that could preferentially direct iPAdo or its analogues to tumour cells. We decided to exploit the 
great potentiality of gold nanoparticles (GNPs), considering their unique chemical and physical 
properties [1] for transporting/unloading pharmaceutically active compounds. The interest in GNPs 
is reinforced by the consideration that the gold core is essentially inert and non-toxic as recently 
suggested examining nanoparticle library consisted of gold spheres with average diameters of 4, 12, 
or 18 nm and containing a variety of surface modifiers [2]. Wyatt et al. have been tested the 
nanoparticle library for cytotoxicity using the K562 leukemia cell [2]. The 18-nm nanoparticle 
preparations with citrate and biotin surface modifiers did not appear to be toxic at concentrations up 
to 250 µM (gold atoms) under these conditions (Figure 1A).  
 
 
Figure 1.  Survival curves for human K562 cells exposed to nanoparticles. Cells were continuously 
exposed to nanoparticles for 3 days. Cell viability was measured by the MTT assay. The 
data are plotted as the percentage of surviving cells compared to untreated controls 
(reported from ref. [2]). 
 
In contrast, the gold-salt precursor (NaAuCl4) solution was over 90% toxic at a 
concentration of 200 μM. The nanoparticle preparations with glucose or cysteine surface modifiers, 
or with a reduced gold surface, were not toxic at concentrations up to 25 μM. Also 18-nm 
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nanoparticles were examined containing citrate, biotin, and the cytotoxic cetyltrimethylammonium 
bromide (CTAB) as surface modifiers. These nanoparticles displayed a toxicity similar to that of 
CTAB (Figure 1B). It was thus necessary to determine whether unbound CTAB or the CTAB-
modified nanoparticles caused the observed cytotoxicity. Therefore, CTAB-modified nanoparticles 
were centrifuged and washed with deionized water three times to remove unbound CTAB. The 
washed CTAB-modified nanoparticles were found to be not toxic under the conditions examined, 
which suggests that CTAB bound to the gold nanoparticles does not cause toxicity (Figure 1B). 
NMR studies of the washed CTAB-modified nanoparticles indicated that all of the remaining 
CTAB was associated with the nanoparticles. 
The lack of detectable cytotoxicity raised the question whether the nanoparticles were 
capable of being taken up into the cells or no. The cells were exposed to 18-nm citrate-capped 
nanoparticles at a concentration of 25 μM for time points from 15 min to 24 h. The presence in cells 
of the 18-nm citrate-capped gold nanoparticles was confirmed by transmission electron microscopy 
(TEM) of the cells following exposure. Figure 2A and B shows electron micrographs at different 
magnifications of a cell that contains gold nanoparticles following exposure (to 18-nm citrate-
capped nanoparticles) for 1 h. The nanoparticles are clustered in a subcellular location that could be 
endocytic vesicles, although further experiments would be necessary to conclusively demonstrate 
this. Interestingly, the images taken at higher magnifications show that the gross morphology of the 
nanoparticles has not changed dramatically, that is, the nanoparticles appear as 18-nm spheres even 
after being taken up by the cells (Figure 2B).  
 
 
Figure 2. Electron micrographs at different magnifications of a cell containing nanoparticles 
(reported from ref. [2]). 
 
Among the conventional methods of synthesis GNPs by reduction of gold(III) derivatives, 
the most popular one for a long time has been that using citrate reduction of HAuCl4 in water, 
which was introduced by Turkevitch in 1951 [3]. It leads to GNPs of ca. 20 nm. In an early effort 
[4] to obtain GNPs of pre-chosen size (between 16 and 147 nm) via their controlled formation, a 
method was proposed where the ratio between the reducing/stabilizing agents (the trisodium citrate-
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gold ratio) was varied. This method is very often used even now when a rather loose shell of ligands 
is required around the gold core in order to prepare a precursor to valuable AuNP-based materials. 
Recently, a practical preparation of sodium 3-mercaptopropionate-stabilized AuNPs was reported in 
which simultaneous addition of citrate salt and an amphiphile surfactant was adopted; the size could 
be controlled by varying the stabilizer/gold ratio (Figure 3) [5].  
 
 
 
Figure 3. Procedure for preparing anionic mercaptoligand-stabilized GNPs in water (reported from 
ref. [5]). 
  
 
The Brust-Schiffrin method for GNPs synthesis, published in 1994, has had a considerable 
impact on the overall field in less than a decade, because it allowed the facile synthesis of thermally 
stable and air-stable AuNPs of reduced dispersity and controlled size for the first time (ranging in 
diameter between 1.5 and 5.2 nm). Indeed, these AuNPs can be repeatedly isolated and re-dissolved 
in common organic solvents without irreversible aggregation or decomposition, and they can be 
easily handled and functionalized just as stable organic and molecular compounds. The technique of 
synthesis is carried out in a two-phase system and uses the thiol ligands that strongly bind gold due 
to the soft character of both gold and sulphur [6, 7]. AuCl4- anions are transferred to toluene using 
tetraoctylammonium bromide as the phase-transfer reagent and reduced by sodium borohydride in 
the presence of dodecanethiol. The organic phase changes color from orange to deep brown within a 
few seconds upon addition of sodium borohydride. The overall sequence of reactions is summarized 
below.  
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The use of gold nanoparticles as biological probes requires a high stability of the colloidal 
state. Although the nature of the bonding of the thiol group on the gold nanoparticle surface is not 
yet fully understood, the interaction between gold and sulfur atoms is sufficiently strong to allow 
immobilization of thiolated species [8, 9]. Their presence on the particles significantly limits the 
aggregation and improves the stability of the colloidal suspension of gold nanoparticles [6, 7, 10, 
11]. Unfortunately, a partial desorption of thiolated species [12] and/or a partial replacement by 
ligand exchange [13, 14] are commonly observed during the aging or in biological media. This 
phenomenon, if it is not controlled, is detrimental for the colloid stability and consequently for 
biological applications [15]. In this respect, it has been suggested that the preparation of gold 
nanoparticles could be successfully carried out in the presence of disulfide species [16]. However, 
in addition to the instability of the dialkyl disulfide adsorption state on gold (vide supra), the S-S 
bond is sensitive to the presence of reducing agents such as sodium borohydride (used for gold 
nanoparticles synthesis) [17, 18].  
To avoid a competition between the reduction of gold salt and thioctic acid (TA), the 
replacement of TA by its reduced form DHLA (a dithiolated molecule) was a good altenative, since 
DHLA has been used to displace trioctylphosphine oxide grafted on CdS/CdSe nanoparticles. As a 
consequence, the nanoparticles became soluble in water and behaved as an electrostatic anchorage 
site for proteins [19]. Thus dihydrolipoic acid (DHLA) appeared very attractive for the stabilization 
and the further functionalization of gold nanoparticles, also considering that in DHLA the ionizable 
carboxylic acid groups ensure, for pH 8, the water solubility of DHLA-capped gold nanoparticles. 
These GNPs can be prepared by the Brust protocol [6, 7, 20] and the stability of the resulting 
colloid is reinforced by electrostatic repulsions.  
Moreover, it cannot be excluded that DHLA obtained by reduction of TA could be adsorbed 
onto gold through a dithiol linkage, not excluding a mono-thiol binding or even absorption of the 
disulfide bridge of LA onto gold (Scheme 1).   
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Scheme 1. The Grafting Mode of Dihydrolipoic Acid or Thioctic Acid on Gold Nanoparticles 
 
It has been proved by sulfur K-edge X-ray absorption near edge structure spectroscopy, an 
appropriate tool for determining the chemical form of sulfur atoms present in the organic 
monolayer, that DHLA is anchored to gold thanks to both sulfur ends [21]. Such a grafting renders 
the DHLA monolayers more resistant to displacement by dithiothreitol than mercaptoundecanoic 
acid monolayers. The presence of DHLA on gold particles allows their functionalization by the 
electroluminescent luminol through amine coupling reactions assisted by 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide. As a 
luminol-functionalized particle is nine times as bright as a single luminol molecule, the use of the 
particles as a biological probe with a lower threshold of detection is envisaged [22].   
5.1.1. Binding Lipoic Acid to isoPentenyl Adenosine for the preparation of gold nanoparticles 
 
On the basis of all previous observations, we decided to study synthetic methods that could 
allow us to covalently bind iPAdo to lipoic acid with the ultimate goal of prepare gold nanoparticles 
(GNPs) as suitable delivery system for iPAdo selective transport into cancer cells. This approach 
could solve the problem of the absence of in vivo activity of iPAdo as antiproliferative agent. LA 
could be reduced to DHLA in the presence of sodium tetrachloroaurate and sodim borohydride and, 
at pH>7, water-soluble DHLA-capped gold (Au@DHLA) nanoparticles could be obtained [20].   
According to the procedure reported for the coupling of luminol to Au@DHLA [22], the 
immobilization of luminol on GNPs may be performed by the formation of amide linkage through 
the condensation between the amino group of the luminol and the carboxylic acid of DHLA 
adsorbed on gold. Amide coupling reactions may be accomplished in aqueous solutions by several 
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well-known protocols, e.g. by using a water-soluble carbodiimide. This approach is outlined in 
Scheme 2.  
However, we preferred a different strategy that seemed more versatile and promising. We 
considered the synthesis of the 5'-O-ester of iPAdo with LA (Scheme 3). This ester could be used 
as such to be absorbed onto Au@citrate water-soluble nanoparticles (Scheme 4) or reduced in the 
presence of NaAuCl4 to form Au@DHLA- iPAdo nanoparticles (Scheme 5). 
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Scheme 2. Approach for coupling isoPentenyl Adenosine to Au@DHLA nanoparticles 
 
N
NN
N
HN
O
OH
OHHO
iPAdo
HOOC
S
S
N
NN
N
HN
O
O
OHHO
O
S
S
DCC
Lipoic Acid
 
Scheme 3. Synthesis of 5'-O-Lipoyl isoPentenyl Adenosine 
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Scheme 4. Grafting 5'-O-Lipoyl isoPentenyl Adenosine to Au@citrate nanoparticles 
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Scheme 5. Preparation the Au@DHLA-iPAdo nanoparticles via NaAuCl4-assisted reduction of 5'-
O-Lipoyl isoPentenyl Adenosine  
 
Independently on the adopted strategy for the preparation of GNPs, the synthesis of iPAdo 
5'-O-Lipoate was required. This 5'-O-ester of iPAdo could be, in principle, prepared by two main 
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approaches. The first approach consisted in the reaction of LA or of suitable derivatives at the 
carboxylic moiety with the 5'-hydroxy group. The formation of the ester linkage could be realized 
chemically or enzymatically on iPAdo only if the reaction proceeds selectively at the mentioned 
position (Scheme 6). 
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Scheme 6. isoPentenyl Adenosine esterification: fighting for desired selectivity at 5'-position 
 
Should the first approach reveal unsuccessful or modest selectivity, the 2'- and 3'-hydroxyls 
must be protected. A great number of these protections are potentially available in the chemistry of 
nucleosides, but we selected the isopropylidene group. The iPAdo derivative could be prepared 
either from iPAdo or from commercially available   2', 3'-O-isopropylidene adenosine, once the N6-
amino group could be alkylated with isopentenyl bromide. 2', 3'-O-Isopropylidene iPAdo could 
safely react with LA and the obtained derivative later hydrolized to afford required iPAdo-5’-O-
Lipoate (Scheme 7).  
 
5.1.2. Kinetin Riboside 5'-O-Lipoate as model compound: synthetic strategy 
Both approaches to 5’-O-Lipoyl iPAdo outlined in Schemes 6 and 7 were considered worth 
of investigation but, due to the high price of commercial iPAdo, we concentrated our synthetic 
efforts on less expensive and more easily available Kinetin Riboside (KR) (Figure 4).  
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Scheme 7. 2',3'-Acetonide protection- chosen prerequisite for selective  
5'-O-functionalisation of isoPentenyl Adenosine  
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Figure 4. Kinetin Riboside as an accessible iPAdo congener for studying its 5´-esterification 
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The reactivity of KR during the synthetic paths to be investigated was expected to be similar 
to that of iPAdo and the same approaches designed for 5'-O-Lipoyl iPAdo were considered for the 
5'-ester of KR with LA, as summarized in Schemes 8-10.  
 
N
NN
N
HN
O
OH
OHHO
KR
ROOC
S
S
N
NN
N
HN
O
O
OHHO
O
S
S
Enzymatic transesterification
selective at 5'
O
O
+ R-OH
KR-5'-O-Lipoate
Lipase,
organic
solvent
R.T.
20-70h
LA
 
 
Scheme 8. Biocatalytic approach: selective transesterification for preparing  
Kinetin Riboside-5'-O-Lipoate 
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Scheme 9. Synthesis of Kinetin Riboside -5'-O-Lipoate: fighting for 
selectivity at 5'-position 
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Scheme 10. 2', 3'-O-Isopropylidene group- chosen protection for synthetic manipulations at  
5'-OH of Kinetine Riboside 
 
5.1.3 Lipoic acid: biological significance and general outline of related derivatives 
Lipoic acid {1,2-dithiolane-3-pentanoic acid (LA), Thioctic Acid (TA)} is a natural 
compound occurring as the R isomer discovered in 1937 by Snell et al. [23] who found that certain 
bacteria needed a compound from potato extract for growth. However, it was not before 1951 that 
the so-called potato-growth factor was isolated and characterized by Reed and colleagues [24, 25]. 
Initially, R-lipoic acid was tentatively regarded as a vitamin; subsequently, R-lipoic acid was found 
to be synthesized by plants and animals [25, 26], where it is covalently bound to the ε-amino group 
of lysine residues and functions as a cofactor of mitochondrial enzymes by catalyzing oxidative 
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decarboxylation of pyruvate, α-ketoglutarate, and branched-chain α-keto acids [27]. The growing 
importance of LA as a food supplement is related to its scavenging ability on  ‘‘Reactive oxygen 
species’’ (ROS), a group of oxygen-containing species such as superoxide anion, hydroxyl radical 
and hydrogen peroxide,  widely considered to induce cancer, aging and some other chronic diseases 
[28].  Among diverse biological functions that can be attributed to LA when used as a food 
supplement it has been shown that, because of its antioxidant properties, LA is particularly suited to 
the prevention and/or treatment of diabetic complications that arise from an overproduction of 
reactive oxygen and nitrogen species [29]. Administration of LA decreases oxidative injury in the 
kidney, and is associated with a significant improvement of renal function [30].  LA 
supplementation displays a protective effect in various models against age-dependent cognitive 
deficits [31].    
The chemistry of LA acid has been investigated in details more than fifty years ago [32, 33] 
and, before applying existing knowledge of lipoic derivatives to our project, we have explored the 
synthesis of LA esters of a few selected primary alcohols (ROH, Scheme 11) by conventional 
procedures. Ester preparation via lipoyl chloride was immediately abandoned, due to difficulty in 
the preparation of the derivative and its instability. The Fisher esterification of LA with simple 
primary alcohols (ethanol, 1-butanol) was carried out with excess of alcohols in the presence of 
sulphuric acid (Schemes 11 and 12). 
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Scheme 11. Synthesis of Lipoic acid esters: Lipoyl Ethyl Carbonate (LA-EC) and Lipoyc Acid 
Imidazolide (LA-IM) as chosen intermediates for efficient preparation of LA-esters. 
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Scheme 12. Lipoc Acid esters: preparation and stability 
 
After a conventional work-up the esters were obtained in good yields and characterized by 1H-NMR 
but spontaneously polymerized at 0-4 °C, conditions of their storage. This behaviour can be 
connected with the spontaneous polymerization of LA itself [33, 34], while occasional reports on 
the tendency of LA-derivatives to polymerize have been reported, within LA derivatives 
involvement in formation of copolymers [35-37]. 
Several examples of LA esters are available in the literature and most of them have been 
prepared by direct esterification of LA and the alcohol moiety of compound that has to be 
covalently bound to LA. In this case, generally carbodiimides like dicyclohexylcarbodiimide (DCC) 
or N-(3-dimethylaminopropyl)-N´-ethylcarbodiimide  (ECD) are used as a dehydrating agent, as 
illustrated in Scheme 12 [38-41].  
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5.1.4 Direct esterification of Kinetin Riboside with Lipoic Acid and Lipase-catalyzed 
transesterification 
 
We studied the direct esterification of KR with LA in the presence of N,N’-dicyclohexyl 
carbodiimide (DCC) as a dehydrating agent (Scheme 13).  An example of pharmacologically active 
5´-esters of nucleosides has been recently reported in a patent [42].  
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Scheme 13. DCC-promoted coupling of Kinetin Riboside with Lipoic Acid 
 
The reaction proceeded in the presence of 4,4-dimethylaminopyridine (DMAP) and after 3h 
at room temperature, TLC analysis showed the formation of three products along with 30% of 
unreacted KR. The absence of selectivity of the chemical procedure prompted us to explore a more 
selective approach and we thought to rely on enzymatic reactions, with special attention to lipase-
catalyzed transesterifications [43]. According to a generally accepted procedure (Scheme 8), an 
activated ester of LA should react, in the presence of a suitable lipase in an organic solvent, to 
furnish the desired LA-ester. This enzymatic procedure has been widely used also in nucleoside 
chemistry and generally the 5´-primary alcoholic function selectively reacts with the activated acid 
that has to be bound as an ester [44-46].  
In the specific case of a LA activated derivative suitable for the enzymatic transesterification 
we selected the trifluoroethyl ester (LA-TFE) that could be, eventually, prepared by reactions 
shown in Scheme 14. Derivatives like Lipoyl Ethyl Carbonate (LA-EC) and Lipoyc Acid 
Imidazolide (LA-IM) (Scheme 11) could constitute useful intermediates for chemical or enzymatic 
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binding of LA to the 5´-primary alcoholic function of KR. The mixed anhydride LA-EC was 
prepared by reaction of LA and ethyl chloroformate in the presence of triethylamine at 0 °C in 90% 
yield and used as such in reaction with trifluoroethanol. This rection was carried out in Et2O by 
using an excess of alcohol (5 eq.) under 30 min reflux; the corresponding LA-TFE was obtained in 
82% after work-up of the reaction product. The activated ester could be stored at 0-4 °C and was 
stable only for a few days. After 5 days polymerization was observed and this limited a more 
general application of the enzymatic reaction.  
We studied the enzymatic transesterification of LA-TFE and a suitable alcohol, furfuryl 
alcohol in the presence of lipases, such as porcine pancreas lipase (PPL), specific activity 6.5 U/mg 
or lipase from Candida cylindracea (CCL), specific activity 3.85 U/mg (Scheme 14). The 
heterogeneous reaction mixtures were vigorously stirred at room temperature for 15 h in the 
presence of 3 eq. alcohol and using t-butylmethyl ether as solvent; the reactions afforded furfuryl 
lipoate in 21 and 30% yield correspondingly, after the chromatographic separation of reaction 
mixtures. An additional problem was observed in the enzymatic protocol, namely the very similar 
polarity of the reagent LA-TFE and LA furfuryl ester. This made difficult the TLC monitoring and 
the purification by silica gel chromatography of the product.   
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Scheme 14.  Trifluoroethyl Lipoate (LA-TFE), an activated Lipoic Acid as key-intermediate for 
testing the biocatalytic applications of Lipoic Acid derivatives 
 
The above outlined drawbacks of the enzymatic protocol using LA-TFE were not against a 
possible selective esterification of KR. In this case the very low KR solubility in t-butylmethyl ether 
constituted an additional problem.  
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Scheme 15. Attempted lipase-catalyzed 5’-transesterification of Kinetin Riboside with 
trifluoroethyl lipoate    
 
In fact, the lipase-catalyzed esterification of KR was carried out in DMF, but did not 
proceed in times >72 h at any extent (Scheme 15). The result was not unexpected, since it is known 
that in polar organic solvents such as DMF the lipase-catalyzed reactions tend to become very slow 
[43].  Additionally, a prolonged reaction time could be deleterious for LA-TFE stability and this 
approach was abandoned. Replacement of LA-TFE with LA-EC resulted not convenient, because 
similar difficulties were encountered. LA-EC stability, a polarity very similar to that of product of 
esterification with simple primary alcohols, and virtually no reactivity with KR were not 
encouraging.  
5.1.5 Lipoic Acid Imidazolide, a stable Lipoic Acid derivative 
Differently from LA-TFE and LA-EC, LA imidazolide (LA-IM) could be smoothly 
prepared as a solid derivative and stored in a cold room for months without apparent decomposition. 
This reaction has been performed in tetrahydrofuran (THF) at 0oC, using a small excess (1.1 eq.) of 
1,1´-carbonyldiimidazol (Scheme 11). In 5 h the complete conversion of initial LA has been 
established by TLC and the yield of obtained solid LA-IM constituted 95%. LA-IM formation and 
use, but not its preparation and characterization, has been incidentally reported [47].  
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 Reaction of LA-IM with a few primary alcohols such as furfuryl alcohol, 3-pyridine 
methanol, and 2-thiophene ethanol in diethyl ether at reflux for 30 min proceeded with satisfactory 
yields (59-70%) (Scheme 16). Differently from LA-TFE and LA-EC, products could be well-
separated from unreacted LA-IM.  
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Scheme 16. Lipoic Acid Imidazolide- a convenient precursor for obtaining Lipoic Acid esters 
 
For the reaction of LA-IM with KR milder conditions were chosen because of the versatility 
of the latter. It was carried out in DMF at room temperature and after 24 h the result was an 
incomplete transformation (ca. 40% of initial LA-IM) with the formation of three products. No 
relevant variation in the reaction outcome was noted when it proceeded in the presence of CCL. The 
reaction was not further investigated, since the transformation was not selective (Scheme 17).   
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Scheme 17. The case of Lipoic Acid Iimidazolide: no selective 5´-O-esterification of Kinetin 
Riboside 
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5.1.6 Attempted preparation of Kinetin Riboside 5'-O-Lipoate and 5'-O-Dihydrolipoate  
via its 2', 3'-O-isopropylidene derivative 
 
We have next explored a fully chemical approach to the synthesis of 5'-O-Lipoate and 5'-O-
dihydrolipoate of KR and for this purpose, the 2',3'-O-isopropylidene KR was prepared.  It should 
be mentioned that, in the case of adenosine, the preparation of 2',3'-O-isopropylidene adenosine 
required a large excess of p-toluene sulfonic acid as catalyst (10 eq.) [48]. In the case of KR an 
equimolar amount of the acid catalyst in the presence of 2, 2-dimethoxypropane was sufficient to 
obtain quantitatively KR derivative.  
The reaction of KR 2',3'-O-acetonide derivative with LA proceeded smoothly a room 
temperature in DMF in the presence of DCC as coupling agent and DMAP as catalyst (10 mol%). 
2',3'-O-isopropylidene KR-5´-O-Lipoate was obtained in 88% yield, after purification via column 
chromatography. The acid hydrolysis of the 2',3'-O-isopropylidene protection, however, did not 
afford appreciable yields of the required KR-5´-O-Lipoate and a complex mixture of products was 
obtained, as a consequence of different hydrolytic processes that occurred at various positions of the 
compound (Scheme 18). 
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Scheme 18. 2', 3'-O-isopropylidene KR-5´-O-Lipoate: efficient preparation and fault deprotection 
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Scheme 19. Attempted reduction of disulfide bond of 2', 3'-O-isopropylidene KR-5´-O-Lipoate 
 
Negative results were also obtained from attempts to reduce the disulfide bridge of LA 
bound to KR acetonide with sodium borohydride in methanol/water. In fact, the main product 
recovered from this reduction was KR acetonide, as a consequence of the hydrolysis of the 5'-ester 
moiety of the compound (Scheme 19). 
All above-reported negative results were obtained by the end of the second year of thesis 
and were not encouraging, especially in consideration that LA-KR was only the first step of a long 
series of processes that should lead to colloidal or, better, water-soluble GNPs. In order to invest 
more fruitfully the remaining time of the PhD thesis, the project was addressed to other aspects of 
iPAdo chemistry. The drug delivery project was put aside and the synthesis of iPAdo analogues was 
considered as a mean to overcome the in vivo catabolic pathway.  
 
EXPERIMENTAL to Section 5.1. 
 Preparation of Lipoic Acid esters via Fischer esterification. Lipoc acid (412.66 mg, 2.0 mmol) 
and the corresponding alcohol (20 mmol) were placed and in a conical vial containing a spin vane.  
One drop of concentrated sulfuric acid was added.  A water-jacketed reflux condenser was placed 
on the conical vial.  The solution was heated to reflux on a sand bath for 30 min. Next, the solution 
was cooled in an ice bath, diluted with 5 mL water and subjected to repeated extraction with ethyl 
ether. The etheric layers were repeatedly washed with 5% solution of sodium bicarbonate till 
neutral pH. The organic phase was dried on sodium sulfate and the solvent was evaporated in 
vacuo, giving the corresponding ester.  
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Ethyl lipoate, oil, 187.3 mg, 80% yield, Rf = 0.55 (CH2Cl2/MeOH=19/1). Polimerises. 1H NMR 
(CDCl3) δ = 1.24 (t, J = 7.4 Hz, 3H, CH3), 1.47 (m, 2H, lipoate moiety), 1.67 (m, 4H, lipoate 
moiety), 1.91 (m, 1H, lipoate moiety), 2.30 (t, J = 7.4 Hz, 2H, lipoate moiety), 2.47 (m, 1H, lipoate 
moiety), 3.10 (m, 1H, lipoate moiety), 3.17 (m, 1H, lipoate moiety), 3.55 (m, 1H, lipoate moiety), 
4.11 (q, J = 7.3 Hz, 2H, CH2 of ethyl). Anal. Calcd for C10H18O2S2: C, 51.24; H, 7.76; S, 27.36. 
Found: C, 51.14; H, 7.70; S, 27.03. 
Buthyl lipoate, oil, 223.1 mg, 85% yield, Rf = 0.33 (Petroleum Ether/AcOEt=32/1). Polimerises. 1H 
NMR (CDCl3) δ = 0.87 (m, 3H, CH3), 1.32 (m, 2H, butyl fragment), 1.41 (m, 2H, butyl fragment), 
1.60 (m, 6H, lipoate moiety), 1.85 (m, 1H, lipoate moiety), 2.25 (m, 2H, lipoate moiety), 2.39 (m, 
1H, lipoate moiety), 3.05 (m, 1H, lipoate moiety), 3.12 (m, 1H, lipoate moiety), 3.50 (m, 1H, 
lipoate moiety), 4.00 (m, 2H, butyl fragment). Anal. Calcd for C12H22O2S2: C, 54.91; H, 8.47; S, 
24.47. Found: C, 54.63; H, 8.32; S, 24.23. 
Attempted preparation of 5'-ester of Kinetin Riboside with Lipoic Acid. To a solution of lipoic 
acid (35.65 mg, 0.17 mmol) in DMF (0.7 mL) kinetin riboside (50 mg, 0.14 mmol), N,N´-
dicyclohexylcarbodiimide (35.65 mg, 0.17 mmol) 4-dimethylaminopyridine (1.75 mg, 10 mol%) 
were added under stirring. The solution was stirred at R.T. for 3 h, while protected from light and 
moisture. TLC-control of the reaction product (19/1=CH2Cl2/MeOH) showed traces of two less 
polar compounds, along with a big amount of initial kinetin riboside. Stirring was continued 
overnight; the reaction was stopped when qualitative HPLC-analyses of the reaction product 
showed approx. 30% initial compound yet present in reaction mixture, along with three less polar 
compounds (20 h) of very close polarity.  The chromatographic separation of the components by 
using the increasing gradient of a solvents mixture: methanol / dichloromethane failed.  The 
reaction was not further investigated, as it was not selective.  
 Preparation of Lipoyl Ethyl Carbonate. To a cooled to 0ºC solution of lipoic acid (412.66 mg, 
2.0 mmol) in CH2Cl2 (8 mL) triethylamine (558 µL, 4.0 mmol) and ethylchloroformate (192 µL, 2.0 
mmol) were added under stirring. The solution was stirred at 0ºC for 45 min, while protected from 
moisture. The obtained heterogeneous mixture was filtrated; the crystals, representing triethylamine 
hydrochloride were washed with Et2O. The organic liquid phase was evaporated in vacuo; 520 mg 
yellow oil was obtained, 99% yield.  Rf = 0.73 (CH2Cl2/MeOH, 95:5). 1H NMR (CDCl3) δ = 1.26 (t, 
J = 7.3 Hz, 3H, CH3), 1.46 (m, 2H, lipoate moiety), 1.67 (m, 4H, lipoate moiety), 1.92 (m, 1H, 
lipoate moiety), 2.31 (t, J = 7.4 Hz, 2H, lipoate moiety), 2.46 (m, 1H, lipoate moiety), 3.11 (m, 1H, 
lipoate moiety), 3.17 (m, 1H, lipoate moiety), 3.57 (m, 1H, lipoate moiety), 4.13 (q, J = 7.3 Hz, 2H, 
CH2 of ethyl). 13C NMR (CDCl3) δ = 14.2; 24.7; 28.7; 34.1; 34.6; 38.5; 40.2; 56.3; 60.2; 173.5. 
Anal. Calcd for C11H18O3S2: C, 50.35; H, 6.86; S, 24.43. Found: C, 50.09; H, 6.75; S, 24.23. 
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 Preparation of Trifluoroethyl Lipoate from Lipoyl Ethyl Carbonate. To a solution of LA-EC 
(262.43 mg, 1.0 mmol) in ethyl ether (2 mL) trifluoroethanol (0.36 mL, 5.0 mmol) was added. The 
solution was refluxed for 30 min till the complete conversion of the initial compound has been 
attested (TLC-monitoring). Ordinary work-up of the reaction product, including the separation of 
organic from inorganic phase, furnished the LA-TFE as oil after removal of the solvent (236.5 mg, 
82% yield). Rf = 0.39 (Petroleum Ether/Ac-O-Et, 32:1). 1H NMR (CDCl3) δ = 1.48 (m, 2H, lipoate 
moiety), 1.70 (m, 4H, lipoate moiety), 1.92 (m, 1H, lipoate moiety), 2.45 (m, 3H, lipoate moiety), 
3.13 (m, 1H, lipoate moiety), 3.19 (m, 1H, lipoate moiety), 3.57 (m, 1H, lipoate moiety), 4.45, 4.49 
(both d, each 1H, AB- system, J = 9.7 Hz, CH2CF3). 13C NMR (CDCl3) δ = 23.9; 28.1; 32.9; 34.0; 
38.0; 39.7; 55.8; 59.8; 121.4; 173.5. Anal. Calcd. for C10H15O2S2F3: C, 41.65; H, 5.25; S, 22.24; F, 
19.76. Found: C, 41.42; H, 5.12; S, 22.11; F, 19.63. 
Lipase-catalyzed transesterification of Trifluoroethyl Lipoate: preparation of Furfuryl Lipoate 
A. Reaction with porcine pancreas lipase (PPL). To a solution of LA-TFE (29.0 mg, 0.1 mmol) 
in t-Bu-O-Me (0.5 mL) furfuryl alcohol (26 µL, 0.3 mmol) and PPL (20 mg, activity 6.5 U/mg) 
were added. The heterogeneous mixture was vigorously stirred at R.T. for 15 h. TLC-monitoring 
revealed UV-visible spots of formed furfuryl lipoate, in contrast to the initial compound, non-UV-
visible. The lipase was filtrated and the filter was repeatedly washed with ethyl ether. The solvent 
was evaporated in vacuo and the resulting viscous product has been subjected to column 
chromatography on silica gel, using a 20/1 ratio of adsorbent/product. The column was eluted with 
the system of solvents: ethyl acetate/petroleum ether, increasing gradient. Furfuryl Lipoate (6 mg, 
21%) has been eluted as oil with a mixture of 1/32 of ethyl acetate/petroleum ether. Rf = 0.43 
(Petroleum Ether/AcOEt=9/1). 1H NMR (CDCl3) δ = 1.47 (m, 2H, lipoate moiety), 1.68 (m, 5H, 
lipoate moiety), 1.90 (m, 1H, lipoate moiety), 2.31 (m, 2H, lipoate moiety), 2.46 (m, 1H, lipoate 
moiety), 3.11 (m, 1H, lipoate moiety), 3.18 (m, 1H, lipoate moiety), 3.55 (m, 1H, lipoate moiety), 
5.09 (s, 2H, CH2 of furfuryl moiety), 6.36 (m, 1H, J = 3.3 Hz, furan), 6.40 (d, 1H, J = 3.2 Hz, 
furan), 7.41 (s, 1H, furan). Anal. Calcd for C13H18O3S2: C, 54.51; H, 6.35; S, 22.39. Found: C, 
54.37; H, 6.18; S, 22.13. 
B. Reaction with the lipase from Candida cylindracea (CCL). The same protocol has been 
followed, as described in p. A with the difference that CCL-lipase was used (20 mg, activity 3.85 
U/mg) instead of PPL. Furfuryl lipoate (8.6 mg, 30%) showing identical phisico-chemical 
properties with the ester described in p. A has been prepared. 
Preparation of Lipoic Acid Imidazolide. To a cooled to 0ºC solution of lipoic acid (412.66 mg, 
2.0 mmol) in THF (8 mL) 1,1´-carbonyldiimidazol (356.73 mg, 2.2 mmol) was added under 
stirring. The solution was stirred at 0ºC for 5 h (TLC monitoring). The solvent was removed in 
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vacuo giving 461 mg yellow solid, 95% yield. Rf = 0.55 (CH2Cl2/MeOH=19/1). 1H NMR (CDCl3) δ 
= 1.55 (m, 2H, lipoate moiety), 1.73 (m, 2H, lipoate moiety), 1.82 (m, 2H, lipoate moiety), 1.90 (m, 
1H, lipoate moiety), 2.45 (m, 1H, lipoate moiety), 2.85 (m, 2H, lipoate moiety), 3.11 (m, 1H, 
lipoate moiety), 3.20 (m, 1H, lipoate moiety), 3.44 (m, 1H, lipoate moiety), 7.48 (t, J = 1.5 Hz, 1H, 
imidazol ring), 7.70 (s, 1H, imidazol ring), 8.17 (s, 1H, imidazol ring). Anal. Calcd. for 
C11H16OS2N: C, 54.50; H, 6.66; S, 26.45; N, 5.78. Found: C, 54.27; H, 6.49; S, 26.30; N, 5.66. 
Preparation of Lipoic Acid esters via Lipoic Acid Imidazolide 
A.  General procedure. To a solution of LA-IM (100.00 mg, 0.33 mmol) in ethyl ether (1 mL) the 
corresponding alcohol (0.99 mmol) was added. The solution was refluxed for 30 min till the 
complete conversion of the initial compound has been established (TLC-monitoring). The reaction 
mixture was cooled and the solvent was evaporated under reduced pressure. The liquid residue was 
subjected to column chromatography on silica gel, using a 20/1 ratio of adsorbent/product. The 
column was eluted with the system of solvents: ethyl acetate/petroleum ether, increasing gradient. 
The corresponding esters were eluted respectively: Furfuryl Lipoate and the Ester of Lipoic Acid 
with 2-Thiophene Ethanol: with a 49/1 mixture of petroleum ether/ethyl acetate; the Ester of Lipoic 
Acid with 3-Pyridine Methanol: with a 4/1 mixture of the same solvents.  
B. Characterisation of esters. The chromatographic separation furnished 78 mg (66% yield) of 
Furfuryl Lipoate as oil, the spectral data of which were identical with that of above-described 
compound.  
Lipoic Acid ester with 2-Thiophene Ethanol was isolated as oil (73.35 mg, 70% yield). Rf =0.85 
(CH2Cl2/MeOH, 9:1). 1H NMR (CDCl3) δ = 1.49 (m, 2H, lipoate moiety), 1.68 (m, 5H, lipoate 
moiety), 1.88 (m, 1H, lipoate moiety), 2.32 (m, 2H, lipoate moiety), 2.45 (m, 1H, lipoate moiety), 
2.79 (m, 1H, lipoate moiety), 3.15 (m, 4H: 2H, lipoate moiety and 2H, ethyl), 4.32 (m, 2H, ethyl 
vic. COO-), 6.82 (m, 1H, thiophene ring), 6.90 (m, 1H, thiophene ring), 7.14 (m, 1H, thiophene 
ring). Anal. Calcd for C14H21O2S3: C, 52.95; H, 6.68; S, 30.29. Found: C, 52.82; H, 6.58; S, 30.01. 
Lipoic Acid ester with 3-Pyridine Methanol was separated as oil (65 mg, 59% yield). Rf = 0.59 
(CH2Cl2/MeOH, 9:1). 1H NMR (CDCl3) δ = 1.46 (m, 2H, lipoate moiety), 1.65 (m, 4H, lipoate 
moiety), 1.92 (m, 1H, lipoate moiety), 2.38 (m, 2H, lipoate moiety), 2.74 (m, 2H, lipoate moiety), 
3.09 (m, 1H, lipoate moiety), 3.16 (m, 1H, lipoate moiety), 3.56 (m, 1H, lipoate moiety), 5.12 (d, 
2H, J = 8.6 Hz, carbinolic CH2),  7.31 (m, 1H, pyridine ring), 7.68 (m, 1H, pyridine ring), 8.57 (m, 
1H, pyridine ring), 8.61 (m, 1H, pyridine ring). Anal. Calcd for C14H20O2S2N: C, 63.09; H, 7.58; S, 
24.06; N, 5.26. Found: C, 62.92; H, 7.49; S, 23.91; N, 5.05. 
Attempted preparation of 5'-ester of Kinetin Riboside with Lipoic Acid Imidazolide To a 
solution of LA-IM (15.50 mg, 0.05 mmol) in DMF (0.8 mL) KR (52.00 mg, 0.15 mmol) was added. 
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The solution was vigorously stirred at R.T. for 24 h. TLC-monitoring revealed the presence of three 
products along with an intense spot of the initial LA-IM. The reaction was not further investigated, 
since the transformation was not selective. A parallel experiment that proceeded in the presence of 
CCL (11 mg, activity 3.85 U/mg) showed analogous results. 
Preparation of 2´, 3´-O-isopropylidene Kinetin Riboside. To a suspension of KR (52.00 mg, 0.15 
mmol) in dry acetone (10.0 mL) p-TsOH (28.5 mg, 0.15 mmol) and 2,2-dimethoxypropane (0.1 
mL, 0.75 mmol) were added. The mixture was vigorously stirred at R.T. overnight while protected 
from light and moisture. TLC-monitoring revealed the complete conversion of initial compound. 
The reaction mixture was neutralized with 0.3N solution of sodium bicarbonate and the volatiles 
were evaporated in vacuo. Water (10 mL) was added to the residue and the mixture was repeatedly 
extracted with ethyl acetate. The combined organic extracts were dried on sodium sulfate and after 
removal of the solvent 58 mg (quantitative yield) of the 2´, 3´-isopropylidene ketal of Kinetin 
Riboside was obtained as oil. Rf = 0.55 (CH2Cl2/MeOH, 9:1). 1H NMR (CDCl3) δ = 1.35 (s, 3H, 
CH3 acetonide), 1.66 (s, 3H, CH3 acetonide), 3.78 (apparent d, 1H,  J = 12.4 Hz, H5′b), 3.93 
(apparent d, 1H,  J = 12.4 Hz, H5′a), 4.50 (br. s, 1H,  H4′), 4.73 (br. s, 2H, CH2 -11), 4.83 (dd, 1H, J 
= 4.4 Hz, J = 4.6 Hz, H3′), 5.21 (dd, 1H, J = 4.9 Hz, J = 4.5 Hz, H2′), 5.34 (dd,  1H, J = 7.2 Hz, J = 
4.4 Hz, 5′OH), 6.02 (d, 1H, J = 5.0 Hz, H1′), 6.36 (m, 1H, CH-13), 6.40 (d, 1H, J = 3.2 Hz, 1H, 
CH-14), 7.37 (s, 1H, CH-15), 8.20 (br. s, 1H, NH-10), 8.21 (s, 1H, CH-8), 8.32 (s, 1H, CH-2). Anal. 
Calcd for C18H21O5N5: C, 55.81; H, 5.47; N, 18.08; N. Found: C, 55.68; H, 5.40; N, 18.01. 
Synthesis of 5´-O-Lipoate of 2´, 3´-O-isopropylidene Kinetin Riboside. To a solution of lipoic 
acid (37.21 mg, 0.18 mmol) in DMF (1.0 mL) 2´,3´-O-isopropylidene KR (34.61 mg, 0.09 mmol), 
N,N´-dicyclohexylcarbodiimide (20.31 mg, 0.1 mmol) and 4-dimethylaminopyridine (1.13 mg, 10 
mol%) were added under stirring. The solution was stirred at R.T. overnight. TLC of the reaction 
product showed complete conversion of the initial KR. Next, saturated brine was added to the 
solution and the mixture was repeatedly extracted with ethyl acetate. The organic phase was treated 
with 5% solution of sodium bicarbonate, water and dried on anhydrous sodium sulfate. After 
removal of the solvent a brown viscous residue (60 mg) was obtained that was subjected to column 
chromatography. With the elution mixture 99/1=MeOH/CH2Cl2 45.6 mg pure 5´-O-Lipoate of 
2´,3´-O-isopropylidene KR has been obtained as oil (88% yield). Rf = 0.66 (CH2Cl2/MeOH, 9:1). 1H 
NMR (CDCl3) δ = 1.49 (s, 3H, CH3 acetonide), 1.50 (s, 3H, CH3 acetonide), 1.47 (m, 2H, lipoate 
moiety), 1.67 (m, 4H, lipoate moiety), 1.91 (m, 1H, lipoate moiety), 2.30 (m, 2H, lipoate moiety), 
2.47 (m, 1H, lipoate moiety), 3.11 (m, 1H, lipoate moiety), 3.16 (m, 1H, lipoate moiety), 3.55 (m, 
1H, lipoate moiety), 4.31 (apparent d, 1H,  J = 12.4 Hz, H5′b), 4.38 (br. s, 2H, CH2 -11), 4.40 
(apparent d, 1H,  J = 12.4 Hz, H5′a), 4.65 (br. s, 1H,  H4′), 4.91 (dd, 1H, J = 4.4 Hz, J = 4.6 Hz, 
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H3′), 5.22 (dd, 1H, J = 4.9 Hz, J = 4.5 Hz, H2′), 6.01 (d, 1H, J = 5.1 Hz, H1′), 6.31 (m, 1H, CH-13), 
6.41 (d, 1H, J = 3.3 Hz, 1H, CH-14), 7.39 (s, 1H, CH-15), 8.20 (br. s, 1H, NH-10), 8.22 (s, 1H, CH-
8), 8.33 (s, 1H, CH-2). Anal. Calcd for C26H33O6S2N5: C, 54.24; H, 5.79; S, 11.14; N, 12.17. Found: 
C, 54.03; H, 5.67; S, 11.09; N, 12.08. 
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5.2. N6-isoPENTENYL ADENOSINE: DETAILED BIOACTIVITY ASSAYS ON  
MDA-MB-231 AND MCF-7 HUMAN BREAST CANCER CELLS  
5.2.1. Studies on MDA-MB-231 cell line 
 
5.2.1.1. Evaluation of iPAdo cytotoxic activity in vitro 
 
The cytotoxicity was evaluated in vitro against selected human tumor cells derived from 
breast cancer MDA-MB-231. The MDA-MB-231 breast cancer cell line was obtained from pleural 
effusions of a Caucasian breast cancer patient in 1973 at M. D. Anderson Cancer Center [1]. It plays 
a significant role in finding new solutions against breast cancer invasion. 
Sulforhodamine B (SRB) assay has been used to estimate cell viability or growth [2, 3].  In 
the presence of different doses of iPAdo, the cells were inhibited to a greater extent ranging from 
10% to 90% with a loss of viable cells (Figure 1).  
 
 
 
Figure 1. Effects of iPAdo on the proliferation of MDA-MB-231. Dose of compound required to 
inhibit cell growth by 50% compared to untreated cell controls. All experiments were 
carried out in triplicate wells and each experiment was repeated twice. 
 
 
iPAdo dramatically inhibited the proliferation of MDA-MB-231 cells in a concentration and 
time-dependent manner. The concentration of iPAdo which caused 50% inhibition of cell viability 
(IC50) was about 6.2 μmol/L at 72 h by employing the SRB assay (Figure 2).  
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Figure 2. Inhibition growth of iPAdo on MDA-MB-231. The percentage of growth inhibition was 
calculated by using the equation: (1- At/Ac) x 100, where At and Ac represent the absorbance 
in treated and control cultures, respectively. IC50 was determined by interpolation from 
dose–response curves. 
 
5.2.1.2. Assessment of cell shape and cell morphology 
For more than 150 years, morphological features played the leading role in the description of 
cell death [4]. However, during the past three decades cell death has been characterized on the 
molecular level, which markedly increased our understanding of the morphology [5]. Under 
inverted microscope, cell shape and its changes can be observed clearly. Treated and untreated 
(control) cells were viewed using an inverted phase-contrast microscope model Zeiss and 
photographed using a Nikon camera attached to the microscope. Figure 3 shows the incubation of 
the cells with different concentrations of iPAdo after 48 h treatment. Control group showed regular 
polygonal shape and cell antennas were short. The cell morphology of treated cells was affected 
including the loss of adhesion, rounding, cell shrinkage and detachment from the substratum. 
 
Figure 3. Morphological analysis for the effects of iPA on MDA-MB-231 after 48 h incubation 
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5.2.1.3. Binding Study: iPAdo – Bovine Serum Albumin 
Additionally, we have investigated the interaction of iPAdo and Bovine Serum Albumin 
(BSA), as a model of the analogous human protein (HSA) one, to which BSA shows a high 
homology [6]. BSA is the most abundant protein constituent of the blood plasma, and this facilitates 
the disposition and transport of various exogenous and endogenous ligands to particular biotargets 
[7-9]. Since protein–drug binding greatly influences absorption, distribution, metabolism, and 
excretion properties of typical drugs [10], studies on the protein–drug binding are important for the 
elucidation of the reaction mechanisms, providing a pathway to the pharmacokinetics and 
pharmacodynamic mechanisms of these substances in various tissues. The structural changes of 
BSA on addition of iPAdo were monitored by UV–vis absorbance spectra of BSA that were 
measured at different concentrations of iPAdo (Figure 4). 
UV–vis spectra of BSA indicated that on addition of iPAdo, the absorption peaks in the 
visible region showed a moderate blue-shift. This indicated that with iPAdo, the peptide strands of 
the BSA molecules extended moderately and the hydrophobicity decreased [11]. 
 
 
Figure 4. UV-vis absorbance spectra of BSA in the presence of iPAdo. 
 
The iPA–BSA binding constant was determined using UV absorption spectroscopy [12, 13] 
and the following equations can be established [14]. 
 
BSA + iPA ↔ BSA : iPA  
K1 =[BSA : iPA]/{[BSA][ iPA]} 
BSA : iPA + iPA ↔ BSA : iPA2  
K2 =[BSA : iPA2]/ {[ BSA : iPA] [iPA]} 
BSA : iPA2 + iPA ↔ BSA : iPA 3  
K3 =[BSA : iPA 3]/ {[ BSA: iPA 2] [iPA]} 
BSA : iPA3 + iPA ↔ BSA : iPA4 
K4= [ BSA : iPA4 ]/ {[ BSA : iPA3] [iPA]} 
Overall K = K1 ·  K2 · K3 · K4 = 
[BSA: iPA 4]/ [BSA] [iPA]4 
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The double reciprocal plot of 1/ (A-A0) vs. 1/(L) is linear and the binding constant (K) can 
be estimated from the ratio of the intercept to the slope (Figure 5). A0 is the initial absorption of the 
free BSA at 279 nm and A is the recorded absorption at different iPAdo concentrations (L). The 
overall binding constant K for iPAdo-BSA complexes is estimated to be 4.9 x 104 M-1. The value 
obtained is indicative of a good iPAdo-protein interaction [15]. The reason for the low stability of 
the iPAdo-BSA complexes can be attributed to the presence of mainly hydrogen bonding 
interaction between protein donor atoms and the iPAdo polar groups or an indirect drug-protein 
interaction through water molecules. 
 
Figure 5. The plot of 1/(A-A0) vs 1/L for BSA and iPAdo complexes where A0 is the initial protein 
absorption band (279 nm) and A is the recorded absorption at different drug 
concentrations (L). 
5.2.2. Studies on MCF-7 cell line 
In 1973, the MCF-7 cell line was derived from a pleural effusion of a patient with metastatic 
breast cancer [16] and was later recognized as the first hormone-responsive breast cancer cell line 
[17]. The usefulness of the MCF-7 cell line as an investigative tool led to its adoption in 
laboratories worldwide and several decades of use in independent laboratories have facilitated the 
evolution of distinct MCF-7 lineages [18, 19]. Documented differences include the ability to 
undergo DNA fragmentation, differential sensitivities to estrogens and anti-estrogens, differential 
expression of estrogen receptors (ER), ER-mRNA, progesterone receptors and differences in 
tumorigenicity and proliferative rates. It has been well established that the MCF-7 cell line is a 
novel tool for the study of breast cancer resistance to chemotherapy, because it appears to mirror the 
heterogeneity of tumor cells in vivo [20]. In this respect, it has already been proved that breast 
cancer cell lines are considered as representative models of transformed cells in vivo [21].  
We have determined the dose-dependent cell cycle arrest and apoptogenic effect of iPAdo 
on MCF-7 cancer cell line. As a complementary information related to the antiproliferative activity, 
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iPAdo interaction with DNA has been studied analyzing absorbance changes in the UV–vis 
frequency range with the aim of obtaining structural information regarding the iPAdo binding 
mode, apparent binding constant, and the effects of iPAdo complexation on the biopolymer 
secondary structure. 
5.2.2.1. Evaluation of iPAdo cytotoxicity in vitro 
The human breast cancer cell line MCF-7 provides an unlimited source of homogenous self-
replicating material, free of contaminating stromal cells, and can be easily cultured in simple 
standard media. Such a cell line is ideal to study the interaction between a chemopreventive drug 
and a cancer cell. The mechanism by which a chemopreventive drug inhibits the proliferation of a 
cancer cell can be best studied in vitro where the other physiological regulatory mechanisms, which 
are present in the in vivo system, are absent. In vitro studies provide the advantages, from an 
experimental point of view, of being able to observe cells and tissues in isolation and away from the 
controlling and modifying influences of other tissues in the body. In the presence of different doses 
of iPAdo, the cells were inhibited to a greater extent ranging from 10% to 90% with a loss of viable 
cells (Figure 6A). iPAdo inhibited the proliferation of MCF-7 cells in a concentration and time-
dependent manner. The iPAdo concentration which caused 50% inhibition of cell viability (IC50) 
was 12. 2 μmol/L at 72 h by employing SRB assay (Figure 6B). 
 
 
Figure 6. A. Effects of iPAdo on the proliferation of MCF-7 cells; B. Inhibition growth of iPAdo 
on MCF-7 cells. The percentage of growth inhibition was calculated by using the equation: 
(1- At/Ac) x 100, where At and Ac represent the absorbance in treated and control cultures, 
respectively. IC50 was determined by interpolation from dose–response curves. 
 
5.2.2.2. Apoptosis and cell cycle analysis 
 
To study the mechanism of antiproliferative activity by iPAdo in detail, we analyzed the 
effects of iPAdo treatment on cell cycle distributions of MCF-7 cells. Cells were treated with 
various concentration of iPAdo for 72 h and subjected to fluorescence-activated cell sorting analysis 
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(FACS) after propidium iodide staining of the chromosomal DNA. In histograms of FACS analysis, 
untreated proliferative MCF-7 cells showed cell cycle distributions of 25.9% in G1/G0, 11.1% in S, 
52.3% in G2/M, and 12.2% in sub G1/G0 phase. At all concentrations, iPAdo leads to decrease in the 
percentage of cells in G2/M phase, and also increase percentage of cells in sub G1/G0 phase. At 
10µM of iPAdo, these populations reached 23.9% for G2/M and 40.6% for sub G1/G0 phase 
(Figures 7 and 8). These data indicates that iPAdo has an activity to arrest MCF-7 cell growth in 
G2/M. 
In addition, cell cycle analysis was performed and it was found that the drug addition did not 
change the duration of the cell cycle in S and G0/G1 phases but, as shown in Figures 7 and 8, 
treatment of MCF-7 cells with 10µM iPAdo induces approximately 40.6 % apoptosis by increasing 
the percentage of cells in sub G1/G0 phase. 
 
 
Figure 7. Flow cytometric analysis of MCF-7 cells. Values are expressed as percentage of the cell 
population in the G0-G1, S, and G2/M phase of cell cycle.  
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Figure 8. Cell cycle analysis of MCF-7 cells treated with 0, 1, 5, 10µM of iPAdo. 
5.2.2.3. Assessment of cell shape and cell morphology 
It is now generally accepted that cell death is an important phenomenon, reflected by the 
appearance of numerous publications on the subject every year. For more than 150 years, 
morphological features played the leading role in the description of cell death [22]. However, 
during the past three decades cell death has been characterized on the molecular level, which 
markedly increased our understanding of the morphology. Under inverted microscope, cell shape 
and its changes can be observed clearly. Treated and untreated (control) cells were viewed using an 
inverted phase-contrast microscope model Zeiss and photographed using a Nikon camera attached 
to the microscope. Figure 9 shows the incubation of the cells with different concentrations of 
iPAdo after 48 h treatment. Control group showed regular polygonal shape and cell antennas were 
short.  The cell morphology of treated cells was affected including the loss of adhesion, rounding, 
cell shrinkage and detachment from the substratum.  
 
 
Figure 9. Morphological analysis for the effects of iPAdo on MCF-7 cells after 48 h incubation. 
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5.2.2.4. Absorption spectra of iPAdo –DNA complexes and association binding constant 
The UV spectra of free iPAdo and DNA are reported in comparison with iPAdo-DNA 
complex (Figure 10). The increase in intensity of iPAdo characteristic UV–vis band at 269 nm is 
due to major drug–DNA interaction at DNA surface [23].  
 
 
 
Figure 10. UV-vis absorbance spectra of DNA in the presence of iPAdo 
 
The calculation of the overall binding constants was carried out on the basis of UV 
absorption as reported [24-26]. The equilibrium for iPAdo and DNA complex can be described as 
follows:  
[DNA + iPAdo] ↔ [DNA - iPAdo]KiPAdo 
K iPAdo = [DNA - iPAdo]/ [DNA][iPAdo] 
The double reciprocal plot of 1/[A -A0] vs 1/[ligand] is linear and the association binding 
constant (K) is calculated from the ratio of the intercept on the vertical coordinate axis to the slope 
[27-29]. Concentrations of complexed ligand were determined by subtracting absorbance of free 
DNA at 260 nm from those of the complexed DNA. Concentration of the free ligand was 
determined by subtraction of complexed ligand from total ligand used for the experiment. Our data 
of 1/[ligand complexed] almost proportionally increased as a function of 1/[free ligand] (Figure 
11), and thus the overall binding constants are estimated to be KiPAdo–DNA=4.1 x  103 M-1 for iPAdo–
DNA. 
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Figure 11. The plot of 1/(A-A0) vs 1/L for DNA and iPAdo complexes where A0 is the initial 
protein  absorption band (259 nm) and A is the recorded absorption at different drug 
concentrations (L). 
 
Our results show that the cytotoxic effect of iPAdo on human breast cancer MDA-MB-231 
and MCF-7 cells is dose-dependent, with an IC50 value of 6.2 and 12.2 μmol/L, respectively, at 72 h 
after iPAdo addition to the culture. The cell cycle analysis of MCF-7 cells by mean of flow 
cytometry showed that there was a prominent increase in the amount of sub G1/G0 phase on iPAdo 
treatment. This increase of hypoploid DNA is an indication of the inhibition of cell growth through 
a mechanism of apoptosis that has been suggested also for other cell lines [30, 31]. 
At 12.5 mM DNA concentration and variable iPAdo concentrations (0.05–12.5 mM), an 
increase in intensity of iPAdo characteristic UV–vis band at 269 nm was observed and a binding 
constant KiPAdo–DNA=4.1 x 103 M-1 was calculated. These results suggest affinity of iPAdo for DNA 
complexation with an association constant similar to those reported for DNA complexes with 
zanamivir [32-34].  
 
EXPERIMENTAL to Section 5.2. 
 
Cell culture. Breast cancer cell lines were supplied from American Type Culture Collection and 
were maintained in the standard medium and grown as a monolayer in Dulbecco’s Modified Eagle 
Medium (DMEM) containing 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, 
and 100 µg/ml streptomycin. Cultures were maintained at 37 °C with 5% CO2 in a humidified 
atmosphere. 
In vitro evaluation of cytotoxic activity. iPAdo stock solutions (10 mM in DMSO) were prepared 
and stored at 4°C and were diluted with DMEM to 0.1–1 mM range at room temperature before 
experiment. The final percentage of DMSO in the reaction mixture was less than 1% (v/v). Cancer 
cells (2 x 103 cells/ well) were plated in 5 multiple in the 96-well plates and incubated in medium 
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for 24 h. Serial dilutions of individual compounds were added. The microtiter plates were incubated 
at 37°C, 5% CO2, 95% air, and 100% relative humidity for 72 h prior to addition of iPAdo. The 
assay was terminated by the addition of 50 μL of cold trichloroacetic acid and incubated for 60 min 
at 4°C. The plates were washed five times with tap water and air-dried. SRB solution (50 µL) at 
0.4% (w/v) in 1% acetic acid was added to each of the wells, and plates were incubated for 30 min 
at room temperature. The residual dye was removed by washing five times with 1% acetic acid. The 
plates were air-dried or under hood. Bound stain was subsequently eluted with 10 mM trizma base, 
and the absorbance was read on an ELISA plate reader at a wavelength of 540 nm and used as a 
relative measure of viable cell number. The percentage of growth inhibition was calculated by using 
the equation: percentage growth inhibition (1- At/Ac) x 100, where At and Ac represent the 
absorbance in treated and control cultures, respectively. IC50 was determined by interpolation from 
dose–response curves. 
Assessment of cell shape and cell morphology. Cell shape was monitored by phase-contrast 
microscopy. For this morphological study MDA-MB-231 cancer cell line was seeded at a density of 
5 x 105 cells/well into 6-well plates. After attachment the cells were incubated in the presence of 
different concentrations or absence of iPAdo for different time intervals. MCF-7 cells, plated at 
about 20,000 cells/well on chamber slides (eight wells), were treated with 0, 2.5, 5, and 10 mM of 
iPAdo for 48 h. After rinsing in PBS, treated and untreated (control) cells were fixed in methanol 
and stained with 10% Giemsa. Next the cells were  viewed using an inverted phase-contrast 
microscope model Zeiss HBO 50 and photographed using a Nikon camera attached to the 
microscope. 
Binding study to BSA. Purified BSA “essentially globulin and fatty acid free” (Aplichem Co. 
Germany) was used to prepare the stock 2.5 × 10−5 M solution by dissolving an appropriate amount 
of BSA in 0.05 mol L-1 Tris-HCl buffer of  pH 7.4 containing 0.1 M NaCl solution, then stored at 
4°C. The purity of BSA  stock solution (10 × 10−3 M  in DMSO) was estimated to be 99% based on 
an absorbance value at 279 nm using a reference value of 0.667 for 1.0 g L−1 of pure BSA. All stock 
solutions were stored at 4 °C in dark. All solutions were diluted to the required volume with Tris–
HCl buffer of pH 7.4. All the other reagents involved in this work were of analytical-reagent grade, 
and doubly distilled water was used throughout. UV–vis absorption spectra were measured on a 
Beckman  UV spectrophotometer with the use of a 10 mm quartz cuvette. 
Chemicals and materials. Trypsin, Trypan Blue, antibiotic and antimycotic agent, Fetal Bovine 
Serum (FBS), sulforhodamine B (SRB), dimethyl sulfoxide (DMSO), and fish sperm DNA were 
purchased from Sigma Chemical. iPAdo was prepared following the protocol described in Section 
5.4, experimental part.  
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Cell cycle analysis. Apoptosis and cell cycle profile were assessed by DNA fluorescence flow 
cytometry. MCF-7 cells were plated at a density of 5 x 105 cells/well on six-well plates. Cells 
treated with iPAdo at different concentration of 1, 5 and 10 µM  for 72 h were harvested, rinsed in 
PBS, re-suspended in  600µl of PBS containing 1% FBS and fixed by 1.4 ml ethanol 80%, and 
stored at -20 °C in fixation buffer until ready for analysis. Then the pellets were suspended in 1 ml 
of fluorochromic solution [0.08 mg/ml propidium iodide in 1x PBS] at room temperature in the 
dark for 60 min. The DNA content was analyzed by FACScan flow cytometer (Beckman Counter, 
cytomics FC 500) and CellQuest software (Becton Dickinson). The population of apoptotic nuclei 
(subdiploid DNA peak in the DNA fluorescence histogram) was expressed as the percentage in the 
entire population. 
DNA titration experiments. The absorbance at 260 and 280 nm was recorded, in order to check 
the protein content of DNA solution. The A260/A280 ratio was 1.83, showing that the DNA was 
sufficiently free of protein. DNA (5 mg/mL) was dissolved in distilled water (pH 7) at 4°C for 24 h 
with occasional stirring to ensure the formation of a homogeneous solution. The final concentration 
of the DNA solution was determined spectrophotometrically at 260 nm using molar extinction 
coefficient ε260 = 6600 cm-1 M-1 (expressed as molarity of phosphate groups) [32]. The UV 
absorbance at 260 nm of a diluted solution (1/250) of DNA used in our experiments was 0.661 and 
the final concentration of the DNA solution was 12.5 mM in DNA phosphate. The appropriate 
amounts of iPAdo (0.05–12.5 mM) were prepared in distilled water and added dropwise to DNA 
solution in order to obtain the desired ligand/DNA molar ratios (r) of 1/80, 1/40, 1/20, 1/10, 1/5, 1/2 
and 1 with a final DNA concentration of 6.25 mM. The pH of solutions was adjusted to 7.0 ± 0.2 
using NaOH solution. 
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5.3. SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY OF MODIFIED N6-
isoPENTENYL ADENOSINE AGAINST CATABOLIC DEACTIVATION 
 
This section will report on the results obtained from the investigation dealing with the 
synthesis of iPAdo analogues designed to prevent catabolic transformations of the compound  that 
could in vivo deactivate iPAdo and, consequently, be one of the main cause of lack of in vivo 
activity. The study will be limited to in vitro assay of the antiproliferative activity of the synthesized 
compound. Only iPado analogues showing an in vitro activity similar or higher than that of iPAdo 
will be selected for the in vivo experiments.  In fact, studies of in vivo activity require time 
consuming procedures and expensive experiments with living animals. From the observations on 
iPAdo metabolism reported in Sections 2 and 3, the plausible catabolic transformations of the 
compound could involve oxidation/cleavage of various positions of iPAdo molecule (paths a-e, 
Figure 1, Section 3). Path a represents the possible hydration of the isopentenyl double bond, path b 
the cleavage of the isopentenyl chain as a consequence of a few transformations that are at present 
unknown. The paths c and d indicate the possible oxidation of the purine positions 2 and/or 8 and 
path e refers to the cleavage of the β-glycosidic bond catalyzed either by a phosphorolytic enzyme 
or by a non-specific hydrolase present in the tumor cell. 
5.3.1. N6-isoPentyl Adenosine 
 
One of the plausible catabolic transformations of iPAdo can involve hydration of the 
isopentenyl double bond (path a, Figure 1, Section 3) with the formation of N6-(3-Methyl-3-
hydroxybutylamino)-9-(β-D-ribofuranosy1)-purine and N6-(3-Methyl-3-hydroxybutylamino)-purine 
that  has already been demonstrated both chemically [1]  and  from the results of an in vivo studies 
[2] (Scheme 1). 
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Scheme 1. Hydration of isoPentenyl chain of iPAdo 
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  The saturated analog of iPAdo, N6-isopentyladenosine (iPAdoS) should block the catabolic 
mechanism represented by path a and could represent one of the solutions to iPAdo deactivation. 
iPAdoS  has been  prepared with other N6-substituted analogues by reaction of isopentylamine and 
6-chloropurine riboside (Scheme 2) and the growth inhibitory activity was examined with cell 
cultures of Sarcoma 180 and its subline AH/S  [3]. In particular, iPAdoS exhibited an appreciable 
IC50 value (11 μM) for the subline AH/S.  
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Scheme 2. Synthesis of N6-isoPentyl Adenosine 
 
It has been later shown that iPAdoS, compared to iPAdo that at 10 μM abrogated colony 
formation in 9 of 10 tested cell lines, completely inhibited clonogenicity of only 6 of the 10 cell 
lines (Figure 1). Thus, besides being less effective that iPAdo, appeared to have a certain cells 
specificity [3, 4].  
 
 
 
Figure 1. Inhibition of clonogenicity after in vitro treatment of 10 human cancer cell lines of 
epithelial origin with compound 1 (iPAdoS) at 100 μM) (reported from [4]). 
 
The potential in vivo antitumour activity of iPAdoS was tested in nude mice inoculated i.p. 
with IGROV1 cells, an in vivo model that can be considered the most similar to an in vitro assay 
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because i.p.-injected IGROV1 cells grow in the peritoneal cavity as ascites and the i.p.-injected 
drug quickly comes in contact with tumour cells. However, as in the case of iPAdo, iPAdoS did not 
affect mouse survival as compared to untreated mice, suggesting that the pharmacokinetics of both 
compounds do not allow them to reach time-average concentrations comparable to those in vitro. 
Analysis of nude mice bearing i.p. IGROV1 ascites and treated i.p. daily with 10 mg/kg of iPAdo or 
iPAdoS revealed a limited increased survival of treated mice (median survival time of 21, 20 and 18 
days in iPAdo, compound 1-treated, or untreated mice, respectively), but the increase was not 
statistically significant. Interestingly, doses of iPAdoS of 15 mg/kg caused a rapid abdominal 
contraction and lethargy lasting for about 30 min but had no significant effect on the median 
survival time. 
In conclusion, the modification of iPAdo isopentenyl group, possible responsible of 
deactivation according to the catabolic path a, caused a lower activity with respect to iPAdo and did 
not improve the survival time of animals injected with a tumor in vivo. This observation determined 
the decision that only iPAdo analogues showing an in vitro activity similar or higher than that of 
iPAdo would be selected for further in vivo experiments. 
5.3.2. N6-isoPentenyl Aristeromycin 
Another plausible catabolic in vivo transformation of iPAdo is related to path e (Figure 1, 
Section 3) and refers to the cleavage of the β-glycosidic bond that can be catalyzed either by a 
phosphorolytic enzyme or by a non-specific hydrolase present in the tumor cell. Should this 
catabolic pathway be active in vivo, a carbocyclic analogue of iPado would most suitably resist to 
the hydrolytic cleavage of the β-glycosidic bond.  
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Figure 2. isoPentenyl Adenosine and isoPentenyl Aristeromycin 
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We, therefore, envisaged N6-isopentenyl aristeromycin (iPAry) as our synthetic target, due 
to the fact that the endemic problem of the hydrolytic instability of the glycosidic linkage of a 
nucleoside might be solved simply and generally by replacing the furanose ring oxygen atom by 
carbon. This removes the element responsible for the instability of the O-C-N bond system 
(hemiamine acetal) and generates a C-C-N group that is very stable to hydrolysis and to various 
chemical modifications (Figure 2). At the same time, the difference between iPAdo (an oxygen 
atom) and iPAry (a methyllene group) should have little influence on the interaction of the 
compounds with the biological systems present in the in vitro or in vivo systems.  The same concept 
has been utilized for DNA-N-glycosylase studies, since it had been previously demonstrated that 
replacement of a single 2'-deoxynucleoside in DNA by a carba-analogue does not alter the Watson-
Crick base pairing, yet at the same time provides a chemically and enzymatically stable 
“glycosidic” linkage. Therefore, a few enzymatically non-cleavable carbocyclic nucleosides have 
been prepared in order to investigate their activity as enzyme inhibitors of the DNA-repair enzymes 
involved in oxidative damage [5]. Although the transformation of Ary into iPAry (Figure 3) should 
not present any apparent difficulty, a major problem was the availability of Ary. Ary is the 
carbocyclic adenosine analogue (Figure 4) [6], that was obtained from the fermentation broth of 
Streptomyces citricolor [7]. The compound exhibits a number of interesting biological properties, 
including inhibition of AMP synthesis in mammalian cells, cell division and elongation in rice 
plants, and inhibition of the enzyme S-adenosylhomocysteine hydrolase [8]. 
N
NN
N
NH2
OHOH
HH
HH
HO
Ary
N
NN
N
NH
OHOH
HH
HH
HO
iPAry
 
 
Figure 3. Aristeromycin and N6-isoPentenyl Aristeromycin 
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We have attempted to start some collaboration with microbiologists, in order to prepare 
microbiologically Ary, but we encountered several difficulties, such as not easy availability of the 
strain and also the low concentration of Ary in the culture medium.  On the other hand, the unusual 
structure of Ary and its important biological   activity have stimulated various synthetic studies and 
several syntheses have been published since a few years ago [6, 9].     
Therefore, we considered the opportunity to start a synthetic project that was very 
stimulating and challenging from a chemical point of view, also in view of the fact that most of 
published syntheses of Ary suffers of several limitations ranging from the number of steps to non-
stereospecificity paths, to low yields [10-24]. 
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Figure 4. β-D-Adenosine and Aristeromycin 
 
However, one main disadvantage was constituted by the long time that a multi-step 
synthesis would require. On the other hand, the synthetic approach should be selected in such a way 
that it should be versatile enough to open the possibility to prepare iPAry as well as many other N6-
substituted derivatives of Ary. Therefore, a suitably protected cyclopentanetriol (compound I, 
Scheme 3) should react with 6-chloropurine in order to prepare the 6-chloropurine carbonucleoside 
II. This, by reaction with a suitable primary amine R-CH2NH2 should potentially afford a full series 
of N6-substituted Ary derivatives to be screened for their cytostatic activity.  
The preparation of the cyclopentane derivative I was considered as the crucial point of the 
all synthetic strategy, since it is a multi-step synthetic sequence, where the single yields could be 
lowered by intrinsic difficulty of the experimental protocol. Furthermore, several steps could be 
hampered by a reduced stereoselectivity, due to the procedure adopted. A better stereocontrol could 
not be easily obtained under chemical conditions and a biocatalytic approach could be attempted for 
the purpose. 
  In spite of these considerations, we decided to explore the feasibility of preparing the 
cyclopentane derivative I (or analogous compound) from a suitable starting material. 
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Scheme 3. Strategy for preparing N6-substituted Aristeromycin analogs from protected 
cyclopentanetriol.  
 
After a careful inspection of available literature, we decided to follow two promising 
approaches. According to Jin et al. [25], D-(-)-ribose could be used as a convenient starting material 
that presented the requisite 2α,3α-dihydroxyl stereochemistry. From D-ribose 1, the cyclopentenone 
8 could be prepared in eight steps through an apparently convenient series of synthetic protocols 
that has been reported for a multi-gram scale. The synthesis of the required cyclopentenone 8 from 
D-ribose 1 is reported in Scheme 4. Although the overall synthetic scheme has been fully described, 
we were unable to repeat the reported high yields of single steps and, in our hands, starting from 10 
g of D-ribose only 400 mg of pure compound 8 could be prepared. In more details,  D-Ribose 1 was 
converted to the isopropylidene protected derivative with 2,2-dimethoxypropane in the presence of 
a catalytic amount of p-toluenesulfonic acid (78% yield), followed by silylation of the primary 
hydroxyl group using tert-butyldimethylsilyl chloride to give compound  2 in 82% yield (Scheme 
4). Compound 2 was reacted with vinylmagnesium bromide to obtain a ring opened olefin 3 as a 
single stereoisomer (58% yield). The stereoselectivity is probably due to the steric as well as the 
electronic effect of the isopropylidene group, which prevents the coordination of vinylmagnesium 
bromide at the R site. To introduce another olefinic moiety, deprotection of the silyl group was 
accomplished by using a 1 M solution of TBAF in THF followed by an oxidative cleavage of the 
vicinal diol 4 with sodium periodate to give the aldehyde 5 in overall 55 % yield. 
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Scheme 4. Transformations for preparation of 2-D-cyclopentenone 8 from D-ribose 1. 
 
Reagents and conditions: (a) 2,2-dimethoxypropane, p-TsOH, acetone, 0 °C to R.T., 1 h; (b) 
TBDMSCl, imidazole, CH2Cl2, R.T., 1 h; (c) vinylmagnesium bromide, anh. THF, -78 °C 
to R.T., 1 h; (d) TBAF, THF, R.T., 1 h; (e) NaIO4, H2O, R.T., 1 h; (f) NaH, DMSO, 
methyltriphenylphosphonium bromide, THF, 0 °C to reflux, 3 h; (g) Grubbs´ catalyst, anh. 
CH2Cl2, 24 °C, 4 h; (h) pyridinium dichromate, 4 Å molecular sieves, AcOH, CH2Cl2, 
R.T., 12 h. 
 
The aldehyde 5 was subjected to the Wittig reaction using NaH, DMSO, and 
methyltriphenylphosphonium bromide to give the diene 6 in 60% yield. The ring-closing metathesis 
reaction was carried out using Grubbs´ catalyst to obtain D-cyclopentenol 7. It was found that the 
metathesis reaction was affected by the reaction temperature. Although the diene 6 was converted to 
ring-closed cyclopentenol 7 at 15 °C with 1 mol % Grubbs´ catalyst for 24 h, the reaction was 
completed within 4 h at 25 °C with the same amounts of catalyst. However, the ring-closed 
cyclopentenol 7 was highly volatile and yield of recovered material was not superior to 42%. 
Therefore, the desired key intermediate D-2-cyclopentenone 8 was directly obtained by oxidation 
with pyridinium chlorochromate of the secondary alcohol 7 without its isolation in 7.3% overall 
yield from D-ribose. While performing the passage 6 → 8 ca 0.8 g of initial diene 6 was consumed 
for optimizing the comprised metathesis and oxidation transformations.   
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Scheme 5. Synthesis of isoPentenyl Aristeromycin from D-2-cyclopentenone 8. 
 
Reaction conditions: (a) Vinylmagnesium bromide, TMSCl, HMPA, CuBr‚ Me2S; (b) LiAlH4, 
THF; (c) 6-Chloropurine, DIAD, Ph3P, THF; (d) NaIO4, OsO4, MeOH/H2O; (e) NaBH4, 
MeOH; (f) isopentenylamine/MeOH; (g) 1 N HCl/MeOH. 
 
As earlier reported, in our hands, starting from 10 g of D-ribose only 400 mg of pure 
compound 8 could be prepared. However, repetition of the overall procedure, considering that a 
critical revision  of the most critical steps was necessary,  required a few months of synthetic work. 
Therefore, we decided to continue our synthetic effort starting from 400 mg of cyclopentenone 8. In 
turn, we decided to utilize compound 8 as the intermediate for the synthesis of [6-(6-Chloropurin-9-
yl)-2,2-dimethyltetrahydrocyclo-penta[1,3]dioxol-4-yl]methanol 12, following the procedure 
described in the literature [26].  Seven additional steps were required to transform the 
cyclopentenone 8 into iPAry (Scheme 5). Isopentenylamine that was required for the introduction 
of the N6-isopentenyl group (step f, Scheme 5), was suitably prepared according to Semenow [27]. 
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A vinyl moiety was chosen as the source of its C-5'-hydroxymethylene in the final compound 12.   
The incorporation of a vinyl group onto a cyclopentyl ring by 1,4-enone addition is known to be a 
high-yielding reaction [28] and the related modified procedure [29] were encouraging to us.  
In our hands, the 1, 4-addition of vinylmagnesium bromide to 8 afforded the ketone 9 in 
67% yield in optimal variant. Several experiments in order to improve the outcome of the above 
reaction preceded the reduction of 9 with lithium aluminum hydride that yielded the alcohol 10 as 
the main isomer.  
However, a careful silica gel chromatography was required and the α-isomer 10 was 
obtained in 75% yield. Mitsunobu reaction of 10 with 6-chloropurine gave the coupled product 11, 
which was inseparable from an azadicarboxylate byproduct and used as same in the next step. 
Transformation of the ethylene moiety of 11 to the hydroxymethyl group was accomplished in a 
two-step sequence, as described [27]. Oxidative cleavage of the double bond with osmium 
tetroxide/sodium periodate followed by sodium borohydride reduction provided 12 in 52% yield 
(three steps from 10).  Reaction of the chloropurine derivative 12 with freshly prepared 
isopentenylamine afforded the protected iPAry that was directly hydrolyzed with 1 N HCl and 
methanol at room temperature (3 h). The TLC control showed the appearance of two main spots, the 
more polar and abundant presumably constituted the byproduct of addition of water to the double 
bond of N6-isopentenyl moiety. The required iPAry was isolated (5 mg) and characterized only 
through 1H-NMR spectroscopy. The few milligrams of iPAry so obtained were sufficient for 
preliminary tests of the antiproliferative activity against MCF-7 cells.  
 
5.3.3. Cell proliferation activity of N6-isoPentenyl Aristeromycin on MCF-7 cells 
 
The results of the studied proliferation activity of the synthesized iPAry in comparison with 
that of reported analogous compounds are shown in Figure 5. Surprisingly for us, analysis of dose-
dependent effects of iPAry on MCF-7 in vitro cell proliferation by AlamarBlue assay revealed 
almost no effects of compound up to 3 days of treatment. The 3- and even 9-fold augment of iPAry 
concentration (27 to 81M) had no notable modification on cell proliferation. Interestingly, some 
modificated at N6 iPAdo analogues (cm_102, cm_116, cm_121 and saturated iPAdo (iPAdoS) 
(Figure 6) promoted the inhibition of cell proliferation at an extent very close to that of iPAdo, 
showing almost the same cytotoxic activity (Figure 5) [30]. From the obtained results, one can 
conclude on the essentiality of intact ribose moiety in iPAdo and derivatives for exerting 
antiproliferative properties, wheareas variations at N6 are well-tolerated.  
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Figure 5. Results on cell proliferation activity of N6-isoPentenyl Aristeromicin and N6-
isoPentenyl Adenosine analogues on MCF-7 cell proliferation. i6A- iPAdo, i6Ary-
iPAry, sat-iPAdoS, ntc-untreated cells, cm_102 =N6-butyl adenosine; cm_116 = 
N6-allyl adenosine; cm_121 = benzyladenosine. AlamarBlue Assay _ MCF 7 cells 
(700 cells/well in 96/well plate)_day 3. RFU-relative fluorescence units. 
Compounds in H2O e DMSO, at final concentration=10 µM, iPAdo in H2O, 
DMSO finale < 0.1%.   
 
HO
N
NN
N
HN
O
OHOH
HH
HH
R
cm_102 R=butyl 
cm_116 R=allyl
cm_121 R=benzyl
iPAdoS R=isopentyl
 
 
Figure 6. Structures of iPAdo congeners tested for cytotoxic activity 
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Successively we have studied the possibility of preparing iPAry from commercial Ary in 
order to consolidate the preliminary data on surprisingly modest biological properties of iPAry and 
for its better characterization by NMR-techniques.  
 
EXPERIMENTAL to Section 5.3. 
6-(3-Methyl-butylamino)-9-(β-D-ribofuranosyl)-purine (iPAdoS) was prepared following the 
general procedure for chlorine substitution starting from 6-chloropurine riboside   and 1-amino-3-
methylbutane.  Thus, K2CO3 (4.5 mmol) and 3-Methyl-butylamine (4.5 mmol) were added to a 
solution of 6-chloropurine riboside (1.5 mmol) in DMF (20 mL). The mixture was heated at 120-
130°C for 3h, cooled to room temperature, filtered on celite pad and the solvent was removed under 
vacuum.  Rf = 0.48 (CH2Cl2/MeOH, 90:10); white solid 68% yield; m.p. 152-154 °C; [α]D20  -58.7 (c 
1, MeOH) [lit. [32] m.p. 154.5-156 °C, [α]D20  -42.0 (c 1.03, EtOH)]; 1H NMR (DMSO-d6) δ = 0.9 
(d, J = 6.6 Hz, 6H, CH3 14 and 15), 1.49 (ddd, J = 6.6 Hz, J = 6.6 Hz, J = 6.6 Hz, 2H, CH2 12), 1.62 
(m, 1H, J = 6.6, CH 13), 3.05 (m, 2H, CH2 11), 3.53 (ddd, J = 3.7 Hz, J = 7.3 Hz, J =12.1 Hz, 1H, 
H5´b), 3.67 (ddd, J = 3.8 Hz, J = 4.5 Hz, J = 12.1 Hz, 1H, H5´a), 3.96 (ddd, J = 3.0 Hz, J = 3.7 Hz, 
J = 3.8 Hz, 1H, H4´), 4.14 (ddd, J = 3.0 Hz, J = 4.6 Hz, J =5.2 Hz, 1H, H3´), 4.61 (ddd, J = 5.2 Hz, 
J = 6.3 Hz, J = 6.3 Hz, 1H, H2´), 5.16 (d, J =4.6 Hz, 1H, OH 3´), 5.41 (dd, J = 4.5 Hz, J = 7.3 Hz, 
1H, OH 5´), 5.42 (d, J = 6.3 Hz, 1H, OH 2´), 5.87 (d, J = 6.3 Hz, 1H, H1´), 7.83 (bs, 1H, NH 10), 
8.20 (s, 1H, CH 2), 8.33 (s, 1H, CH 8); 13C NMR δ = 22.53 (C14 and C15), 25.23 (C13), 37.95 
(C11 and C12), 61.64 (C5'), 70.61 (C3'), 73.41 (C2'), 85.85 (C4'), 87.91 (C1'), 119.71 (C5), 139.51 
(C8), 148.17 (C4), 152.32 (C2), 154.43 (C6); ESIMS m/z 336 (M-1, 30%), 673 (2M-1, 100%). 
Anal. calcd for C15H23N5O4: C, 53.40; H, 6.87; N, 20.76. Found: C, 53.56; H, 6.79; N, 20.65. 
Proliferation assay. Cell proliferation was analyzed using the AlamarBlue® Assay (Biosource, 
Camarillo CA). MCF-7 cells were plated at 700 cells per well in 96-well plates and cultured for 4 
days in the presence of 10 µM i6A or 9, 27 or 81 μM i6Ary and 10% AlamarBlue. Cell proliferation 
of treated and untreated cells was monitored based on fluorescence intensity (excitation 535 nm, 
emission 590 nm) measured on a Tecan ULTRA multiplate reader (Tecan Group Ltd. 
Mannedorf/Zurich, Switzerland). Six replicas were performed for each dose and for each compound 
tested. 
(4R, 5S)-(+)-1-[4-[2-(tert-Butyldimethylsilyloxy)-1-hydroxyethyl]-2,2-dimethyl-1,3-dioxolan-5-
yl]-(S)-2-propen-1-ol (3). A solution of 2 (14.47 g , 47.72 mmol) in dry THF (150 mL) was cooled 
to -78 °C, and vinylmagnesium bromide (1M solution in THF, 140 mL, 140.0 mmol) was added 
dropwise at -60 °C. After addition was completed, the reaction mixture was allowed to stir at R.T. 
for 1 h. Upon re-cooling the resulting clear brown mixture to -78 °C, saturated NH4Cl solution (150 
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mL) was added dropwise to quench and the resulting solution was repeatedly extracted with Et-O-
Ac (180 mL). The organic layer was washed with brine, dried over MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by silica gel column chromatography (Et-O-
Ac/hexane=1:20), giving compound 3 (9.20 g, 58%) as a colorless oil: [α]D23 +6.86 (C 0.59, 
CHCl3); 1H NMR (CDCl3) δ= 6.02 (m, 2H), 5.43 (d, J= 17.2 Hz, 1H), 5.26 (d, J= 10.4 Hz, 1H), 
4.35 (bs, OH, D2O exchangeable, 1H), 4.31 (bs, 1H), 4.07 (m, 2H), 3.86 (m, 2H), 3.65 (dd, J= 6.7 
and 9.9 Hz, 1H), 3.36 (bs, OH, D2O exchangeable, 1H), 1.39 (s, 3H), 1.32 (s, 3H), 0.91 (s, 9H), 
0.10 (s, 6H); 13C NMR (CDCl3) δ= 137.3, 115.9, 108.6, 80.6, 76.5, 69.6, 69.2, 64.1, 27.9, 25.7, 
25.3, -5.5. Anal.Calcd for C16H32O5Si: C, 57.79; H, 9.70. Found: C, 58.13; H, 9.80. 
(4R,5S)-(-)-1-[4-(1,2-Dihydroxyethyl)-2,2-dimethyl-1,3-dioxolan-5-yl]-(S)-2-propen-1-ol (4). 
Tetrabutylammonium fluoride (1 M solution in THF, 29 mL, 29 mmol) was added to a solution of 3 
(9.15 g, 27.53 mmmol) in THF (85 mL) and stirred at R.T. for 1 h. The resulting brown mixture 
was concentrated in vacuo, and the residue was purified by column chromatography on a silica gel 
(Et-O-Ac/hexane=2:1), giving compound 4 (4.27 g, 71%) as white crystals: mp 72.4-73.9 °C; [α]D23  
-31.33 (c 1.00, CHCl3); 1H NMR (CDCl3) δ= 6.03 (m, 1H), 5.40 (dd, J= 0.8, 17.2 Hz, 1H), 5.31 
(dd, J= 0.8, 10.5 Hz, 1H), 4.34 (t, J= 8.1 Hz, 1H), 4.16 (dd, J= 5.4, 9.4 Hz, 1H), 4.06 (dd, J=5.4, 
9.2 Hz, 1H), 3.95-3.87 (m, 1H D2O exchangeable, 3H), 2.15 (bs, OH, D2O exchangeable, 1H), 1.40 
(s, 3H), 1.34(s, 3H); 13C NMR (CDCl3) δ 137.6, 117.1, 80.0, 77.8, 69.3, 64.6, 28.0, 25.4. Anal. 
Calcd for C10H18O5: C, 55.04; H, 8.33. Found: C, 55.21; H, 8.28. 
(1S,2S,3S)-2,2-Dimethyl-6-vinyltetrahydrofuro[3,4-d]-1,3-dioxol-4-ol (5). A solution of triol 4 
(4.25 g, 19.47 mmol) in H2O (45 mL) was cooled to 0 °C, and NaIO4 (6.3 g, 29.0 mmol) was added 
portionwise. After being stirred at R.T. for 1 h, the reaction mixture was extracted with Et-O-Ac (3 
x 55 mL), and the extracts were dried over MgSO4, filtered, and concentrated to dryness under 
reduced pressure. The residue was purified by silica gel column chromatography (Et-O-
Ac/hexane=1:10), giving compound 5 (2.83 g, 78%) as a colourless oil: 1H NMR spectral data were 
identical to the literature [32]. 13C NMR (100 MHz, CDCl3) δ 137.9, 134.4, 117.3, 117.0, 114.3, 
112.5, 103.0, 102.9, 96.2, 88.5, 86.6, 84.7, 80.5, 79.0, 26.4, 26.2, 25.0. Anal. Calcd for C9H14O4: C, 
58.05 H, 7.58. Found: C, 58.38; H, 7.74. 
(1S,2S,3R)-(-)-1-(2,2-Dimethyl-5-vinyl-1,3-dioxolan-4-yl)-(S)-2-propen-1-ol (6). A suspension of 
NaH (0.9 g, 22.5 mmol, 60% dispersion in mineral oil) in THF (90 mL) was cooled to 0 °C, and 
then DMSO (2.68 mL, 37.6 mmol) was added. After being stirred at R.T. for 0.5 h, the resulting 
white suspension mixture was cooled to 0 °C and treated with methyltriphenylphosphonium 
bromide (8.03 g, 22.5 mmol). The reaction mixture was stirred at R.T. for 1 h and then re-cooled to 
0 °C. A solution of lactol 5 (2.80 g, 15.0 mmol) in THF (25 mL) was added to the resulting reaction 
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mixture at 0 °C. After being heated at reflux for 3 h, the reaction mixture was cooled to room 
temperature. Diethyl ether (90 mL) was added to the reaction mixture and washed with H2O (50 
mL) and brine (50 mL). The organic layer was dried over MgSO4, filtered, and concentrated in 
vacuo. The residue was purified by silica gel column chromatography (Et-O-Ac/hexane=1:10), 
giving compound 6 (1.66 g, 60%) as a colorless oil. All the spectral data were identical to the 
literature [32]. 
(4R,5R)-(-)-4,5-O-Isopropylidene-2-cyclopentenone (8). To a 25 mL round-bottom flask filled 
with the Grubbs’ catalyst (37 mg, 1 mol %, flushed with N2 three times) was added a solution of the 
diene 6 (0.81 g, 4.40 mmol) in anhydrous CH2Cl2 (15 mL). After being stirred at 24 °C for 4 h, 4 Å 
molecular sieve (1.65 g), pyridinium dichromate (1.94 g, 8.94 mmol), and acetic acid (12.6 µL, 5 
mol %) were added to the resulting dark brown mixture. The reaction mixture was stirred at the 
same temperature for 12 h and filtered over a silica gel pad (≈ 3 cm) with Et-O-Ac. The filtrate was 
concentrated in vacuo, and the residue was purified by column chromatography on a silica gel (Et-
O-Ac/hexane=1:10), giving compound 8 (0.4 g, 59%) as white crystals: m.p. 68.5-70.3 °C; [α]D23 -
69.3 (c 0.60, CHCl3) [lit. [32] m.p. 68.6-70.1 °C; [α]D23 -70.4 (c 0.92, CHCl3)]; 1H NMR (CDCl3) δ 
7.61 (dd, J= 2.4, 6.0 Hz, 1H), 6.22 (d, J= 6.0 Hz, 1H), 5.28 (dd, J= 2.4, 5.6 Hz, 1H), 4.47 (d, J= 
5.6 Hz, 1H), 1.42 (s, 3H), 1.41 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.6, 134.6, 115.4, 78.6, 
76.5, 27.4, 26.1. Anal. Calcd for C8H10O3: C, 62,33; H, 6.55. Found: C, 62.15; H, 6.52. 
 (3aR,6R,6aR)-2,2-Dimethyl-6-vinyltetrahydrocyclopenta-[1,3]dioxol-4-one (9). To a suspension 
of CuBr٠Me2S (0.02 g, 0.11 mmol) in THF (5 mL) at -78 °C was added dropwise vinyl magnesium 
bromide (1.63 mL, 1.63 mmol). The mixture was stirred for 10 min before a solution of 8 (0.20 g, 
1.30 mmol), TMSCl (0.34 mL, 2.64 mmol), and HMPA (0.74 mL, 3.34 mmol) in THF (1 mL) was 
added dropwise. After the reaction mixture was stirred at -78 °C for 3 h and warmed to 0 °C, 
saturated NH4Cl (2 mL) was added and the resulting mixture stirred for 30 min. To this was added 
Et-O-Ac (20 mL). The organic layer was separated, washed with H2O (3 x 2 mL) and brine (5 mL), 
and dried (MgSO4). The solvent was removed under reduced pressure and the residue purified by 
silica gel column chromatography (Et-O-Ac/hexane=1:3) to give 9 as a colorless liquid (0.164 g, 
67%): 1H NMR (250 MHz, CDCl3) δ 5.85 (ddd, J= 17.3, 10.6, 6.4 Hz, 1H), 5.17- 5.07 (m, 2H), 
4.65 (d, J= 5.3 Hz, 1H), 4.21 (d, J= 5.3 Hz, 1H), 3.11 (m, 1H), 2.85 (dd, J= 19.4, 8.6 Hz, 1H), 2.28 
(dm, J= 19.4 Hz, 1H), 1.44 (s, 3H), 1.35 (s, 3H); 13C NMR (62.9 MHz, CDCl3) δ  213.1, 137.2, 
116.4, 112.4, 81.4, 77.9, 39.8, 38.6, 26.9, 25.0. 
(3aS,4S,6R,6aR)-2,2-Dimethyl-6-vinyltetrahydrocyclopenta[1,3]dioxol-4-ol (10). To a 
suspension of LiAlH4 (43 mg, 1.12 mmol) in dry THF (2 mL) at 0 °C was added dropwise a 
solution of 9 (119 mg, 0.65 mmol) in THF (0.7 mL). The reaction mixture was then stirred at R.T. 
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for 3 h before it was quenched sequentially with H2O (0.1 mL), aqueous NaOH (15%, 0.1mL) and 
H2O (0.2 mL). The resulting solid was removed by filtration and the filtrate was evaporated in 
vacuo. Pure 10 has been isolated after column chromatography on silica gel (elution mixture Et-O-
Ac/hexane=1:10) as a colourless liquid (90 mg, 75%). 1H NMR (CDCl3) δ 5.75 (ddd, J= 17.3, 10.6, 
6.4 Hz, 1H), 5.08 (m, 2H), 4.48 (m, 1H), 4.06 (m, 1H), 2.75 (m, 1H), 2.48 (br s, 1H), 1.90 (m, 2H), 
1.52 (s, 3H), 1.36 (s, 3H); 13C NMR (CDCl3) δ 138.2, 115.5, 111.8, 84.5, 79.2, 71.3, 44.5, 36.2, 
26.3, 24.5. Anal. Calcd for C10H16O3: C, 65.19; H, 8.75. Found: C, 64.95; H, 8.77. 
(3aS,4R,6R,6aR)-[6-(6-Chloropurin-9-yl)-2,2-dimethyltetrahydrocyclo-penta[1,3]dioxol-4-
yl]methanol (12). A solution of DIAD (0.18 mL, 0.75 mmol) was added dropwise to a suspension 
of 6-chloropurine (97 mg, 0.62 mmol), Ph3P (7.14 g, 27.3 mmol), and 10 (81.80 mg, 0.44 mmol) in 
dry THF (2.5 mL) at 0 °C. The mixture was stirred at the same temperature for 30 min and allowed 
to warm to R.T. After the reaction was stirred at R.T. for 12 h, it was brought to 50 °C and stirred 
for another 8 h. The solvent was removed under the reduced pressure, and the residue was purified 
by silica gel column chromatography (Et-O-Ac/hexane=1:3) to afford 11 contaminated with the 
azadicarboxylate byproduct. The above mixture was dissolved in MeOH (1.0 mL) and H2O (0.5 
mL), and NaIO4 (140.0 mg, 0.65 mmol) was added. After the mixture was cooled to 0 °C, OsO4 
(1.0 mg) was added. The reaction was stirred at the same temperature for 1 h and then at R.T. for 2 
h. The white solid that resulted was removed by filtration and the filtrate removed at ambient 
temperature. Methylene chloride (10 mL) was added to the residue and the organic solution washed 
with H2O (1.0 mL) and brine (1.0 mL) and dried (MgSO4). The CH2Cl2 was removed under reduced 
pressure at ambient temperature and the residue dissolved in MeOH (1.5 mL). This solution was 
cooled to 0 °C, and NaBH4 (39.0 mg, 0.99 mmol) was added portionwise. After the reaction was 
stirred at the same temperature for 1 h, the solvent was removed and CH2Cl2 (5.0 mL) and water 
(1.0 mL) were added. The organic layer was separated and washed with brine and dried (MgSO4). 
After removing the solvent under reduced pressure, the product was purified by a short silica gel 
column chromatography (beginning with Et-O-Ac/hexane=1:2 and then Et-O-Ac) to give 12 as a 
white solid (75 mg, 52% from 10): mp 169-170 °C; 1H NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 
8.26 (s, 1H), 5.03 (dd, J= 6.5, 6.0 Hz, 1H), 4.88 (m, 1H), 4.75 (dd, J= 6.9, 3.9 Hz, 1H), 3.87 (dq, 
J= 21.5, 10.6, 4.3 Hz, 2H), 2.57 (br, 1H), 2.54 (m, 3H), 1.60 (s, 3H), 1.33 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 151.7, 151.6, 151.3, 144.6, 132.3, 113.9, 84.0, 81.8, 63.5, 63.0, 45.4, 33.0, 27.6, 
25.1. Anal. Calcd for C14H17O3N4Cl: C, 51.77; H, 5.29; N, 17.25; Cl, 10.92. Found: C, 51.64; H, 
5.23; N, 17.19; Cl, 10.87. 
2´, 3´-Isopropylidene-N6-isopentenylamine arysteromycine (13). To a suspension of compound 
12 (68.20 mg, 0.21 mmol) in dry acetone (12.0 mL) p-TsOH  (40.0 mg, 0.21 mmol) and 2,2-
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dimethoxypropane (0.14 mL, 1.05 mmol) were added. The mixture was vigorously stirred at R.T. 
overnight while protected from light and moisture. Tlc-monitoring revealed the complete 
conversion of initial compound. The reaction mixture was neutralized with 5% solution of sodium 
bicarbonate and then the volatiles were evaporated in vacuo. Water (10 mL) was added to the 
residue and the mixture was repeatedly extracted with ethyl acetate. The combined organic extract 
was dried on sodium sulfate and after removal of the solvent 58 mg of brown oil was obtained. It 
was subjected to column chromatography that furnished 50 mg of compound 13 (64% yield), 
elution mixture CH2Cl2 : MeOH = 10 : 1. Anal. Calcd for C19H27O3N5: C, 61.10; H, 7.30; N, 18.76. 
Found: C, 59.98; H, 7.26; N, 18.69.  
 (-)-(1R,2S,3R,5R)-3-(6-isoPentenylaminopurin-9-yl)-5-hydroxymethylcyclopentane-1,2-diol 
(iPAry). Compound 13 (46.67 mg, 0.125 mmol) was dissolved in a mixture of 1N HCl (1.0 mL) 
and MeOH (1.0 mL). This reaction mixture was stirred at R.T. for 3 h and neuturalized with basic 
ion-exchange resin (Amberlite IRA-67). Filtration and evaporation of this mixture afforded a 
mixture of compounds from which iPAry was isolated by column chromatography (elution mixture, 
CH2Cl2 : MeOH = 9 : 1) as a liquid (5 mg, 12% yield). 1H NMR (CD3OD) δ = 1.79 (s, 6H, 2 x 
CH3), 1.96 (ddd, J = 8.0 Hz, J = 10.1 Hz, J = 12.9 Hz, 1H, H6′a), 2.03-2.24 (m, 1H, H4′), 2.48 (ddd, 
J = 8.7 Hz, J = 8.7 Hz, J = 12.9 Hz, 1H, H6′b), 3.69-3.76 (m, 2H, AB part of ABX system, H5′a 
and H5′b),  4.06 (dd, J = 3.2 Hz, J = 5.2 Hz, 1H, H3′), 4.20 (br, 2H, -CH2), 4.52 (dd, J = 5.2 Hz, J 
= 8.7 Hz, 1H, H2′), 4.84 (ddd, J = 8.1 Hz, J = 8.1 Hz, J = 8.7 Hz, 1H, H1′), 5.41 (t, J = 6.9 Hz, 1H, 
-CH), 8.17 (s, 1H, H2), 8.25 (s, 1H, H8). 
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5.4. SYNTHESIS OF N6 -isoPENTENYL ARYSTEROMYCIN via N1/N6 ALKYLATION OF 
ARISTEROMICIN  
 
The few milligrams of iPAry obtained from the above-outlined synthetic approach (Section 
5.3.) have been sufficient for 1H-NMR characterization of the compound and for preliminary tests 
of the antiproliferative activity against MCF-7 cells. We needed additional material for a full 
characterization of the compound and for more detailed spectroscopic studies. However, the time 
left in the third year of doctorate was not enough to cover the repetition of the experimental 
procedure and improvement of several unsatisfactory steps still present in the synthetic approach 
described in Section 5.3. Thus, commercial Ary was bought (only two companies could furnish Ary 
in 5 mg samples at a price ranging from 20 to 30 euro/mg) and attempted its transformation into 
iPAry. This conversion consisted in the N6-alkylation by means of isopentenyl bromide (Scheme 1) 
and is reminiscent of the similar procedure that allows the synthesis of iPAdo from Ado. The 
chemical procedure was expected to be similar to the transformation of adenosine (Ado) into iPAdo 
that has been reported nearly fifty years ago and was modelled on the scale of 20 mg of Ado, in 
order to be repeated for the transformation of the amount of Ary in our hands. 
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Scheme 1. N6-alkylation of Aristeromycin 
 
5.4.1. N1/N6-Alkylation of Adenosine: The Dimroth Rearrangement 
Alkylation of nucleic acids plays an important role in the aetiology and treatment of cancer. 
N-Alkylated nucleosides are the primary origin of many carcinogenic processes caused by the 
interaction of alkylating agents with nucleic acids. These modified nucleosides avoid normal 
mitosis, interfere with transcription and in many cases induce apoptosis [1]. In the case of adenosine 
the main alkylated position is the more basic nitrogen (N1) [2]. Interestingly, N1-alkylated 
adenosines are not only formed by the action of an external source. Thus, 1-methyladenosine is 
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naturally formed by a methyltransferase enzyme and it is commonly found in the tRNA from all 
three biological domains (Eukaryota, Bacteria and Archaea) [3]. All the methodologies for the 
preparation of N1-alkylated purines are based on the nucleophilic attack of N1 to electrophiles [2]. 
Historically, the main research work on alkylated adenosines is related to N-methylation, since a 
substantial number of N-methylpurines have been isolated and identified from various biological 
sources. As, for instance l-methyl-hypoxanthine, 8-hydroxy-7-methylguanine and 7-methylguanine 
that were found in the urine of patients with leukaemia [4]. N-methylpurines might arise as 
degradation products of methylated purine nucleosides or nucleotides hydrolyzed enzymatically in 
vivo or cleaved during isolation procedures [5]. Several of these N-methylpurines have been 
isolated directly from nucleic acids [6-10]. 
Littlefield and Dunn [11] identified N6-methyladenosine and N6,N6-dimethyladenosine  as 
degradation products of ribonucleic acid from various microbial, plant and mammalian sources. The 
first preparation and characterization of N-methylated purine nucleosides was reported in 1963 [12].   
 In this seminal paper, the conditions for methylation were carefully selected to prevent loss of D-
ribose or 2'-deoxy-ribose. Since preliminary studies indicated that the purine 2'-deoxynucleosides 
were particularly unstable to methylation conditions at temperatures near 100° and the loss of 2'-
deoxy-ribose from the purine was noted at 100° in solvents such as dimethylformamide, the 
methylation studies were performed at room temperature. The methylating agents employed were 
methyl iodide, dimethyl sulfate and methyl p-toluenesulfonate. Dimethylacetamide, 
dimethylformamide or dimethyl sulfoxide was selected as a reaction solvent, since these solvents 
were necessary to gain sufficient solubility of the purine nucleoside at room temperature employed. 
These solvents also acted as good buffering solutions which allowed the methylation studies to 
proceed at approximately pH 5-6, thus preventing loss of the sugar by acid hydrolysis.  
5.4.1.1. Methylation of adenosine 
It is noteworthy that before the report from Jones and Robins, no alkylated purine 
nucleosides resulting from studies of nucleic acid and various antitumor alkylating agents had been 
adequately characterized or identified. The N1/N6-methylation of adenosine had been investigated 
by several authors [13-19], but results were unreliable. Jones and Robins reported that adenosine 
was methylated in N,N-dimethylacetamide at room temperature with excess methyl p-
toluenesulfonate. 1-Methyladenosine was isolated as the tosylate salt. No adenosine or other 
methylated purine nucleoside derivative could be detected by a chromatographic study of the 
filtrates. This compound was fully characterized by treatment with aqueous sodium hydroxide 
which readily converted it to the known N6-methyladenosine which has previously been prepared 
[20] from 6-chloro-9-β-D-ribofuranosylpurine. An excess of methyl iodide and adenosine in 
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dimethylacetamide at room temperature similarly gave 1-methyladenosine which was isolated as 
the iodide and converted to the free crystalline 1-methyladenosine with dilute aqueous ammonia at 
pH 9. Under these conditions no rearrangement to N6-methyladenosine was noted. Acid hydrolysis 
of N1-methyladenosine (V) gave D-ribose and 1-methyladenine (VII), obtained for the first time as 
the free base (Scheme 2). From these studies it was apparent that adenosine in neutral or weakly 
acidic media alkylates most readily at position 1.  Interestingly, when adenosine was heated two 
hours in dimethylformamide at 100 °C in the presence of dimethyl sulphate, adenine and 3-
methyladenine was formed.  
 
Scheme 2. Methylation studes on natural purine nucleosides; reported from ref. [12]. 
The rearrangement of N1-methyladenosine to N6-methyladenosine has been later described 
[21] and it has been observed that the rearrangement of l-methyl-adenosine to 6-methylaminopurine 
ribonucleoside followed good first-order kinetics. At pH between 8 and 10 the break from rate-
determining hydroxide attack on the protonated nucleoside to rate-determining attack on the neutral 
nucleoside could be observed (Figure 1).  
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Figure 1. Observed rate of rearrangement of l-methyl-adenosine to 6-methylaminopurine 
ribonucleoside, as a function of pH; ionic strength 0.50, 25ºC; reported from ref. [21].  
 
5.4.1.2. Dimroth rearrangement 
 
The rearrangement of N1-methyladenosine to N6-methyladenosine constitutes an example of 
the so-called Dimroth rearrangement. The Dimroth rearrangement is an isomerization of 
heterocycles that consists in a translocation of endo- or exocyclic heteroatoms through a ring-
opening-ring-closure sequence. It can be catalyzed by acids, bases, heat or light [22-24]. Taylor and 
Loeffler have converted several 1-substituted-7-methyladenines to the isomeric N6-substituted-7-
methyladenines by refluxing in water for a prolonged period of time and have postulated a 
reasonable mechanistic sequence for the conversion (of other heterocyclics, as well) involving 
nucleophilic attack of the hydroxide ion at the 2-position [25]. In the specific case of N1/N6-
isopentenyl adenine, the Dimroth rearrangement has been studied by Leonard [26] that observed 
that the conversion of N1-isopentenyl Ade (I) to N6-isopentenyl Ade (II) proceeded in very dilute 
aqueous solution and also on the acid side. Therefore it was suggested the intervention of water as 
the base in a similar mechanistic sequence involving reversible steps leading to the more stable 
aromatic system (Scheme 3). However, in the same paper the authors describe the conversion of 
N1- into N6-isopentenyl adenosine that has been performed in alkaline medium. In fact, treatment of 
Ado with γ,γ-dimenthylallyl bromide initially gave 1-(γ,γ-dimethylallyl)-9-β-D-
ribofuranosyladenine hydrobromide, followed by alkaline rearrangement (Scheme 4). Crude N1-
isopentenyl adenosine (N1-iPAdo) hydrobromide (50% yield), obtained from the alkylation in 
anhydrous dimethylformamide at 20° followed by evaporation and treatment with acetone to effect 
partial solidification, was dissolved in water, brought to pH 7.5, and heated on the steam bath (2.5 
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hr) while adding 0.1 N sodium hydroxide to maintain the pH at about 7.5. Extraction with ethyl 
acetate was followed by drying and evaporation to yield 76% of rearranged product, 6-(γ,γ-
dimethylallylamino)-9-β-D-ribofuranosylpurine (iPAdo) as crystals. This compound has been 
characterized by the means of UV-spectroscopy and elemental analysis; its optical rotation has been 
determined, after its recrystallisation from acetonitrile-ethanol (1: 1).  
 
Scheme 3. Conversion of 1-(γ,γ-dimethylallyl)adenine to 6-(γ,γ-dimethylallyl)adenine; reported 
from ref. [26]. 
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Scheme 4. Dimroth rearrangement of adenosine in alkaline medium; reported from ref. [26]. 
 
Next, studying the relative rates of rearrangement of 1- to N6-dimethylallyl compounds in 
concentrated ammonium hydroxide at 60ºC for base, nucleoside and nucleotide, Leonard and 
Grimm showed that the transformation 1-(γ,γ-dimethylallylamino)-9-β-D-ribofuranosylpurine → 6-
(γ,γ-dimethylallylamino)-9-β-D-ribofuranosylpurine proceeds faster than 1-(γ,γ-
dimethylal1yl)adenine  → 6-(γ,γ-dimethyl-ally1amino)purine [27]. These results point out to the 
conclusion, that the presence of ribose exerts an accelerating effect on Dimroth rearrangement.  
In the synthesis of N6-(3-Methyl-2-butenyl)adenosine (iPAdo) [26], the yield of the alkylation step 
was observed to be about 50% in agreement with the results, reported later by other researchers 
[28].  
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Robins and Trip [29] observed that the alkylation step proceeded to about 50-60% and then 
ceased. If sufficient hydrogen bromide is generated to protonate about 50% of the adenosine 
molecules by the time that alkylation has occurred to 50%, the adenosine N1-hydrobromide would 
be inaccessible to alkylation and addition of further quantities of the alkenyl bromide would have 
no effect (as has been observed). Therefore, non-nucleophilic acid acceptors, such as barium 
carbonate, were added to the reaction mixture and, indeed, 80-90% alkylation of adenosine to the 
N1 isomer occurred. Both Reese [28] and Robins [29] used a solution of dimethylamine in methanol 
or ethanol for the Dimroth rearrangement. In another paper Robins present the protocol with the use 
of a concentrated aqueous ammonia solution to promote the above Dimroth rearrangement [30]. In 
this paper, however, no acid acceptor to neutralize the formed hydrogen bromide was used.  
 
5.4.1.3. N6-alkylation of adenosine: our results 
Taking into account all the described procedures, we have decided to follow a combined 
one, which makes use of the main advantages offered by the known methods. In fact, the protocol, 
we have selected to follow, represents a modification of the method of Leonard et al. [26], firstly 
proposed by Robins [30], considering also the observation of the latter on the appreciable value of 
barium carbonate for the outcome of reaction. Reaction has been performed in N,N-
dimethylformamide (DMF), as suggested [26, 29], though N,N-dimethylacetamide was reported to 
be another solvent of choice [30]. When performing the conversion, we operated some simplifying 
changes, e.g. by avoiding laborious filtration of reaction mixture after N1-alkylation, evaporation of 
toxic DMF, co-evaporation of solvent [27], that have not significantly influenced the yield. For 
promoting Dimroth rearrangement of the N1-alkylation product the use of highly accessible 
ammonium hydroxide instead of expensive methanolic solution of dimethylamine was chosen by 
us. The yields of alkylations carried out according to our “symbiotic” procedure, are comparable 
with the literature ones, being of ca. 50-60%. In the light of the above-mentioned, it can be 
concluded, that our synthetic approach for preparing N6-isopentenyl derivatives of adenosine is 
rather attractive, both in terms of handling and cost-effectiveness.  
 
5.4.2. N6-alkylation of Arysteromicin 
As stated before, the N6-alkylation of commercial, expensive Ary was modelled on the scale 
of 20 mg of Ado, with the aim of repeating the transformation sequence with the amount of Ary we 
had in our hands. The above-reported adjustments to the original procedures, operated on the N1-
alkylation of Ado and subsequent Dimroth rearrangement of N1-alkylation product, were 
successfully applied to Ary, furnishing 63% of pure iPAry, identical in all respects with the sample, 
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obtained by the synthesis, reported in Section 5.3. and used for antiproliferative assays (Section 
5.5.). 1H NMR comparative analyses of the samples obtained via different synthetic routes 
confirmed the identity of products and showed remarkable stability of previously synthesized iPAry 
(see: Section 5.3.).  
 
EXPERIMENTAL to Section 5.4. 
N6-Alkylation of Adenosine 
To a solution of adenosine (0.075 mmol) in DMF (1.5 mL), BaCO3 (0.128 mmol) and 3,3-
dimethylallylbromide (0.128 mmol) were added. The mixture was stirred at room temperature for 
37 h, while protected from light and humidity. Tlc indicated that N1-alkylation was about 90% 
complete. To the heterogeneous reaction medium water (1.5 mL) was added and the pH was 
adjusted to 10.0 with ammonium hydroxide and the solution was refluxed for 5.0 hr. The pH of the 
solution was maintained at 10.0 by periodic additions of ammonium hydroxide. The solution was 
cooled to room temperature and was extracted with three 5-ml portions of ethyl acetate. 
Chromatographic analysis (MeOH/CH2Cl2=1/9) showed complete extraction of iPAdo into the 
ethyl acetate while adenosine remained in the aqueous phase. The ethyl acetate solution was dried 
over sodium sulfate, evaporated to dryness in vacuo, and the residue was, crystallized from 0.8 mL 
of acetonitrile-ethanol (3:1), furnishing 18.0 mg crystals. On recrystallization from 1 mL of 
acetonitrile-ethanol (3:l) pure crystalline iPAdo (14.8 mg, 59% yield) was obtained, which showed 
identical physico-chemical properties with the previously described compound [26,30,31] and with  
commercial sample. 
N6-Alkylation of Aristeromycin 
This reaction has been performed using the same recipe and scale, as for adenosine, (20 mg Ary, 
0.075 mmol). After usual work-up of the reaction product, the crude residue was subjected to 
column chromatography on 3 g. silica gel. The column was eluted with increasing gradient of 
methanol in dichloromethane; with the elution system 1:9=MeOH/CH2Cl2 pure iPAry (15.9 mg, 
63% yield) was isolated as solid. Rf = 0.56 (CH2Cl2/MeOH, 70:30). Anal. Calcd for C16H23N5O3: C, 
57.64; H, 6.97; N, 21.01. Found: C, 57.52; H, 6.89; N, 20.87. 1H NMR (DMSO-d) δ = 1.65 (s, 3H, 
CH3), 1.69 (s, 3H, CH3), 1.72 (ddd, 1H, J = 5.1 Hz, J = 7.6 Hz, J = 12.8 Hz, H6′a), 1.99-2.05 (m, 
1H, m, H4), 2.22 (ddd, 1H, J = 8.5 Hz, J = 8.5 Hz, J = 12.8 Hz, H6′a), 3.44 (ddd, 1H, J = 3.4 Hz, J 
= 4.6 Hz, J = 12.1 Hz, H5′a), 3.50 (ddd, 1H, J = 3.6 Hz, J = 4.5 Hz, J = 12.1 Hz, H5′b), 3.82 (ddd, 
1H, J = 3.1 Hz, J = 4.5 Hz, J = 4.7 Hz, H3′), 4.01-4.11 (m, 2H, CH2CH), 4.33 (ddd, 1H, J = 4.7 Hz, 
J = 6.1 Hz, J = 6.2 Hz, H2′), 4.64 (d, 1H, J = 4.5 Hz, 3′OH),  4.67 (ddd, 1H, J = 6.2 Hz, J = 7.6 Hz, 
J = 8.5 Hz, H1′), 4.70 (t, 1H, J = 4.6 Hz, 5′OH),  4.91 (d, 1H, J = 6.1 Hz, 2′OH),  5.29 (t, 1H, J = 
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6.6 Hz, CH), 7.70 (bs, 1H, H2), 8.16 (s, 1H, H8). 13C NMR (DMSO-d) δ = 18.0 (CH3), 25.5 (CH3), 
29.5 (C-6´), 37.8 (α-CH2), 45.5 (C-4´), 59.5 (C-1´), 63.2 (C-5´), 71.8 (C-3´), 74.7 (C-2´), 120.0 (C-
5), 122.5 (β-CH), 133.2 (C-γ), 139.9 (C-8), 149.4 (C-4), 152.1 (C-2), 152.1 (C-6).  
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5.5. BIOACTIVITY ASSAYS: iPAry versus iPAdo 
  
As reported in Section 5.3., preliminary assays on antiproliferative activity of iPAry showed 
that it is not able to inhibit in vitro cell proliferation of breast cancer cell line MCF 7. Herein we 
report the results of detailed studies of the cytotoxic activity of iPAry in order to validate the 
previously obtained data. Successive more profound investigations of iPAry capability to induce the 
inhibition of cell proliferation in MCF 7 cells confirmed the reported results: no effect of compound 
up to 3 days of treatment, even at increased doses (Figure 1).  
No explanation of this result could be found till now and further investigations are necessary 
for understanding the mechanisms of iPAry uptake in the cell and its sub-structures, mechanisms of 
action and metabolic pathways involved.  
The property of iPAry to induce apoptosis on HL-60 cells, in comparison with iPAdo and 
related analogous compounds was investigated. Considerations regarding receptor-mediated 
iPAdo/iPAry biological action are presented.  
 
Figure 1. MCF 7 – cell proliferation. Data are shown as mean percentage of inhibition of 
cell proliferation at day 3 (6 replicas) ± SE with respect to untreated cells; the line 
marks the reference value of untreated cells.  
  
5.5.1. Human Promyelocytic Leukemia cell line HL-60 
For leukaemia studies the human leukaemia cell line, HL-60, is often used as a model 
system. The HL-60 cell line is a leukemic cell line that has been used for laboratory research on 
how certain kinds of blood cells are formed. The cell line was derived from a 36-year-old woman 
with acute promyelocytic leukemia at the National Cancer Institute [1]. Proliferation of HL-60 cells 
occurs through the transferrin and insulin receptors, which are expressed on cell surface. The 
requirement for insulin and transferrin is absolute, as HL-60 proliferation immediately ceases if 
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either of these compounds is removed from the serum-free culture media [2]. With this line, 
spontaneous differentiation to mature granulocytes can be induced by compounds such as dimethyl 
sulfoxide, or retinoic acid. Other compounds like 1,25-dihydroxyvitamin D3, 12-O-
tetradecanoylphorbol-13-acetate (TPA) can induce HL-60 to differentiate to monocytic, 
macrophage-like and eosinophil phenotypes, respectively. The HL-60 cultured cell line provides a 
continuous source of human cells for studying the molecular events of myeloid differentiation and 
the effects of physiologic, pharmacologic, and virologic elements on this process.  
HL-60 cell model was used to study the effect of DNA topoisomerase (topo) IIα and IIβ on 
differentiation and apoptosis of cells [3].  
Leukocyte migration in the innate immune system has been studied in the human neutrophil-
like cell line HL-60 in the investigation of external chemical cues of chemotaxis [4]. Thus, the 
maintenance and transfection of HL-60 cells and the explaination of how to analyze their behavior 
with two standard chemotactic assays was presented. The technique of fluorescent microscopy 
imaging was employed for fixation and staining the actin cytoskeleton of polarized cells [4]. 
Isaza et al. have engineered HL-60 cells that stably express firefly luciferase and produce 
light that can be detected using an in vivo imaging system (IVIS) [5]. Bioluminescent HL-60luc 
cells could be rapidly detected in whole blood with a sensitivity of approximately 1000 viable 
cells/200 µl blood. Treatment of HL-60luc cells with the drug chlorambucil revealed that the 
bioluminescent viability assay is able to detect cell death earlier than the Trypan blue dye exclusion 
assay. HL-60luc cells administered intraperitoneally (i.p.) or intravenously (i.v.) were visualized in 
living mice. The rapidity and ease of detecting HL-60luc cells in biological fluid indicates that this 
cell line could be used in high-throughput screens for the identification of drugs with anti-leukaemia 
activity under physiological conditions. 
In the frame of their research regarding the control of differentiation and apoptosis of human 
myeloid leukemia cells by cytokinins and cytokinin nucleosides, Ishii et al established, that iPAdo 
induces differentiation of HL-60 cells [6]. This served as a good premise for testing the bioactivity 
of iPAdo derivatives and analogues on HL-60 cells. 
 
5.5.2. Apoptosis tests on HL-60 cells 
Recently the data were reported on the investigations of iPAdo influence on apoptosis of 
human lung cancer cell line A549 [7]. Taking into consideration the literature data [6] on iPAdo as 
compound that induces apoptosis, as well as differentiation in a human myeloid leukemia cell line, 
Spinola et al. [7] detected only a modest increase in apoptosis of human lung cancer cell line A549 
after iPAdo treating. Thus, analysis of apoptosis using a caspase-3 or -7 activation assay revealed 
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only a slight increase in luminescence, suggestive of increased apoptosis levels, in 100 M iPAdo-
treated human lung cancer cells at 4–20 hr of treatment as compared to control values, with no clear 
time-dependent increase. The authors associated the tumor growth suppression by iPAdo with its 
mediation by inhibition of cell proliferation due to a block of DNA synthesis rather than apoptosis. 
Our results about the apoptotic activity of iPAdo complementarily to the known literature data [6] 
demonstrated that HL-60 cells are sensitive to iPAdo treatment that induces apoptosis specifically 
and dose-dependently in this cell line (Figure 2A).  
 
      Figure 2. iPAdo apoptosis assays on HL-60 and MCF -7 cells. Data are shown as means 
of ratio of relative luminescence units (RLU) of i6A-treated vs. untreated cells 
± SE (three replicas); the line: reference value of untreated cells. i6A-iPAdo. 
 
Convergent results obtained with human colon cancer cell line DLD1 cells by Laezza et al. 
showed, that annexin V-positive cells were significantly increased in cells treated with 25 and 50 
M of iPAdo compared with the untreated cells [8] (Figure 3). No apoptotic activity on MCF 7 
cells was established, even when a high concentration (100 M) of iPAdo was used (Figure 2B).  
 
 
 
Figure 3. Apoptosis in human colon cancer cell line DLD1 cells (rep. from ref. [8]). 
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Taking into consideration the iPAdo apoptotic activity, it was interesting to elucidate 
whether the “N6-isopentenyl carbocyclic-adenosine” (iPAry) exerts the same effects on HL-60 cells.  
The apoptotic activity of iPAry was studied in comparison with that of iPAdo and some its 
analogous compounds, whose synthesis have been recently described [9] (Figure 4). To investigate 
the cell death process as the mode of action of tested compounds, we performed the caspase-3 or -7 
activation assay in HL-60 cells and the results confirmed the presence of cell death induction by 
apoptosis for some of the tested compounds.  
 
 
Figure 4. Apoptosis assays on HL-60 cells. Data are shown as means of ratio of relative 
luminescence units (RLU) of i6A-treated vs. untreated cells ± SE (three replicas); the line: 
reference value of untreated cells. i6A-iPAdo, i6Ary-iPAry.  
 
Unpleasantly for us, we established that iPAry is not able to induce apoptosis in HL-60 cells, 
even when a 10-fold augment of the 10 M effective iPAdo concentration was employed: the 
caspase 3/7 activation induced by iPAry treatment of human leukaemic cells corresponded to that of 
untreated cells. Thus, the ribose moiety appears to be essential for maintenance of the apoptotic 
effects of iPAdo and analogues on human leukaemia cells (Figure 4). Particularly, it was 
established that the property of iPAdo analogs: N6-isopentyl adenosine (SAT), N6-butyl adenosine 
(CM102), N6-allyl adenosine (CM116), N6-benzyl adenosine (CM121) to induce cell cycle arrest 
and apoptosis in these cell lines, comparable to that of iPAdo, is expressed in a dose-dependent 
manner. Thus, it was found that only CM121 promotes the increase of caspase 3 or 7 activity quasi 
at the same extent as iPAdo in close concentration range, while the other tested compounds: SAT, 
CM102 and CM116 induced apoptotic activity similar to iPAdo at higher concentration (4-7-fold 
value). It is worth of mentioning here the results of Colombo et al. [10] on the clonogenicity of 
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human lung cancer A549 cells. The authors established that the antitumour effect of iPAdo may be 
conserved after subtle changes (i.e., saturation) of the isopentenyl side chain, but not after its 
substitution with another chemical group (i.e., the benzoyl group). The results, we reported here on 
apoptotic activity of iPAdo analogues, can not be explained in the same terms, as the afore-
mentioned, obtained with the clonogenicity of A549 cells [10]. On the contrary, N6-benzyl 
adenosine which is the most structurally “non-familiar” at N6 to iPAdo shows the effects 
comparable to the latter, and not its “congeners”, e.g. N6-isopentyl adenosine. Further investigations 
are needed for better understanding the obtained data.   
 
5.5.3. Docking studies and molecular modeling 
Transcriptional profile results suggest a receptor-mediated iPAdo action [10]. iPAdo induces 
a rapid change in transcriptional profile: gene expression profile analysis of iPAdo-treated or 
untreated A549 and MCF7 cells revealed induction of genes (e.g., PPP1R15A, DNAJB9, DDIT3, 
and HBP1) involved in the negative regulation of cell cycle progression and reportedly upregulated 
during cell cycle arrest in stress conditions. Transcripts of transcriptional factors showed a strong 
induction by iPAdo at 6 h and then a return to control values at 24 h.  It can not be excluded, that 
iPAdo binds to specific receptor(s) and activates transcriptional factors, which, in turn, modulates 
cell cycle progression and cause cell death. The obtained results of microarray analysis involving 
the gene expression related to the receptors hA2b and hA3 are not reliable and further investigations 
are necessary to validate the preliminary obtained data. Interestingly, even if neither iPAdo nor 
iPADoS turn out to exert in vivo antitumor activity [10], the latter induced pronounced convulsions 
in nude mice inoculated i.p. with IGROVI cells (unpublished results). This fact can give a favorable 
indication to a receptor-mediated iPAdoS biological action hypothesis.  
Adenosine has been found to exert its effects on proliferation and cell death mainly through 
the A3 adenosine receptors, which are present in different cell types [11]. Some agonists of A3 
adenosine receptors are in preclinical trials for cancer treatment [11,12].  
The results we report herein regard the docking studies on the human adenosinic receptors 
hA2b and hA3.  
5.5.3.1. The human adenosinic receptor hA2b 
Docking experiments of iPAdo / iPAry with modeled adenosinic receptor hA2b were 
performed with the aim of identifying amino acid residues crucial to their interaction.  The 
comparison of the two putative complexes, depicted in Figure 5, enlightens that: 
‐ iPAry conserves the hydrophobic contacts generated by isopentenyl chain (with Ile67 and 
Leu172) and some of the key interactions stabilized by adenine (with Asn254 and Phe173); 
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‐  The different arrangement of the cyclopentyl ring in iPAry hampers the pivotal interactions 
of Asn186 which in iPAdo complex bridges the 5‘-hydroxy group with N7 purine atom, 
while in iPAry complex Asn186 can interact only with the hydroxy function; 
‐  The methylene group can also clash against Val85 and Met182 (not displayed for clarity) 
further destabilizing the iPAry complex; 
‐ Despite the few interactions elicited by ribose ring, the iPAry modification can clearly 
destabilize the complex with hA2b, thus justifying its poor activity. 
 
 
Figure 5. Modelled iPAdo/iPAry complexes with adenosinic receptor hA2b 
 
 
5.5.3.2. The human adenosinic receptor hA3 
The comparison of the two putative complexes enlightens that: 
‐ iPAry conserves the hydrophobic contacts generated by isopentenyl chain (with Phe168 and 
Leu264) and a key-conserved interaction between adenine and Asn254; 
‐  In hA3 (and quite differently compared to hA2B), the ribose moiety appears vastly 
stabilized by polar interactions (with Thr94, Ser181, and Ser247). Consequently, the iPAry 
modification induces clear detrimental effects on the corresponding complex which impact 
on all monitored H-bonds so that Ser181 is no more involved in H-bonds.  
 
In conclusion, although with different mechanisms, docking results can well explain the poor 
activity of iPAry in both adenosinic receptors. 
 
‐  
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Figure 6. Modelled iPAdo/iPAry complexes with adenosinic receptor hA3 
 
 
EXPERIMENTAL to Section 5.5. 
Proliferation assay. Cell proliferation was analyzed using the AlamarBlue® Assay (Biosource, 
Camarillo CA). MCF7 cells were plated at 700 cells per well in 96-well plates and cultured for 4 
days in the presence of 10 µM i6A or 9, 27 or 81 μM i6Ary and 10% AlamarBlue. Cell proliferation 
of treated and untreated cells was monitored based on fluorescence intensity (excitation 535 nm, 
emission 590 nm) measured on a Tecan ULTRA multiplate reader (Tecan Group Ltd. 
Mannedorf/Zurich, Switzerland). Six replicas were performed for each dose and for each compound 
tested. 
Apoptosis assay. Activation of caspase-3 or -7 was evaluated using the Caspase-Glo 3/7 assay 
(Promega, Madison, WI). Luminescence in HL-60 cells plated at 15,000 cells per well in white-
walled 96-well plates and treated, for 24 hr, with 10 μM i6A or 100 μM i6Ary was measured on a 
Tecan ULTRA multiplate reader and compared with untreated cells. 
Docking experiments. The amino acid sequences of human A2b and A3 receptors were retrieved 
from the UniProt database (entry codes: P29275, AA2BR_HUMAN and P33765, 
AA3R_HUMAN). The primary sequences were submitted to Swiss-Model, a fully automated 
protein structure homology modeling server which selects suitable templates based on a Blast E-
value limit providing truly reliable models when target and template share a significant percentage 
of identical residues. The proposed models were generated using the resolved structure of crystal 
structure of a human A2a adenosine receptor bound to ZM241385 as the template (PDB Id: 3EML, 
resolution 2.6 Å, identity hCES1 vs. hCES2 = 46.6%). The quality of such models appears 
satisfactory as assessed by: a) the remarkable percentage of residues which fall in the allowed 
regions of Ramachandran plot (89.07 and 90.53%); b) the lacking of relevant gaps apart from some 
residues in the terminal domains which were manually added using the VEGA peptide builder; and 
iPAdo iPAry
Asn250 
Leu264 
Phe168 
Ser247
Ser181Thr94 
Asn250 
Leu264
Phe168
Ser247
Ser181
Thr94
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c) the perfect agreement of secondary structure with that of template as evidenced by sequence 
alignment computed by ClustalX. 
With the full-length backbone constructed, side-chains and hydrogen atoms were added 
using VEGA. To remain compatible with physiological pH values, the side-chains of Arg, Lys, Glu, 
and Asp were ionized, while His and Cys residues were considered neutral by default. The complete 
model was carefully checked to avoid unphysical occurrences such as cis peptide bonds, wrong 
configurations or colliding side-chains. Then, the models underwent an initial minimization until 
RMS gradient was equal to 1 kcal mol-1Å-1 to discard high-energy interactions. Finally, the models 
were optimized by a final minimization made up by two phases: first a minimization without 
constraints until RMS = 0.1 kcal mol-1Å-1 and then a second minimization with backbone fixed until 
RMS = 0.01 kcal mol-1Å-1 to preserve the predicted structures. 
The conformational behavior of the ligands was investigated by a MonteCarlo procedure (as 
implemented in the VEGA suite of programs) which generated 1000 conformers by randomly 
rotating the rotors. All geometries so obtained were stored and optimized to avoid high-energy 
rotamers. The 1000 conformers were clustered according to their similarity to discard redundant 
ones; in this analysis two geometries were considered as non-redundant when they differed by more 
than 60 degrees in at least one torsion angle. For each ligand, the so obtained lowest energy 
structure was then exploited in the following docking simulations. 
Docking simulations were performed by the AutoDock4.0 engine. In detail, the grid boxes 
were set to include all residues within a 12 Å radius sphere around the some relevant residue 
(namely Asn254 and Thr89 for A2b as well as Asn250 and Thr94 for A3) thus comprising the 
entire binding cavity. The resolution of the grid was 60×60×60 points with a grid spacing of 0.450 
Å. Each substrate was docked into the grids with the Lamarckian algorithm as implemented in 
AutoDock. The genetic-based algorithm ran 20 simulations per substrate with 2,000,000 energy 
evaluations and a maximum number of generations of 27,000. The crossover rate was increased to 
0.8, and the number of individuals in each population to 150. All other parameters were left at the 
AutoDock default settings [13]. The best complexes were minimized keeping fixed all atoms 
outside a 15 Å radius sphere around the bound substrate to favor the mutual adaptability between 
ligand and enzyme. The optimized complexes were then used to re-calculate AutoDock docking 
scores and the VEGA energy scores. 
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5.6. N6- SUBSTITUTED ADENOSINE ANALOGUES: ARE iPAdo ANALOGUES NOVEL 
ANTIPROLIFERATIVE AGENTS? 
The current panoply for the chemotherapy of viral infections, as the result of several decades 
of research, includes syntheses and biological evaluations of nucleoside analogues [1]. Currently, 
nucleoside analogues are prominent drugs in the management of several viral infections, including 
herpes simplex virus (HSV), human immunodeficiency virus (HIV), hepatitis B virus (HBV), 
hepatitis C virus (HCV) and human cytomegalovirus (HCMV) infections [1]. The nucleoside 
analogues at present formally approved for the treatment of viral infections are shown in Figure 1. 
 
Figure 1. Nucleoside analogs currently used in antiviral therapy (reported from ref. [1]). 
 138
As part of our investigations in this area, the synthesis of a number of adenosine analogs was 
undertaken, potentially endowed with interesting biological properties. Testing their potential 
antiproliferative properties constituted a prioritized direction, as soon as related iPAdo showed 
remarkable activities as potential therapeutic agent for a variety of epithelial cancers (see: Chapter 
2). 
5.6.1. N6-alkylation of Tubercidin 
Tubercidin (7-deazaadenosine; 4-amino pyrrolo (2,3-d) pyrimidine β-D-ribofuranoside, Tu), 
is an interesting antibiotic analogue of adenosine (Scheme 1) that has been found in culture filtrates 
of Streptomyces tubercidicus [2, 3]. The structure of Tu is well established [4], and its chemical 
synthesis has been achieved [5]. It has been reported that Tu inhibits the growth of some 
experimental tumors, but its toxicity to mice is rather low [3, 5, 7]. The metabolism of Tu in mouse 
fibroblasts (strain L-929) and some effects of this antibiotic on cellular and viral functions have 
been reported, showing that tubercidin is incorporated into both cellular nucleic acids [2]. The 
consequences of this incorporation, which occurs even when Tu is present at very low 
concentrations in the culture media (0.1-1.0 µg/mL), are lethal both for mouse fibroblasts and for 
some viruses which are capable of growing in these cells, such as DNA-virus: vaccinia, RNA-
viruses: Reovirus III and Mengovirus [2]. 
 The synthesis of a number of analogs of tubercidin has been reported since its discovery 
(references [5, 8-11] report only a few of them), but none was as active as Tu, against L 1210 
Leukaemia cells (Tu was very active, ED50 0.002 μmol/L) [11].   
 Interestingly, Tu was found to inhibit the uracil tRNA-methylating enzymes of Escherichia 
coli [12]. The uracil tRNA-methylating enzyme system, which specifically catalyzes the 
biosynthesis of ribothymidine in transfer RNA, is relatively resistant to inhibition by a number of 
adenine derivatives that were previously shown to interfere with the activity of enzymes that 
catalyze the methylation of guanine in tRNA. Amongst the substances that inhibited the enzymatic 
transfer of methyl groups to tRNA guanine, but at comparable concentrations did not significantly 
affect uracil tRNA methylation, were KR and iPAdo. Tu, however, inhibited both guanine and 
uracil tRNA-methylating enzymes. The authors concluded on the different structural requirements 
for inhibitors of the various base specific tRNA-methylating enzymes [12]. 
In the light of the above-mentioned and taking into account the multiple biological activities 
of iPAdo, we have carried the synthesis of N6-isopentenyl tubercidin (N6-iP-Tu), starting from 
commercial compound Tu available in mg scale. For the synthesis of N6-iP-Tu we were guided by 
the same background considerations as in the case of iPAdo, (see: Section 5.4., N1/N6-Alkylation 
of Adenosine: The Dimroth Rearrangement). The N6-alkylation of commercial, rather expensive 
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Tu was modelled on the scale of 20 mg of Ado. Following the representative experimental protocol, 
desribing the N1-alkylation of Ado and successive Dimroth rearrangement of N1-alkylation product, 
pure N6-iP-Tu has been prepared in 50% yield (Scheme 1). 
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Scheme 1. Synthesis of N6-isopentenyl tubercidin 
5.6.2. Preparation of 2', 3'-O-isopropylidene N6-iPAdo 
2', 3'-O-Isopropylidene N6-iPAdo could represent a simple and interesting derivative of 
iPAdo that contains the ribose moiety modified only at the 2', 3'-hydroxyls. Although the 
preparation of the 2', 3'-isopropylidene derivative of nucleosides is expected to be a simple process, 
in the case of adenosine good yields of the product can be obtained only using a large excess of p-
toluenesulfonic acid (p-TsOH, 10 moles pTsOH per 1 mol Ado) [13]. Consequently, the work-up 
the reaction is complicate and a few attempts to obtain comparable yields to those obtained by 
Hampton were not successful.  
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Scheme 2. Synthesis of 2', 3'-O-isopropylidene iPAdo 
Interestingly, the formation of 2', 3'-O-isopropylidene iPAdo from iPAdo required only a 
limited excess of the catalyst- 5 equivalents and the presence of 2,2-dimethoxypropane [14]. Thus 
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we could transform quantitatively 25 mg of commercial iPAdo into the required 2', 3'-
isopropylidene derivative (Scheme 2).   
We considered worth of investigation also other synthetic approaches to  2', 3'-
isopropylidene iPAdo, since the preparation of the starting iPAdo, although feasible by established 
protocols, is not easily available. Starting from 2’,3’-O-isopropylidene adenosine a few advantages 
appeared interesting from a practical point of view. For instance, we were able to prepare 2',3'-O-
isopropylidene adenosine from adenosine according to Hampton’s method or could rely on 
commercial product that is available and not expensive. Starting from 2',3'-O-isopropylidene 
adenosine we could study in some details the formation of the N1-alkylated intermediate that cannot 
be easily followed if adenosine is the substrate. In this case, the highly polar solvent needed to 
dissolve the nucleoside constitutes a complication for the work-up, isolation and purification of any 
product. Specifically, the N1-alkylated intermediate, which is sensitive to the Dimroth 
rearrangement, cannot be isolate in a pure form from adenosine.  Furthermore, the preparation of 
2’,3’-O-isopropylidene iPAdo from 2’,3’-O-isopropylidene adenosine by a direct N6-alkylation 
could constitute a useful alternative to the N6-alkylation of adenosine that would produce iPAdo, 
later transformed into 2’,3’-O-isopropylidene iPAdo (Scheme 3). The conversion of 2’,3’-O-
isopropylidene Ado to 2’,3’-O-isopropylidene iPAdo via N1/N6-alkylation was smoothly carried out 
in dry DMF, using the Ado-model (see: Section 5.4., subchapter N1/N6-Alkylation of Adenosine: 
The Dimroth Rearrangement). Barium carbonate-assisted interaction of 2’,3’-O-isopropylidene 
Ado with 3,3-dimethylallylbromide for 37 h furnished the N1-alkylation product that was 
subsequently subjected to basic conditions with conc. ammonia solution (pH 10) of the Dimroth 
rearrangement, producing in 74% yield the pure target-compound, 2’,3’-O-isopropylidene iPAdo, 
after chromatographic separation of the crude reaction product. As for the majority of the Ado 
derivatives (but not for all), the notably different physico-chemical properties of the N1- and N6-
alkylation products facilitated the monitoring of this two-step reaction by TLC.  
A rapid survey of the literature did not offer much alternative to the direct N6-alkylation 
procedure. For instance, the method described in Scheme 4 relies on the formation of N6-amides 
and their reduction with LiAlH4 [15]. However, yields were not satisfactory in a few instances and, 
in case of the isopentenyl group reduction of the double bond could constitute an undesirable side-
reaction. In another report, the synthetic approach that involves the formation of a N6-imine, 
followed by reduction to N6-alkyl derivatives has been described only in one paper [17]. However, 
the reaction of formation of the intermediate imine, its instability, and the side reactions of the 
reducing system were limiting factors. After a few attempts of finding new reactions for the 
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formation of the imine and for its reduction, the approach has been abandoned, due to severe 
limitations of time left for the completion of the PhD Thesis.   
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Scheme 3. Two synthetic routes to 2’,3’-O-isopropylidene iPAdo starting from Ado 
 
Thus, while comparing two different pathways we have followed for the synthesis of 2’,3’-
O-isopropylidene iPAdo, a few conclusions seem in order:  
1. Both methods can be successfully applied for the synthetic preparation of 2’,3’-O-
isopropylidene iPAdo, being suitable in terms pf handling, costs and yields; 
2. Starting from commercially available, but rather expensive iPAdo the corresponding 
acetonide derivative can be prepared quantitatively by using a moderate excess of the 
catalyst- p-TsOH, 5 eq. and the presence of 2,2-dimethoxypropane; 
3. For bigger-scale preparations commercial cost-friendly 2', 3'-isopropylidene Ado is more 
indicated; the limiting factors of this route could be considered long reaction time (of the 
time-determining N1-alkylation step) and diminished yield (74%). 
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Scheme 4.  On the way to N6-alkyl nucleosides: N6-amides and their subsequent reduction with 
LiAlH4. 
 
5.6.3. Preparation of N6-isoPentenyl-L-adenosine (L-iPAdo) 
It is a matter of common knowledge, that D-ribose constitutes an essential component of 
RNA, providing its three-dimensional structure that transmits genetic information. Ribose is also 
contained in ATP and NADH, which have crucial functions in metabolism. In this decade, the 
pharmaceutical industry has expanded its application of L-ribose [18] (Figure 2), which is the 
enantiomer of natural D-ribose. The academic interest to L-ribose owes to the belief that 
stereospecificity prevents L-nucleosides from interacting with enzymes in living systems, as well as 
a limited availability of L-ribose as a starting material [19].  
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Figure 2. Structural formulae of L-ribose and Lamivudin (3TC).  
 
Nucleoside-analogue antiviral agents inhibit the nucleoside synthesis–replication process of 
a virus by exploiting small differences in the nucleoside synthesis process between normal cells and 
virus cells. From the numerous works in this area, [19 and ref. therein] it appears that favorable 
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features of L-nucleoside analogues may include an antiviral activity comparable and sometimes 
greater than their D-counterparts, more favorable toxicological profiles and a greater metabolic 
stability. From this perspective, many nucleoside derivatives have been designed as antiviral agents.  
Recently nucleoside analogues, which bear a sugar moiety of the L-form (L-nucleoside), 
emerged as a new class of antiviral agents for hepatitis B virus (HBV), hepatitis C virus (HCV), 
hepatitis D virus (HDV), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) [19, 20]. The 
mechanism of action of nucleoside analogues is based upon the intracellular phosphorylation to 
their 5-triphosphate form which can interact with virus-specific polymerases, acting as a 
competitive inhibitor or an alternate substrate for these target enzymes, usually preventing further 
viral nucleic acid chain elongation [19]. 
Although the first synthesis of L-nucleoside was reported in 1964 (Smejkal and Sorm) [21], 
little attention was paid to L-nucleoside analogues until the discovery of lamivudine (3TC) that 
possesses strong anti-HIV and HBV activity (Figure 2) [22, 23].  
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Scheme 5. Synthesis of L-isoPentenyl Adenosine 
Until recently, it was believed that L-isomers of nucleosides could not be effective 
anticancer drugs as they would not be recognized by the cellular enzymes responsible for their 
transport and activation [24]. Now there is growing evidence that enzymes involved in nucleoside 
metabolism that lack enantioselectivity with respect to D- and L-nucleosides are more common than 
it was previously believed [25]. The very last data [26] report on a series of novel 5′-deoxy-4′-thio-
L-nucleosides that was designed and synthesized. The antitumor activities of the target compounds 
were tested against the growth of human carcinoma of colon (LOVO), human leukemia cell line 
(CEM) and human breast cancer cell line (MDA-MB-435) cells in vitro. Some of them (6-
Cyclopentylamino- and 6-cyclohexylamino purine derivatives), both in α-configuration and in β-
form, exhibited strong inhibition to CEM. 
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The afore-mentioned considerations on known antitumor activity of L-nicleosides and their 
derivatives along with the reported strong antiproliferative activity of iPAdo (see: Chapter 2) 
prompted us to explore the same the antiproliferative profile of L-iPAdo in comparison with that of 
its natural counterpart. For this reason commercial L-adenosine was employed that was subjected to 
the similar experimental protocol, as β-D-adenosine, see: Section 5.4. Following the N6-alkylation 
of L-adenosine, including the N1-alkylation and subsequent Dimroth rearrangement, the L-iPAdo 
was obtained in 45% after the chromatographic separation of the reaction product (Scheme 5). 
 
5.6.4. N6-Adenosine analogs starting from 6-chloropurine riboside 
 We have prepared a few N6-substituted adenosine analogues starting from 6-chloropurine 
riboside (Scheme 6).  
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Scheme 6. Preparation of N6-propargyl adenosine analogs starting from 6-chloro-9-
ribofuranosylpurine 
5.6.4.1. Preparation of N6-propargyl- and N6-Methyl-N6-propargyl adenosines 
N6-propargyl adenosine showed biological activity in a number of in vitro and in vivo tumour 
cell systems [27]. It revealed good growth inhibition activity in vitro on a series of tumour cell 
lines, such as leukaemia L-1210, carcinoma TA-3, Hela, human bladder carcinoma, human Burkitt 
lymphoma, human fibroblasts and mouse fibroblasts (ID50 between 1.0 and 8.3 µM). This 
compound proved to be particularly active for L-1210 leukemia cells, where it had an ID50 of 1 µM. 
In the case of human breast tumors grown in culture, the MCF-7 cells (sensitive to estrogen) were 
sensitive to the N6-propargyl adenosine (ID50 1.6 µM), in comparison with the SW-613 cells 
(insensitive to estrogen). An extensive in vivo study was done by the same authors [26] with fast 
growing (MT-F) and slows growing (MT-S) mammary tumors. N6-propargyl adenosine showed 
good increases in life span (60%) of mice bearing slow growing spontaneous mammary tumor. The 
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in vivo results reflected the good activity these agents demonstrated in vitro with the human MCF-7 
human breast cell line. Thus, the authors [27] suggested that N6-propargyl adenosine may be useful 
for the treatment of estrogen receptor positive, human breast carcinoma.  
In the line of our investigations on potential antiproliferative properties of N6-substituted 
adenosines, we have considered useful to compare the cell proliferation activity of N6-propargyl 
adenosine (previously reported [27]) with that of its homologous N6-Methyl-N6-propargyl 
adenosine. With this aim, both compounds were synthesized via the substitution of 6-chloro-9-
ribofuranosylpurine with propargylamine or N-methyl-propargylamine, correspondingly. The 
reactions were carried out at 60 oC for 24 h, in ethanol in the presence of a small excess of 
triethylamine (1.33 eq.). The target compounds were obtained in acceptable yields (ca 50%) after 
re-crystallisations of the reaction products.  
5.6.4.2. Preparation of N6-allyloxyadenosine 
N6-allyloxyadenosine has a molecular structure very close to N6-alkyl adenosines, for which 
remarkable bioactivities were found (see: Chapter 1). To the best of our knowledge, no reported 
data on its antitumour activity are reported in the literature, as in the case of N6-methyl-N6-
propargyl adenosine. It has been recently synthesised and fully characterized by D. Loakes et al. in 
their effort for searching the purine analogues as potential anti-malarial agents [28]. These 
investigators were guided by the fact, that Plasmodium falciparum, which causes one of the 
deadliest forms of malaria, is unable to synthesise purines de novo and to this end often has multiple 
purine uptake. N6-allyloxiadenosine was amongst the library of compounds that have been designed 
and synthesised. It showed moderate in vitro activity against malarial parasite (ID50 33.31 µM).   
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Scheme 7. Synthesis of N6-allyloxyadenosine from 6-chloro-9-ribofuranosylpurine 
 
The synthesis and testing the antiproliferative activity of N6-allyloxyadenosine has been 
considered in the context of finding new N6-substituted adenosine analogs endowed with 
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antitumour activity. For the preparation of this compound the procedure described by D. Loakes et 
al. [28] has been followed, consisting in the reaction of 6-chloro-9-ribofuranosylpurine and O-
allylhydroxylamine hydrochloride, see also p. 3.1. N6-allyloxyadenosine was obtained in 50% yield, 
as a 4:1 mixture of its tautomers (Scheme 7).  
5.6.5. N6-isopentenyl derivative of 5´-N-Ethylcarboxamido Adenosine 
Adenosine is a key endogenous molecule that regulates tissue function by activating four G-
protein-coupled adenosine receptors: A1, A2A, A2B and A3. The recent heightened awareness of the 
role of adenosine in the control of immune and inflammatory systems has generated excitement 
regarding the potential use of adenosine-receptor-based therapies in the treatment of infection, 
autoimmunity, ischaemia and degenerative diseases [29]. The recent exhaustive review of P.A. 
Borea et al outlines the role of different type adenosine receptors (ARs) in the in vitro and in vivo 
study of cancer [30]. ARs are found to be upregulated in various tumor cells and activation of the 
receptors by specific ligands, agonists or antagonists, modulates tumor growth via a range of 
signaling pathways. In particular, A3 AR was found to be highly expressed in tumor cells and 
tissues, while low expression levels were noted in normal cells or adjacent tissue. Receptor 
expression in the tumor tissues was directly correlated to disease severity. A3 AR agonists were 
found to induce tumor growth inhibition, both in vitro and in vivo, via modulation of the Wnt and 
the NF-κB signaling pathways. Thus, A3 ARs that are abundantly expressed in tumor cells may be 
targeted by specific A3 AR agonists, leading to tumor growth inhibition [30]. 
The adenosine derivatives bearing an N6-(3-iodobenzyl) group, are reported to enhance the 
afinity of adenosine-5’-uronamide analogues as agonists at A3 ARs [31]. Particularly, optimization 
of substituent groups has led to the development of the highly potent A3 agonist N6-(3-
iodobenzyl)adenosine-5’-N-methyluronamide (IB-MECA, Figure 3) which is 50-fold selective for 
A3 vs either A1 or A2 receptors. The same authors described their synthesis starting from methyl β-
D-ribofuranoside along with the study of the influence of 2-substitution in these compounds on 
their selectivity for A1, A2A and A3 rat brain adenosine receptors via radioligand binding assays [32-
34]. As a result of their study, the effects of 2-substitution in the case of chloro-, methylamino- and 
thioamino ligands (Figure 3) to enhance A3 affinity was established to be additive with effects of 
uronamides at the 5'-position and a 3-iodobenzyl group at the N6-position.  
2-Chloro-N6-3-iodobenzyladenosine-5´-N-methyluronamide (Cl-IB-MECA, Figure 3) was 
reported to promote p53-Independent induction of Fas and apoptosis in leukemic cells [35] along 
with the growth inhibition of melanoma and colon carcinoma cells both in vitro and in vivo [36]. 
Thio-Cl-IB-MECA cause inhibition of cell proliferation through cell cycle arrest and apoptosis in 
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human lung cancer cells [37] and induces G0/G1 cell cycle arrest and apoptosis in human 
promyelocytic leukemia HL-60 cells [38].  
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Figure 3. Structures of high-affinity adenosine receptor agonists. 
 
The adenosine receptor agonist 5′-N-ethylcarboxamidoadenosine (Adenosine-5′-N-
ethyluronamide, NECA, Figure 3) produced a significant inhibition of PHA-induced proliferation 
of human peripheral blood mononuclear cells from healthy and asthmatic subjects (10 μM, P<0.05; 
n=6) [39]. The data on NECA functionality are still in the process of study: Landells describe 
NECA as A1/A2-selective AR agonist [38], while Panjehpour attribute NECA to nonselective AR 
agonists [40].   
A. Desai et al. have recently determined whether A2A receptor occupation stimulates 
angiogenesis by modulating the antiangiogenic matrix protein thrombospondin 1 (TSP1) secretion 
[41]. Human microvascular endothelial cells were treated with NECA–analog, 2-p-[2-
carboxyethyl]phenethyl-amino-5´-N-ethylcarboxamido-adenosine (CGS-21680, Figure 3), 
selective A2A receptor agonist. The authors found that TSP1 protein secretion was down-regulated 
after treatment with CGS-21680 in a dose-dependent manner (EC50 = 6.65 nM).  
The results obtained by Panjehpour [40] are interesting, as they regard the AR expression in 
the estrogen receptor-positive MCF-7 cells and estrogen receptor-negative MDA-MB-231 cells. A 
most striking observation was that the estrogen receptor-positive MCF-7 cells appeared to be 
devoid of any detectable amount of ARs, whereas the estrogen receptor-negative MDA-MB-231 
cells express very high levels of A2B ARs. Both binding and functional experiments showed that 
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other AR subtypes were not present in detectable levels in these tumor cells. Stimulation with 
NECA resulted in the activation of adenylate cyclase, whereas 10 μM CGS21680 which, at this 
concentration, activates all but the A2B AR subtype had no effect. 
In the light of the afore-mentioned literature data on NECA and its derivatives activity, we 
were interested in the investigation the antiproliferative properties of the N6-isopentenyl 5′-N-
ethylcarboxamidoadenosine (N6-iP-NECA), thus continuing the line of study the N6-iPAdo analogs.  
To this end, commercial NECA was subjected to the N1-alkylation and subsequent N1- N6 
rearrangement, following the representative protocol described for β-D-adenosine, see: Section 5.4. 
The conversion proceeded smoothly, giving N6-iP-NECA in 58% yield after chromatographic 
separation of the reaction product (Scheme 8).  
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Scheme 8. Preparation of N6-isopentenyl 5′-N-ethylcarboxamidoadenosine  
 
5.6.6. 1,N6-ethenoadenosine 
 
1,N6-ethenoadenosine (εAdo) represents an adenosine analogue characterized by the etheno 
bridge between the heterocyclic N atom at position 1 and the NH2 group attached (Figure 5). This 
structural feature confers the fluorescence to the molecule [42, 43]. Fluorescence techniques proved 
to be extremely valuable in gaining information on tRNA tertiary structure and the first reported 
synthetic preparation of a fluorescent adenosine derivative by Leonard et al. constituted a very 
significant discovery in the nucleic acid chemistry. These researchers have synthesized the 
fluorescent derivatives of adenosine and cytidine by reaction with chloroacetaldehyde in aqueous 
solution at mild pH and temperature, yielding 1,N6-ethenoadenosine hydrochloride and 3,N4-
ethenocytidine hydrochloride, respectively. Analogous derivatives of 3´-AMP, 5´-AMP, 3´,5´-
cyclic AMP, ADP, ATP, and NAD+ were also synthesized. Observation of the spectroscopic 
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properties of the highly fluorescent adenosine derivatives included the emission maximum for 1,N6-
ethenoadenosine at ca. 415 nm (corrected) in buffered aqueous solution at pH 7.0, a quantum yield 
of 0.56, and a fluorescence lifetime of 20 nsec [43]. 1,N6-ethenoadenosine triphosphate (e-ATP) 
was used for the investigation the anisotropic rotational diffusion of the adenine moiety in viscous 
solvents by time-resolved fluorescence spectroscopy [44]. The 1,N6-etheno-ATP analog showed 
considerable substrate activity as a replacement of ATP with adenylate kinase, hexokinase, and 
phosphofructokinase, and exhibited allosteric inhibition of phosphofructokinase. The 1,N6-etheno- 
ADP analog proved to be an excellent substitute for ADP in the pyruvate kinase system, affording a 
facile assay for a wide variety of kinases [43].  
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Figure 4. 1,N6-Ethenoadenine and 1,N6-Ethenoadenosine. 
 
1,N6-Ethenoadenine (εA, Figure 4) is formed in DNA by the metabolism of vinyl chloride, 
a known human and rodent carcinogen [45]. It has been identified in organs of rats and mice given 
vinyl chloride or related carcinogens, such as ethyl carbamate and acrylonitrile [46-49]. Although 
the specific effects of εA in animals are not known, replication of εA in polynucleotides in vitro 
results in a low level of transversions and transitions [50]. In their study on a human DNA binding 
protein Singer et al. describe interesting data on εA activity [51]. For the characterization of this 
protein, not reported to bind to carcinogen-modified DNA, a 25-base oligonucleotide containing a 
single site-specifically placed εA was used. When annealed to form an εA -T or εA -C pair, a strong 
affinity to the protein was observed, with a binding constant of 1x109 M-l. In contrast, very little 
binding was found with an εA-A pair and none was found with an εA-G pair. This suggests protein 
recognition of a specific structural alteration. In addition, the human cell extracts and a rat liver 
extract were found to nick specifically at the 5' side of the εA adduct, which could indicate a 
possible associated repair activity [51].  
The known synthetic investigations in the field of 1,N6-εAdo deal with the developing the 
facile synthetic methods to 2',5'-dideoxy-, 2’,3’-O-dideoxy- and 3'-deoxy-l,N6-ethenoadenosine 
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nucleosides by either an enzymatic dideoxyribosyl transfer reaction or a simple chemical reaction 
[52]. These modified nucleoside analogs are of potential value to be studied further for biological 
activity such as anticancer and antiviral properties. 
1,N6-εAdo was employed in the systematic research of Robins [13] on 2´,5´-oligoadenilates 
and related 2´,5´-oligonuleotide analogues, concerning with their effect on cellular proliferation, 
protein synthesis and endoribonuclease activity. 2´,5´-Oligonuleotide trimers containing 1,N6-εAdo 
showed less pronounced effect on the inhibition of protein synthesis and cellular proliferation after 
uptake into intact L and HeLa cells, in comparison with tubercidin. 2´,5´-Oligonuleotide analogue 
containing 1,N6-εAdo inhibited the protein synthesis in the in vitro rabbit reticulocite lysase system 
[13].  
5.6.7. Cell proliferation activity of N6-isopentenyl substituted adenosine analogues and 
derivatives on MCF -7 cells 
 
Figure 5 depicts the results on the studied proliferation activity of the synthesized N6-
isopentenyl substituted adenosine analogues and derivatives.  
 
Figure 5. Results on cell proliferation activity of N6-isopentenyl substituted adenosine analogues 
and derivatives. NTC- untreated cells, i6A- iPAdo, ES1- N6-allyloxyadenosine, ES2- 
N6-propargyladenosine, ES4- 2’,3’-O-isopropylidene iPAdo, ES5- L-iPAdo, ES6-  N6 -
iP-NECA, ES7- 1,N6-εAdo, ES9- N6-iP-Tub, ES10- N6-Methyl-N6-propargyl adenosine. 
AlamarBlue Assay _ MCF -7 cells (700 cells/well in 96/well plate)_day 3. Each 
compound at final concentration=10 µM, iPAdo in H2O, ES1-10 in H2O e DMSO, 
DMSO finale < 0.1%. 
 
Analysis of the effects of the tested compounds on MCF 7 in vitro cell proliferation by 
AlamarBlue assay revealed for N6-propargyladenosine an activity close to that of iPAdo, while N6-
Methyl-N6-propargyl adenosine promoted the inhibition of cell proliferation, but to a lesser extent 
than iPAdo. No effects of all the other tested compounds at up to 3 days of treatment were noted. 
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Treatment with 10 M N6-propargyladenosine or N6-Methyl-N6-propargyl adenosine caused the 
inhibition of cell proliferation by approximately 42 and 16%, respectively, as compared to untreated 
control cells, whereas treatment with the other tested compounds at 10 M had no significant effect 
(Figure 5). The reported results on N6-propargyladenosine antiproliferative activity confirm the 
literature data [27].  
 
EXPERIMENTAL to Section 5.6.  
General procedure for N6-alkylation 
To a solution of suitable nucleoside analogue or derivative (0.075 mmol) in DMF (1.5 mL), BaCO3 
(0.128 mmol) and 3,3-dimethylallylbromide (0.128 mmol) were added. The mixture was stirred at 
room temperature for 37 h, while protected from light and humidity. To the heterogeneous reaction 
medium water (1.5 mL) was added and the pH was adjusted to 10.0 with ammonium hydroxide and 
the solution was refluxed for 5.0 hr. The pH of the solution was maintained at 10.0 by periodic 
additions of ammonium hydroxide. The solution was cooled to room temperature and was extracted 
with three 5-mL portions of ethyl acetate. The ethyl acetate solution was dried over sodium sulfate, 
evaporated to dryness in vacuo and the residue was subjected to column chromatography. The 
column was eluted with increasing gradient of methanol in dichloromethane. 
N6-isoPentenyl Tubercidin was isolated with the elution system MeOH/CH2Cl2=1/9 (12.54 mg, 
50% yield) as amorphous solid.  Rf = 0.79 (CH2Cl2/MeOH=7:3). Anal. Calcd for C16H22N4O4: C, 
57.46; H, 6.64; N, 16.76. Found: C, 57.22; H, 6.54; N, 16.51. 1H NMR (DMSO-d) δ = 1.69 (s, 6H, 
CH3-14 and 15),  3.52 (ddd, 1H, J = 3.4 Hz, J = 4.6 Hz, J = -12.1 Hz, H5′b), 3.60 (ddd, 1H, J = 3.6 
Hz, J = 4.5 Hz, J = -12.1 Hz, H5′a), 3.87 (ddd, 1H, J = 3.1 Hz, J = 4.5 Hz, J = 4.7 Hz, H3′), 4.04-
4.08 (overlap. m, 3H, CH2 -11 and H4′), 4.40 (ddd, 1H, J = 4.7 Hz, J = 6.1 Hz, J = 6.2 Hz, H2′), 
5.07 (d, 1H, J = 4.7 Hz, 3′OH), 5.23 (d, 1H, J = 6.5 Hz, CH-12), 5.30 (overlap. m, 5′OH and 2′OH), 
5.98 (d, 1H, J = 4.3 Hz, H1′), 6.62 (d, 1H, J = 3.6 Hz, H7), 7.31 (d, 1H, J = 3.6 Hz, H8), 7.55 (t, 1H, 
J = 5.3 Hz, NH), 8.11 (s, 1H, H2). 13C NMR (DMSO-d) δ = 18.0 (CH3), 25.5 (CH3), 38.1 (CH2), 
62.0 (C-5´), 70.9 (C-3´), 73.9 (C-2´), 85.2 (C-4´), 87.8 (C-1´), 99.4 (C-7), 103.6 (C-5), 122.3 (C-8 
and C-12), 133.5 (C-13), 149.4 (C-4), 151.5 (C-2), 156.1 (C-6). 15N NMR (DMSO-d) δ = 91.4 (N-
10), 155.6 (N-9), 223.6 (N-3), 226.7 (N-1). 
2',3'-O-Isopropylidene N6-isoPentenyl Adenosine was eluted with the system of solvents 
MeOH/CH2Cl2=1/15 (20.8 mg, 74% yield) as colorless oil.  Rf = 0.73 (CH2Cl2/MeOH, 3:1). Anal. 
Calcd for C18H25N5O4: C, 57.57; H, 6.72; N, 18.66. Found: C, 57.33; H, 6.67 N, 18.31. 1H NMR 
(CDCl3) δ = 1.36 (s, 3H, CH3 acetonide), 1.63 (s, 3H, CH3 acetonide), 1.72 (s, 3H, CH3 -14), 1.73 (s, 
3H, CH3 -15),  3.77 (apparent d, 1H,  J = 12.8 Hz, H5′b), 3.96 (apparent d, 1H,  J = 12.8 Hz, H5′a), 
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4.18 (br. s, 2H, CH2 -11), 4.49 (br. s, 1H,  H4′), 5.10 (dd, 1H, J = 4.5 Hz, J = 4.6 Hz, H3′), 5.19 (dd, 
1H, J = 4.9 Hz, J = 4.6 Hz, H2′), 5.34 (dd,  1H, J = 7.3 Hz, J = 4.5 Hz, 5′OH), 5.82 (d, 1H, J = 4.9 
Hz, H1′), 5.95 (t, 1H, J = 6.4 Hz, CH-12), 7.75 (s, 1H, H2), 6.81 (br., 1H, NH), 8.32 (s, 1H, H8).  
N6-isoPentenyl-L-Adenosine was isolated with the elution system MeOH/CH2Cl2=1/16 (11.32 mg, 
45% yield) as amorphous solid. Rf = 0.58 (CH2Cl2/MeOH=3:1). Anal. Calcd for C15H21N5O4: C, 
53.72; H, 6.32; N, 20.88. Found: C, 53.51; H, 6.29; N, 20.83. 1H NMR (DMSO-d) δ = 1.66 (s, 3H, 
CH3-14 or 15), 1.69 (s, 3H, CH3-15 or 14),   3.55 (ddd, 1H, J = 3.6 Hz, J = 7.4 Hz, J = -12.1 Hz, 
H5′b), 3.66 (ddd, 1H, J = 3.6 Hz, J = 4.5 Hz, J = -12.1 Hz, H5′a), 3.95 (ddd, 1H, J = 3.1 Hz, J = 3.4 
Hz, J = 3.6 Hz, H4′), 4.06-4.07 (m, 2H, CH2 -11), 4.13 (ddd, 1H, J = 3.1 Hz, J = 4.5 Hz, J = 4.9 Hz, 
H3′), 4.59 (ddd, 1H, J = 4.9 Hz, J = 6.1 Hz, J = 6.2 Hz, H2′), 5.14 (d, 1H, J = 4.5 Hz, 3′OH), 5.30 
(t, 1H, J = 6.5 Hz, CH-12), 5.36-5.40 (overlap. m, 5′OH and 2′OH), 5.87 (d, 1H, J = 6.2 Hz, H1′), 
7.87 (br. s, 1H,  NH), 8.19 (s, 1H, H2), 8.30 (s, 1H, H8). 13C NMR (DMSO-d) δ = 18.1 (CH3), 25.5 
(CH3), 37.9 (CH2), 61.8 (C-5´), 70.8 (C-3´), 73.6 (C-2´), 86.0 (C-4´), 88.1 (C-1´), 118.7 (C-5), 
122.3 (C-12), 133.4 (C-13), 139.8 (C-8), 142.9 (C-4), 152.5 (C-2), 154.5 (C-6). 15N NMR (DMSO-
d) δ = 90.12 (N-10), 169,94 (N-9), 240.54 (N-7).  
 
N6-isoPentenyl-5´-N-Ethylcarboxamido Adenosine was isolated with the elution system 
MeOH/CH2Cl2=1/16 (11.32 mg, 45% yield) as amorphous solid. Rf = 0.61 (CH2Cl2/MeOH=3:1).  
Anal. Calcd for C17H24N6O4: C, 54.28; H, 6.44; N, 22.33. Found: C, 54.10; H, 6.38; N, 22.01. 1H 
NMR (DMSO-d) δ = 1.07 (t, 3H, J = 7.2 Hz, CH3-CH2-),  1.66 (s, 3H, CH3-14 or 15), 1.70 (s, 3H, 
CH3-15 or 14), 3.15-3.24 (m, 2H, CH3-CH2-), 4.06 (br. s, 2H, CH2 -11), 4.12 (br. s, 1H, H3′), 4.29 
(d, 1H, J = 1.3 Hz, H4′), 4.59 (ddd, 1H, J = 4.9 Hz, J = 6.1 Hz, J = 6.2 Hz, H2′), 5.30 (t, 1H, J = 6.3 
Hz, CH-12), 5.57 (d, 1H, J = 5.9 Hz, 2′OH), 5.77 (d, 1H, J = 3.8 Hz, 3′OH), 5.95 (d, 1H, J = 7.6 Hz, 
H1′), 8.02 (br. s, 1H,  NH), 8.18 (s, 1H, H2), 8.37 (s, 1H, H8), 8.90 (t, 1H, J = 5.6 Hz, CO-NH). 13C 
NMR (DMSO-d) δ = 14.9 (CH3-CH2-), 18.0 (CH3-15 or 14), 25.6 (CH3-14 or 15), 33.5 (CH3-CH2-),  
38.6 (CH2 -11), 72.2 (C-2´), 73.3 (C-3´), 84.9 (C-4´), 88.0 (C-1´), 120.3 (C-5), 122.2 (C-12), 133.5 
(C-13), 140.7 (C-8), 148.3 (C-4), 152.6 (C-2), 154.6 (C-6), 169.3 (C-5´).  
Synthesis of 2', 3'-O-isopropylidene iPAdo from iPAdo 
p-TsOH (71.5 mg, 0.375 mmol) was added to a magnetically stirred suspension of commercial 
iPAdo (25.15 mg, 0.075 mmol) in dry acetone (5 mL). Next, 2,2-dimethoxypropane (50 µL, 0.375 
mmol) was added and the mixture was stirred at room temperature overnight, while protected from 
light and humidity. TLC (CH2Cl2/MeOH, 3:1) showed the complete consumption of initial iPAdo. 
To the reaction medium sat. NaCl solution (50 mL) was added and the mixture was extracted with 
three 10-mL portions of ethyl acetate. The ethyl acetate solution was dried over sodium sulfate and 
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evaporated to dryness in vacuo, giving 29 mg (quantitative yield) colorless oil that showed identical 
physico-chemical properties with the sample obtained by N6-alkylation of 2’,3’-O-isopropylidene 
adenosine.   
Synthesis of N6-propargyl- , N6-Methyl-N6-propargyl- and N6-allyloxyadenosines 
 
The reported procedure [28] was used by replacing diisopropylethylamine with triethylamine we 
had at our disposal. A. A mixture of 6-chloro-9-ribofuranosylpurine (0.10 g, 0.35 mmol) and 
propargylamine (134.5 µL, 2.1 mmol) in EtOH (1.0 mL) and triethylamine (390 µL, 2.8 mmol) was 
heated at 60 oC for 24 h. A dark brown liquid resulted, which was kept at +4oC overnight when 
abundant precipitation occurred. The obtained solid was twice re-crystallized from MeOH-Et2O to 
give (53.4 mg, 50%) of N6-propargyladenosine as a white solid, mp 169-170oC that showed 
identical physico-chemical characteristics to the previously described compound [27].  
B. A mixture of 6-chloro-9-ribofuranosylpurine (0.10 g, 0.35 mmol) and N-methyl propargylamine 
(177.2 µL, 2.1 mmol) in EtOH (1.0 mL) and triethylamine (390 µL, 2.8 mmol) was heated at 60 oC 
for 24 h. A dark brown liquid resulted, which was kept at +4oC overnight when precipitation 
occurred. The obtained solid was twice re-crystallized from MeOH to give (55.9 mg, 48%) of N6-
Methyl-N6-propargyladenosine as a white solid, mp 144-145oC. Anal. Calcd for C14H17N5O4: C, 
52.66; H, 5.38; N, 21.94. Found: C, 52.53; H, 5.30; N, 21.90. 1H NMR (Methanol-d4) δ = 2.57 (t, 
1H, J = 2.4 Hz, C≡CH),   3.47 (br. s, 3H, CH3), 3.69 (dd, 1H, J = 2.6 Hz, J = -12.5 Hz, H5′b), 3.83 
(dd, 1H, J = 2.5 Hz, J = -12.5 Hz, H5′a),  4.12 (dd, 1H, J = 2.5 Hz, J = 5.1 Hz, H4′), 4.27 (dd, 1H, J 
= 2.6 Hz, J = 5.0 Hz, H3′), 4.69 (dd, 1H, J = 5.3 Hz, J = 6.2 Hz, H2′), 5.92 (d, 1H, J = 6.3 Hz, H1′), 
8.18 (s, 1H, H8), 8.19 (s, 1H, H2).  
C. A mixture of 6-chloro-9-ribofuranosylpurine (0.10 g, 0.35 mmol) and O-allylhydroxylamine 
hydrochloride (0.23 mg, 2.1 mmol) in EtOH (1.0 mL) and triethylamine (390 µL, 2.8 mmol) was 
heated at 60 oC for 24 h. All the volatiles were evaporated in vacuo; white solid was obtained that 
was re-crystallized from EtOH, giving 56.5 mg (50% yield) of pure N6-allyloxyadenosine as a 4/1 
mixture of its tautomers. Its spectral data were identical with the literature ones [28]. 
1,N6-Ethenoadenosine was purchased from Carbosynth Limited. 
Proliferation assay. Cell proliferation was analyzed using the AlamarBlue® Assay (Biosource, 
Camarillo CA). MCF 7 cells were plated at 700 cells per well in 96-well plates and cultured for 4 
days in the presence of 10 µM i6A or 9, 27 or 81 μM i6Ary and 10% AlamarBlue. Cell proliferation 
of treated and untreated cells was monitored based on fluorescence intensity (excitation 535 nm, 
emission 590 nm) measured on a Tecan ULTRA multiplate reader (Tecan Group Ltd. 
Mannedorf/Zurich, Switzerland). Six replicas were performed for each dose and for each compound 
tested. 
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6. CONCLUSIONS 
  In this Thesis, different aspects of N6-isoPentenyl Adenosine (iPAdo) cytotoxicity have been 
investigated. The problem of iPAdo selective delivery into cancer cells has been envisaged and with 
this aim the formation of GNPs containing iPAdo has been studied. For this purpose, iPAdo should 
be bound to a compound containing at least one –SH group and lipoic acid (LA) has been selected. 
The feasibility study for efficient preparation of the ester linkage between the 5'-hydroxyl of iPAdo 
and LA has been performed on iPAdo congener, kinetin riboside (KR), a known cytokinin, less 
expensive than iPAdo and commercially available in gram quantities. For the formation of the 5'-O-
ester linkage of KR, a few LA derivatives (lipoyl trifluoroacetate, ethyl carbonate and imidazolide)  
have been prepared and the esterification with model alcohols  has been investigated both 
chemically and enzymatically (lipase-catalyzed transesterification). However, the reaction of KR 
with lipoic acid derivatives gave either incomplete transformation or no reaction of KR. In any 
event, no selective 5´-O-esterification of KR could be achieved. 
A fully chemical approach for the synthesis of KR 5'-O-Lipoate was next investigated. The 
direct esterification of KR with LA in the presence of N,N’-dicyclohexylcarbodiimide has been in 
turn studied. However from the obtained complex reaction product, no 5’-O-selectivity was 
observed. The isopropylidene group was chosen as suitable protection for KR 2'- and 3'-hydroxyls. 
Differently from 2',3'-O-isopropylidene adenosine that requires an experimentally problematic 10-
fold molar excess of acid catalyst (p-TsOH), we obtained quantitatively 2',3'-O-isopropylidene KR 
by using an equimolar amount of p-TsOH as catalyst in the presence of 2, 2-dimethoxypropane. The 
synthesis of 2',3'-O-isopropylidene KR-5´-O-lipoate was then achieved in 88% yield, but  
hydrolysis of the 2', 3'-O-isopropylidene protection afforded a complex mixture of products. From 
this mixture, only a scarce amount of the required KR-5´-O-Lipoate could be recovered and 
attempted reduction of the disulfide bridge of LA bound to KR 2',3'-O-acetonide with sodium 
borohydride in methanol/water did not yield the required reduced form of KR-LA. In the light of 
the above-reported negative results obtained and considering that binding LA to iPAdo should 
constitute only the first of several additional steps required to prepare water-soluble iPAdo-GNPs, 
the iPAdo drug delivery project was abandoned.  
  Our experimental efforts were focused on additional studies of iPAdo bioactivity and on the 
synthesis of iPAdo analogues as a mean to overcome the in vivo catabolic pathway. 
 A detailed bioactivity assays on human MDA-MB-231 and MCF-7 breast cancer cells has 
shown that the cytotoxic effect is dose-dependent, with an IC50 value of 6.2 and 12.2 μmol/L, 
respectively, at 72 h after iPAdo addition to the culture. For both cancer cell lines the assessment of 
the cell shape and cell morphology of iPAdo treated cells established the loss of adhesion, rounding, 
 157
cell shrinkage and detachment from the substratum.  The interaction of iPAdo with Bovine Serum 
Albumin (BSA), as a model of the analogous human protein, has been in turn investigated via UV 
absorption spectroscopy. The value of binding constant for iPAdo-BSA complexes has been 
estimated to be 4.9 x 104 M-1 that is indicative of a good iPAdo-protein interaction. iPAdo 
interaction with DNA has also been studied by the same spectroscopic technique and an association 
binding constant KiPAdo–DNA=4.1 x 103 M-1 has been calculated, similar to those reported for DNA 
complexes with other anticancer drugs.  The dose-dependent cell cycle arrest and apoptogenic effect 
of iPAdo on MCF-7 cancer cell line has been determined. The cell cycle analysis of MCF-7 cells by 
mean of flow cytometry showed that there was an increase in the amount of sub G1/G0 phase on 
iPAdo treatment. This increase of hypoploid DNA was an indication that the inhibition of cell 
growth could be related to a mechanism of apoptosis. 
 However, further studies on the apoptotic activity of iPAdo via caspase-3 or -7 activation 
assay on MCF-7 cells showed no apoptotic activity, whereas the human leukaemia cells (HL-60 cell 
line) resulted sensitive to iPAdo treatment and dose-dependent induction of apoptosis was 
demonstrated in this cell line.  
For the planned preparation of the iPAdo analogues with improved IC50 value and endowed 
with a higher then iPAdo in vitro activity, N6-isoPentenyl Arysteromycin (iPAry), a carbocyclic 
iPAdo analogue, was selected as synthetic target, since the absence of the glycosidic bond 
constituted a reasonable promise of resistance to the action of catabolic enzymes. 
iPAry has been synthesized by two different approaches. The first synthetic strategy started 
from the described transformation of D-(-)-ribose into the carbocyclic key-intermediate (4R,5R)-(-)-
4,5-O-Isopropylidene-2-cyclopentenone. In our hands, this cyclopentenone derivative was obtained 
in 8 steps, 7.3% overall yield. Seven additional steps of fine organic conversions were required to 
obtain iPAry (7 steps, 7.1% yield). Though this synthetic strategy represents a fruitful possibility of 
preparing iPAry, as well as many other its N6-substituted derivatives, it practical value is limited by 
the multi-step laborious sequence comprised. In our hands, the total 0.52% yield from D-(-)-ribose 
has been the result of 15 overall steps.  
Several steps of the above-described synthesis could be revised and improved in terms of 
experimental procedure, but the overall process required too much effort and time, and, in 
alternative, commercial sources of arysteromycin (Ary) were considered. The rare and expensive 
compound was available only from a very few dealers in mg amounts and from a few milligrams of 
Ary, iPAry has been efficiently prepared (63% yield) by a N1/N6-alkylation and subsequent alkaline 
treatment (Dimroth rearrangement).  
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Dose-dependent experiments with iPAry established no notable effects on MCF-7 cells 
proliferation up to 3 days of treatment.  
The apoptotic activity of iPAdo via caspase-3 or -7 activation assay on human leukaemia 
cells (HL-60 cell line) was compared with that of iPAry and previously synthesized N6-alkylated 
adenosines (N6-butyladenosine, N6-allyladenosine, N6-benzyladenosine). iPAry was not found to 
induce apoptosis in HL-60 cells, even when a 10-fold augment of the 10 M effective iPAdo 
concentration was used.   
The lack of bioactivity of iPAry was surprising, considered the subtle structural difference 
between iPAry abd iPAdo. A hypothesis to explain the modest antiproliferative activity of iPAry on 
MCF-7 could be related to a receptor-mediated effect. Among other possibilities, A2 or A3 
adenosine receptors could be involved in iPAdo antiproliferative activity, as suggested by previous 
pharmacogenomic studies on iPAdo transcriptional profile.  
In silico studies on the human adenosinic receptors hA2b and hA3 have been performed and 
docking experiments have analyzed two putative complexes with iPAdo and iPAry. Results have 
shown that iPAry conserves the hydrophobic contacts generated by isopentenyl chain (with Phe168 
and Leu264 in hA3 and with Ile67 and Leu172 in hA2b, respectively) and some of the key 
interactions stabilized by adenine (with Asn254 in hA3 and with Asn254 and Phe173 in hA2b). In 
hA2b the destabilization of iPAry-receptor complex occurs due to the specific arrangement of the 
cyclopentyl ring and the presence of methylene group that hampers the pivotal for complex 
interactions. As it was established, in hA3, quite differently compared to hA2B, the iPAry poor 
activity is justified by its strong detrimental effects on the polar interactions which impact on all 
monitored H-bonds.  
Finally, a few iPAdo analogues were prepared with the aim of finding compounds with 
improved IC50 value and endowed with a higher then iPAdo in vitro activity. Thus, N6-isoPentenyl 
Tubercidin, 2',3'-O-isopropylidene-iPAdo, N6-isoPentenyl-L-adenosine and N6-isoPentenyl 
derivative of 5´-N-Ethylcarboxamido Adenosine were prepared in good yields (45-74%) by N1/N6-
alkylation protocol previously studied and applied to the synthesis of iPAry. The synthesis of N6-
propargyladenosine, N6-Methyl-N6-propargyladenosine and N6-allyloxyadenosine was achieved by 
using the reported in the literature interaction of 6-chloro-9-ribofuranosylpurine with the 
corresponding amine in the presence of triethylamine. The afore-mentioned iPAdo analogues, 
prepared by using diverse synthetic routes, along with commercial 1,N6-ethenoadenosine were 
screened for their in vitro  antiproliferative  activity on MCF-7 breast  cancer cells by AlamarBlue 
assay. The 10 M solutions of tested compounds were employed and only N6-propargyladenosine 
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and N6-Methyl-N6-propargyl adenosine showed 42% and 16% inhibition of cell proliferation (37% 
for iPAdo).  
Further investigations on iPAdo and its analogues uptake in the cell, mechanisms of action 
and metabolic pathways involved are in progress.  
 
 
 
 
 
 
 
 
